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ABSTRACT
This thesis examines genetic factors in susceptibility to the 
autoimmune disease systemic lupus erythematosus (SLE). Candidate genes 
examined for a possible role in the predisposition to SLE included those 
encoding the HLA class I and class II antigens, the complement 
components C4A, C4B and C2, and the T-cell antigen receptor a, ß and y 
chains. Immunoglobulin allotypes, C3 phenotypes, and lymphocytotoxic 
activity of SLE sera has also been examined. Genetic profiles were 
established for approximately 30 Caucasoid SLE patients, for additional 
patients with other connective tissue disorders and for appropriate 
controls.
Several earlier studies have shown associations between ehe HLA 
class II DR antigens and SLE, but these have often been conflicting.
This may be due to the well known difficulty in cellular and serological 
typing of HLA-D and -DR antigens in SLE patients, and due to possible 
clinical heterogeneity between SLE patients from different centres. In 
this study, the technique of DNA-DR typing, which gives unequivocal 
results, was carried out in parallel with serological HLA-DR typing-in 
SLE and showed a potentially high error rate in HLA-DR serology in 
lupus. This can be due to incorrect antigen assignment as well as a 
failure to detect some DR antigens. These errors have the potential to 
introduce bias into serological studies of HLA-DR in lupus as some DR 
antigens, such as DR2, are more easily detected than others.
Examination of DNA-DR antigen frequencies showed that DR3 alone was 
increased in Caucasoids with lupus while DR2 was not. Restriction 
fragment length polymorphism (RFLP) studies of the MHC class II DQ and
-V-
DP genes have also been made, but no role for the DQ or DP antigens in 
SLE was apparent from the RFLP analyses.
Deficiencies of the MHC class III complement components C2 and C4 
have also been implicated in the pathogenesis of lupus, but due to 
linkage disequilibrium with the HLA-B and -DR genes, it has been 
difficult to distinguish the primary susceptibility locus. In this 
study, the role of C4 deficiency has been examined in SLE patients from 
three populations with different MHC gene linkage arrangements.
Caucasoid, Japanese and Chinese SLE patients and controls were C4 
allotyped and the maximum likelihood method used to calculate gene 
frequencies. This study showed a significant increase in the C4A null 
allele (C4A*Q0) frequency in each of the three patient populations when 
compared with their respective controls, indicating a major role for 
complete and partial C4A deficiency in the pathogenesis of lupus. 
Inherited deficiencies of C4B and C2 were not implicated in SLE in this 
study.
Logistic regression analysis was used to compare the relative 
contributions of the C4A null gene and DR3 to lupus in Caucasoids, as 
these two alleles are in significant linkage disequilibrium on the 
haplotype A1.B8.DR3. This statistical analysis strongly supported the 
notion that C4A*Q0 is the primary MHC disease promoting locus, with no 
significant contributions made by HLA-DR3, or C4B*Q0 genes.
However, not ail lupus patients have an inherited deficiency of 
C4A, suggesting genetic heterogeneity in the disease, and some other 
candidate genes in the pathogenesis of SLE include these encoding the T- 
cell antigen receptor (TCR) . RFL? studies of the TCR-a, -ß and -y genes 
have been made in Caucasoid SLE patients. No unusual RFLPs or deletions
were seen. There was no increase in frequency of any particular DNA
-VI-
fragments detected with the Tcr-ot, -ß or -y chain probes, nor any 
interaction between TCR RFLPs and HLA class II RFLPs.
Because of the diversity of clinical features in lupus, 
discriminant analysis has been carried out in an attempt to correlate 
clinical features of lupus with genetic variables. This revealed a 
significant decrease in frequency of a DPß/EcoRV RFLP in patients with 
pleuritis, suggesting a possible role for HLA-DP in some lupus subtypes. 
Discriminant analysis between SLE and various connective tissue diseases 
was also performed, and together with inherited partial C4A deficiency, 
lymphocytotoxic activity against B-cells was an important discriminating 
variable, suggesting that lymphocytotoxins may be more important 
pathogenically than previously thought.
This study has shown that SLE is a genetically heterogeneous 
disease, but one important susceptibility factor, in Chinese and 
Japanese as well as in Caucasoids, is an inherited partial or complete 
deficiency of C4A.
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GENERAL INTRODUCTION
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1.1 INTRODUCTION.
Systemic lupus erythematosus (SLE or lupus) is an autoimmune 
connective tissue disease, the aetiology of which is unknown.
Originally, SLE was thought to be a cutaneous disease but in 1872 Kaposi 
recognized that other organs could be involved and that the disease was 
therefore systemic in nature. Clearer definition of the systemic 
features was later provided by Osler, Libman and Sacks, and Klemperer.
In 1948, Hargraves discovered the "LE cell” (lupus erythematosus cell) 
phenomonen which was later shown to represent an antibody to DNP 
(deoxyribose nucleoprotein). Since then, many other autoantibodies, 
particularly against nuclear antigens, have been found in the sera of 
patients with SLE, with the fluorescent antinuclear antibody (ANA) test 
being used as a routine diagnostic clinical test by the late 1950's. A 
wide variety of more specific ANAs and other autoantibodies have now 
been recognized and described, and have contributed to the understanding 
of the disease (reviewed by Reichlin 1981). The history of lupus has 
been reviewed in more detail by Graninger et al. (1987).
1.2 EPIDEMIOLOGY.
SLE is a disease primarily affecting females from 15 to 35 years of 
age, but can occur in all age groups including the newborn and the 
elderly. SLE has been reported to occur in about one in two thousand 
Caucasoids (Engleman and Shearn 1983), with a higher incidence observed 
in several non Caucasoid populations, including American blacks and 
North American Indians (Steinberg 1985). A study in New Zealand 
estimated that one in 6780 Caucasoids were affected (Meddings and
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Grennan 1980). The differing levels of incidence in Caucasoids may be 
partly due to ethnic heterogeneity in the Caucasiods studied, or 
differences in the way that the cases are ascertained. There is no 
large scale survey of the prevalence of SLE in the Australian community.
1.3 DIAGNOSIS OF SLE.
SLE can vary from a mild cutaneous problem with appropriate 
serology to a severe, life threatening, multi-organ disease, and can 
also go through stages of active disease or remission in individuals, 
with a wide variety of clinical symptoms. In addition, lupus is a 
disease that can develop very quickly or can take many years to evolve.
The extreme diversity of symptoms seen in lupus, many of which are 
non-specific, make the diagnosis difficult, particularly when several 
other connective tissue disases (CTDs) have the same or similar 
features. The issue is further complicated by the fact that SLE may 
well be collection of several diseases rather than one specific disease. 
This complexity has lead to a number of attempts to develop criteria for 
the diagnosis of SLE, for use in both epidemiological surveys and in 
scientific studies, to ensure some uniformity with regard to what is 
described as a case of lupus.
In 1971, the "Preliminary Criteria for the Classification of 
Systemic Lupus Erythematosus" (Cohen et al. 1971) were published by the 
American Rheumatism Association (ARA) which did establish some 
uniformity in the diagnosis of SLE for clinical and research purposes.
The 1971 criteria have since been updated and revised taking into 
consideration newly defined immunological markers such as anti-DNA 
antibodies, antinuclear antibodies, complement levels and complement
- 3 -
TABLE 1 . 1  1982 REVISED CRITERIA FOR THE CLASSIFICATION OF SLE.
Criterion Definition
1. Malar rash Fixed erythema, flat prfaised. over the malar emi­
nences. tending to spare the nasolabial folds
2 Discoid rash Erythematous raised patches with adherent keratotic 
scaling and follicular plugging, atrophic scarring may
occur in older lesions
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight, 
by patient history or physician observation
4. Oral ulcers Oral or nasopharyngeal ulceration, usually painless, 
observed by a physician
5. Arthritis Nonerosive arthritis involving 2 or more peripheral 
joints, characterized by tenderness, swelling, or effu­
sion
6. Serositis a) Pleuritis—convincing history of pleuritic pain or rub 
heard by a physician or evidence of pleural effusion
OR
b) Pericarditis—documented by ECG or rub or evidence 
of pericardial effusion
7. Renal disorder a) Persistent proteinuria greater than 0.5 grams per day 
or greater than 3+ if quantitation not peformed
O R
b) Cellular casts—may be red cell, hemoglobin, granu­
lar, tubular, or mixed
. 8.Neurologic disorder a) Seizures—in the absence of offending drugs or known 
metabolic derangements; e g .  uremia, ketoacidosis, 
or electrolyte imbalance
OR
b) Psychosis—in^the absence of offending drugs or 
known metabolic derangements, e g . uremia, ketoac­
idosis. or electrolyte imbalance
9. Hematologic disorder a) Hemolytic anemia—with reticulocytosis
OR
b) Leukopenia—less than 4.000'mm' total on 2 or more 
occasions
OR
c) Lymphopenia—less than 1.300/mm’ on 2 or more oc­
casions
O R
d) Thrombocytopenia—less than lOO.OOO'mm’ in the ab­
sence of offending drugs
10. Immunologic disorder a) Positive LE cell preparation
b)
OR
Anti-DNA: antibody to native DNA in abnormal titer
O R
c) Anti-Sm: presence of antibody to Sm nuclear antigen
OR
d) False positive serologic test for syphilis known to be 
positive for at least 6 months and confirmed by 
Treponem a pallidum  immobilization or fluorescent 
treponema! antibody absorption test
II. Antinuclear antibody An abnormal titer of antinuclear antibody by immuno­
fluorescence or an equivalent assay at any point in 
time and in the absence of drugs known to be associ­
ated with “drug-induced lupus" syndrome
• The proposed classification is based on 11 criteria. For the purpose of identifying patients in clinical 
studies, a person shall be said to have systemic lupus erythematosus if any 4 or more of the 11 criteria 
are present, serially or simultaneously, during any interval of observation.
(Taken from Tan e t  a l .  1 9 8 2 ) .
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activity (Tan et al. 1982) and these have subsequently been shown to be 
highly specific for the diagnosis of SLE (Passas et al. 1985). The 
classification criteria are shown in Table 1.1 (taken from Tan et al. 
1982). For a patient to be diagnosed with SLE, he or she must have any 
four of the criteria, either serially or simultaneously during the 
course of observation.
It should be mentioned however that these criteria are exclusive, 
rather than inclusive. The criteria are designed to exclude other 
autoimmune CTDs, arthritides and certain systemic illnesses (Tan et al. 
1982), and therefore may exclude individuals whose diagnosis is almost 
certainly SLE.
1.4 CLINICAL AND LABORATORY FEATURES OF SLE.
The clinical features of lupus have been described in depth by 
several authors (Dubois 1976; Ropes 1976; Rothfield 1985) and will only 
be reviewed briefly here. Table 1.2, (taken from Schur 1983), gives the 
incidence with which some of clinical features occur in lupus. These 
frequencies can vary in different studies and may be due to the way in 
which patients are ascertained.
Most patients with lupus suffer from a number of generalized 
symptoms seen in many diseases including fatigue, weight loss, fever and 
a general lack of well being.
Cutaneous disorders of lupus include the diagnostic criteria malar 
rash, discoid lesions, photosensitivity and mouth and nasal ulcerations. 
These cutaneous features are very common with 85% of lupus patients 
affected by some dermatological disorder (Rothfield 1985). Patients are 
particularly affected by the typical '‘butterfly “ rash across the cheeks
- 5 -
TABLE 1.2 FREQUENCY OF CLINCAL FEATURES IN SLE.
FEATURE PERCENT
Fever 83
Weight loss 62
Arthritis, arthralgia 90
Skin 74
Butterfly rash 42
Photosensitivity 30
Mucous membrane lesions 12
Alopecia 27
Raynaud1s phenomonen 17
Purpura 15
Urticaria 8
Renal 53
Nephrosis 18
Gastrointestinal 38
Pulmonary 47
Pleurisy 45
Effusion 24
Pneumonia 29
Cardiac 46
Pericarditis 27
Murmurs 23
ECG changes 39
Lymphadenopathy 46
Splenomegaly 15
Hepatomegaly 25
Central nervous system 32
Psychosis 15
Convulsions 15
(Taken from Schur 1983).
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and nose, and sensitivity to sunlight which can exacerbate the malar 
rash and erythematous maculopapula eruptions. Alopecia is also fairly 
common in SLE but is not specific enough to be part of the diagnostic 
criteria.
Systemic features in SLE involve the joints, kidneys, lungs, heart, 
central nervous system, gastrointestinal tract, liver and spleen. Joint 
disease is very common in lupus, ranging from arthralgias and minor 
tendonitis to joint swelling and arthritis. The arthritis is rarely 
erosive and deformity is seldom seen in contrast to rheumatoid arthritis 
(Labowitz and Schumacher 1971).
Renal disease is seen clinically in about 50% of patients, although 
pathology usually indicates a higher incidence. Renal disorders can 
vary in severity from mild focal lupus nephritis to acute and ultimately 
chronic renal failure.
About 50% of SLE patients are affected with lung problems, with 
pleuritic pain the most common feature. Interstitial lung involvement 
with acute lupus pneumonitis and diffuse chronic interstitial lung 
disease can also occur, and lung function abnormalities may be found in 
asymptomatic patients.
Pericarditis is the most common cardiac disorder, in lupus, and is 
usually acute. Myocardial involvement is uncommon, while vascular 
disease may be seen at autopsy, but is rarely a problem during life.
Central nervous system manifestations include seizures and 
psychoses, both of which are diagnostic criteria of SLE. Patients also 
suffer from headaches (migraine or a more diffuse type), while a small 
number of patients develop cerebrovascular disease. Peripheral 
neuropathy has also been described.
Gastrointestinal involvement is not specific enough to be part of
- 7-
the diagnostic criteria for lupus, and includes anorexia, nausea and 
vomiting (seen in about 20% of patients), while abdominal pain occurs in 
about 10% of patients. Hepatomegaly is sometimes seen, but clinical 
hepatitis is very rare.
Slight to moderate splenomegaly is seen in about 20% of SLE 
patients, especially those with haemolytic anaemia. Approximately 50% 
of patients have enlarged lymph nodes at some stage during the course of 
the disease.
Vascular disease is also seen in lupus, varying from Raynaud’s 
phenomonen (mild to severe), to venous and arterial thrombosis. The 
thrombosis has been associated with anti-phospholipid antibodies (Harris 
et al. 1983).
Several haematological abnormalities have been observed in lupus 
including lymphopenia, leukopenia, thrombocytopenia, and haemolytic 
anaemia (all part of the diagnostic criteria). Leukopenia occurs in 
nearly 50% of lupus patients while haemolytic anaemia and 
thrombocytopenia are seen in about one fifth of patients (Tan et al. 
1982). Thrombocytopenia may be due to the presence of anti-platelet 
antibodies (Maini 1977).
Serology has revealed a number of autoantibodies in SLE including 
antinuclear antibodies (ANAs, seen in more than 95% of patients), 
anti-double standed DNA (anti-dsDNA) antibodies (found in 70% of 
patients) and anti-Sm antibodies (seen in about 30% of patients), where 
Sm is an acidic nucleoprotein. Each of these antibodies are diagnostic 
criteria for SLE, as are the LE cell and a consistently false positive 
standard test for syphilis.
In addition to the above features, other supporting antibodies 
include anti-single stranded DNA (anti-ssDNA) antibodies (very common
- 8-
but not specific), anti-Ro (SS-A) and anti-La (SS-B) antibodies which 
are also seen in patients with Sjogren's syndrome, and anti-nRNP 
antibodies which are seen in a high proportion of mixed connective 
tissue disease (MCTD) patients.
The levels of complement components C3 and C4, and the total 
haemolytic complement activity are usually decreased during active 
disease. However, results of complement assays in SLE patients, 
particularly C4, should be interpretated carefully as inherited C4 null 
alleles may predispose an individual to SLE.
Cold reactive lympnocytotoxins specific for B- and T-cells have 
also been observed in SLE sera, which are frequently specific for a 
patients own lymphocytes (Terasaki et al. 1970). These are of the IgM 
sub class (Winfield et al. 1975a), and are detectable with the 
complement dependant microcytotoxicity test. Rheumatoid factor (RF) is 
another IgM antibody found in the sera of about 20% of SLE patients and 
is reactive against IgG antibodies (Fong et al. 1985). RF was one of 
the original criteria for the diagnosis of SLE but has since been 
omitted as it is not highly specific for SLE.
1.5 ENVIRONMENTAL OR GENETIC?
Both environmental and genetic factors have been implicated in the 
pathogenesis of SLE. Studies have shown that the age of onset of SLE in 
sibling pairs occurs closer in the calendar year than in the actual age 
of the siblings (Arnett and Schulman 1976; Kaplan et al. 1984) which 
would indicate an environmental agent. Further support comes from 
finding anti-nucleic acid antibodies (De Horatius et al. 1975) and anti- 
lymphocyte antibodies (De Horatius and Messner 1975) increased in
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frequency in the sera of close household contacts of patients with SLE. 
Laboratory workers who handle SLE blood also have a higher incidence of 
lymphocytotoxic antibodies (LCAs) compared with the general population 
(De Horatius et al. 1979).
On the other hand, close blood relatives of SLE patients, with 
little patient contact, have an increased incidence of LCAs (De Horatius 
and Messner 1975) and a study by Elkon et al. (1983) has shown an 
increase in circulating immune complex levels in first degree relatives 
of SLE patients, both with and without close household contact, which 
would tend to support a genetic basis. In addition, there is a higher 
concordance rate of disease in identical twins (57%) compared to 
dizygotic twin pairs and sibs (Block et al. 1975) with disease 
expression very similar between identical twins. It has been observed 
that approximately 10% of SLE patients have a first or second degree 
relative with SLE (Arnett et al. 1984) which is suggestive of genetic 
involvement.
The most convincing evidence for the role of genetic factors in the 
pathogenesis of SLE is provided by the association of major 
histocompatibility complex (MHC) genes with the disease, as reviewed 
later in this chapter and Chapter 3. Further evidence for genetic 
involvement is provided by animal models of SLE.
1.6 ANIMAL MODELS OF SLE.
To further understand the genetics of SLE, studies have been made 
of animals which have lupus like diseases such as certain mouse and dog 
strains. The most studied mouse strain has been the New Zealand Black x 
New Zealand White Fl [(NZB x NZW)F1] mouse which develops a lupus like
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disease very similar to that seen in humans. The parental NZW mouse is 
phenotypically normal, and any autoimmune symptoms are rarely seen 
before 18 months of age. The NZB mouse does have some autoimmune 
manifestations such as haemolytic anaemia and occassionally anti-ssDNA 
or anti-dsDNA or anti-histone antibodies. Renal disease rarely occurs 
when the NZB mice are less than one year old and is very mild. However, 
in the (NZB x NZW)F1 hybrids, anti-dsDNA and anti-histone antibodies are 
present, and the mice suffer from fatal immune complex 
glomerulonephritis. The female FI mice have an average life span of 
only eight months. Some new strains of mice with lupus like diseases 
are now available for study such as the MRL mouse and 3XSB mouse. 
However, none of the mice have the same H-2 type (the mouse equivalent 
of the human MHC genes), nor the same immunoglobulin heavy chain type. 
Work on the T cell receptor (TCR) in these mice strains indicates that 
the NZW mice do have differences in their TCR genes, but whether these 
have an effect on the pathogenesis of the lupus like disease in the mice 
is not clear. Different accelerating factors are also seen in the mice. 
For example, hormones play a role in the (NZB x NZW)F1 mice with female 
mice dying much sooner than male mice and the lymphoproliferative (lpr) 
gene in MRL mice reduces life expectancy three-fold. How these 
accelerating factors work is unknown. The murine models suggest that 
there are several mechanisms or abnormalities which can lead to lupus; 
the mice lupus models are reviewed by Theofilopoulos et al. (1986).
1.7 CANDIDATE GENES FOR SLE IN HUMANS.
Several genes are candidates for causing the immunological
abnormalities seen in lupus such as the genes of the major
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histocompatibility complex and the T-cell receptor (TCR) genes. The 
molecular organization, structure and function of the MHC and T-cell 
receptor genes have been the subject of intense investigation and are 
reviewed here in some detail.
1.8 THE MAJOR HISTOCOMPATIBILITY COMPLEX.
The MHC is found on the short arm of chromosome 6, at the 6p21.3 
band, and encodes some of the most polymorphic human genes. The MHC is 
comprised of three classes of genes, (Figure 1.1), which encode the 
class I HLA-A, -3, and -C antigens found on the surface of the majority 
of nucleated cells, the class II HLA-D antigens found primarily on the 
surface of 3-lymphocytes, and the class III serum complement components 
C2, C4 and 3F and also the 21-hydroxylase enzyme. Recently, the tumor 
necrosis factor (TNF) a and 0 chain genes have been localized between 
the class I and III genes.
1.8.1 THE HLA-A, -3, AND -C ANTIGENS.
The class I antigens, (the classic transplantation antigens), 
consist of a polymorphic transmembrane glycoprotein about 4£.kDa in size 
encoded in the MHC, and a noncovalently associated 12kDa 82 
microglobulin (Strominger et al. 1977) which is encoded by a gene on 
chromosome 15 (Goodfellow et al. 1975). The heavy chain has three 
external domains, a transmembrane domain and a cytoplasmic domain. The 
02 microglobulin is associated with the highly conserved third external 
domain next to the cell membrane, while the first two extracellular 
domains are the most polymorphic (Yokoyama and Nathenson 1983).
i
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Polymorphism in the class I antigens is evident by serological, cellular 
and biochemical techniques with the Ninth International 
Histocompatibility Workshop recognizing 23 HLA-A, 47 HLA-B and eight 
HLA-C antigens, which were detected serologically (Bodmer and Bodmer 
1984). The class I antigens are important in the discrimination between 
self and nonself during an immune response, as they are found on the 
majority of cells, and therefore play an important role in 
transplantation. In addition, T-cytotoxic cells recognize antigen in 
association with the MHC class I molecules during an immune response.
1.8.2 THE HLA-D ANTIGENS.
The class II HLA-D antigens are polymorphic heterodimers comprised 
of a heavy a chain about 33 kDa in size and a light ß chain (28 kDa) 
(Snary et al. 1977; Springer et al. 1977). Each polypeptide chain has 
two extracellular domains, the first showing the most polymorphism, a 
transmembrane domain and a cytoplasmic domain (Kaufman and Strominger 
1982). The first external domains of the a and ß chains probably 
combine together to bind antigen. Three HLA-D antigens have so far been 
detected, the DR, DQ and DP antigens, with the possibility of a fourth 
indicated from molecular genetic (Trowsdale et al. 1985) and biochemical 
studies (Carra and Acoila 1987). The Ninth International 
Histocompatibility Workshop recognized 14 DR, three DQ and six DP 
serologically distinct antigens (Bodmer and Bodmer 1984). During an 
immune response, 3-cells, macrophages and other antigen presenting cells 
(which carry the class II antigens on their cell surface), process 
foreign antigen and present it on the cell surface in association with
the class II proteins. T-cells, with their T-cell receptor which
- 13-
recognizes foreign antigen in association with the class II protein, are 
then able to interact and become activated and function as T-helper 
cells, stimulating B-cell involvement and antibody production.
1.3.3 GENETIC ORGANIZATION OF THE MHC CLASS II GENES.
The organization of the genes in the MHC is shown in Figure 1.1.
The MHC covers an area of about 2.5cM and the order of the genes was 
established initially with family studies of people with HLA recombinant 
haplotypes, both serologically and by recombinant DNA techniques. More 
recently, the new method of pulsed field gel electrophoresis (PFGE) and 
the use of overlapping cosmid clones {Dunham et al. 1987; Carroll et al. 
1987) has proved very useful as larger areas of DNA can be covered.
The class II region contains four sets of genes, the DR, DQ, DP, 
and DO/DZ genes. By linkage of ccsmid clones (Korman et al. 1985) and 
southern blotting {Wake et al. 1982a; Bohme et al. 1983), the DR locus 
has been shown to consist of one a gene and a variable number of ß chain 
genes. The number of ß chain genes correlates with serological DR types 
(Bohme et al. 1985). For example, DRw8 has one ß gene while DR4 has at 
least 3 ß genes (Bohme et al. 1985). The ß2 gene appears to be a 
pseudogene in some DR types and it is possible that it has played a role 
in gene conversion (Larhammar et al. 1985; Rollini et al. 1985). The 
DRa gene shows restricted polymorphism (Larhammar et al. 1982; Stetler 
et al. 1982; Wake et al. 1982a) but the ß genes are highly polymorphic
(Bohme et al. 1983; Wake et al. 1982b).
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There are two pairs of genes in the DQ region, known as DQa and 
DQß, and DXa and DXß , which have not been linked with cosmid cloning 
(Okada et al. 1985a; Korman et al. 1985). The DQ RFLPs show strong 
linkage disequilibrium with DR types unlike those at the DX locus 
(Auffray et al. 1984; Trowsdale et al. 1983; Spielman et al. 1984), and 
with supporting evidence from deletion mutant cell lines it has been 
suggested that the DX genes are centromeric to the DR and DQ genes, 
(Auffray et al. 1983a), and that there is a hot spot for recombination 
between the DX and DR/DQ genes (Trowsdale et al. 1985). The DX gene 
pair do not appear to be expressed as no mRNA or protein has yet been 
detected, but from sequencing, the genes do not appear to be pseudogenes 
(Auffray et al. 1984; Okada et al. 1985a). The DQa and DQß genes show 
variability in the splicing points at their 3' ends which can result in 
deletion of part of the untranslated region (Schenning et al. 1984).
The DX gene pair show limited polymorphism but both the DQa and DQß 
genes have extensive polymorphism when examined for RFLPs (Auffray et 
al. 1983b; Spielman et al. 1984; Cohen et al. 1984). The variability in 
the DQa gene has been shown to be clustered to amino acid residues in 
the first external domain (Chang et al. 1983; Trowsdale et al. 1985).
The DP region covers about lOQkb of DNA (Okada et al. 1985b) and 
has been extensively characterized (Roux-Dosseto et al. 1983; Gorski et 
al. 1984; Trowsdale et al. 1985). Two pairs of genes have been found in 
this region, namely DPal and DPßl, and DPa2 and DPß2 and these have been 
linked by cosmid cloning. Sequencing suggests that the a2 and ß2 gene 
pair are pseudogenes due to frame shift mutations and defective slicing 
sites (Kappes et al. 1984; Servenius et al. 1984). Sequencing of the DP 
genes (Kelly and Trowsdale 1985) and the DP protein (Hurley et al. 1982)
indicates that al and ßl encode the DP antigen. Different splicing
- 16-
patterns have been observed as well as variation in the site for the 
poly A tail (Kelly and Trowsdale 1985). The DP genes were originally 
thought to show little polymorphism (Spielman et al. 1984), but it is 
now evident that they are highly polymorphic, with genetic variation 
clustered in regions of the second exon (Bugawan et al. 1987).
The fourth set of genes in the HLA-D region are the newly 
identified DOß and DOa/DZa genes. The DZa gene was originally 
identified by Spielman. et al. (1984) and was later shown to be identical 
to the DOa gene which was isolated by Inoko et al. (1985). DO appears 
to lie between DQ and DP from PFGE and cosmid cloning studies (Hardy et 
al. 1986; Erlich et al. 1986; Amar et al. 1987). DOß and DOa/DZa may 
not be a gene pair as PFGE indicates that they lie about lOOkb apart in 
the MHC and DOa/DZa is inducible by y interferon while DOß is not. From 
their sequences, both could be functional genes. Northern blots have 
shown a low level of expression of the DO genes in some B-cell lines, 
but a very large mRNA was detected (Trowsdale et al. 1985). No RFLPs 
have yet been found (Trowsdale et al. 1985).
1.9 ASSOCIATION OF THE CLASS I AND II GENES WITH DISEASE.
The class I and II genes have shown associations with several 
diseases which are characterized by abnormalities in the immune system 
such as insulin dependent diabetes mellitus, rheumatoid arthritis, and 
multiple sclerosis. These genetic associations may be directly 
attributable to defects in the class I and II genes such as deletions, 
splicing errors, or deviation in the exon sequences from normal. On the 
other hand, as a 100% association with the HLA antigens is not seen in 
these diseases, the HLA genes may be markers for the disease
- 17-
susceptibility gene (a non HLA gene) which could be carried on the same 
haplotype. A high level of linkage disequilibrium is seen in the MHC 
and may be a consequence of selective pressure for certain benefical 
genes, for example during a disease epidemic. However, this linkage 
disequilibrium may have resulted in some less beneficial genes (with 
regard to autoimmunity) being carried on the haplotype, a feature which 
has been called "hitch hiking" (Bodmer and Bodmer 1978). There is still 
an area of the MHC, between the class I and III genes, where new genes 
could be located, or a disease susceptibility gene could lie outside the 
MHC. A third explanation for disease associations with genes in the MHC 
is that certain MHC types are necessary, but not sufficient, for the 
development of disease, with other non-MHC genes and environmental 
factors contributing to disease development in autoimmune disorders.
1.9.1 ASSOCIATION OF THE CLASS I AND II MHC GENES WITH SLE.
SLE was originally reported to be associated with HLA-B5 and HLA-B8 
in several populations, but it was later shown that the class II 
antigens DR2 and DR3 were also increased in frequency in SLE (reviewed 
by Tiwari and Terasaki 1985). However, because of the linkage 
diseqilibrium seen in the MHC, as observed between B8 and DR3 for 
example, it was not possible in studies of small numbers of patients to 
identify which locus conferred the greatest risk for SLE. Further, 
these HLA genes could be part of a haplotype which carries a disease 
susceptiblility gene, such as defective genes at the class III locus.
- 18-
1.10 THE CLASS III GENES IN THE MHC.
The early acting complement components C2, C4, and BF are encoded 
in the class MHC III region along with the genes for 21-hydroxylase 
(Figure 1.1). Mapped with overlapping cosmid clones (Carroll et al. 
1984) the class III genes lie between the class I and HLA-D genes with 
C2 and BF only 421bp apart, while the C4 genes are about 30kb away from 
BF. The C4A and C4B genes lie about lQkb apart from each other while 
the 21-OH genes are located close to the 3' ends of the C4 genes 
(Carroll et al. 1985; White et al. 1985). PFGE has established the gene 
order as HLA-B, C2, BF, C4A, 21-OHA, C4B, 21-OHB, HLA-DR (Dunham et al. 
1987; Carroll et al. 1987).
1.10.1 THE COMPLEMENT SYSTEM.
The complement system is comprised of about 18 plasma proteins 
which are involved in a series of sequential reactions and which show a 
wide variety of immunological activities including solubilization of 
immune complexes, viral neutralization, lysis of foreign cells, 
opsonization, and stimulation of the inflammatory response. There are 
two pathways in the complement system - the classical, and the 
alternative which join together in the terminal attack cascade (Figure 
1.2).
In the classical pathway, complement component Cl is activated by 
antigen:antibody complexes (Ag:Ab), particularly those with IgG or IgM 
antibodies, resulting in the activation of Cl. The Cls subunit of Cl in 
turn activates complement component C4, cleaving lOkDA, (C4a, released), 
from the amino terminal of the a chain of C4 and leaving C4b which binds
FI
GU
RE
 1
.2
 
TH
E 
CO
MP
LE
ME
NT
 C
AS
CA
DE
- 19-
Ss0o
<0c3§s■H
CO 0)03 •H 5-1 03 -Cu o cdCO 
>rH a) o I-(au 123X fHa) or-l COa, a£ -H0ü d) Jd^  O' <2 
iJ ••
01 it) Di c{ hU
<do>M
u01M
2C3iM
ä
03 0 12 
•I- (
+JC■=c
01
c<DO'•H
4->c
iiouuid
i404Joidb
12CQ 3d M 
Ü  S-l
12m
CM
■=*U ■
OisC
0)
4-1CO 01a:
j3atdccd
cdCu
C5
-9
 -
--
---
--
--
--
--
--
> C
5b
-9
b 
(t
er
mi
na
l 
at
ta
ck
 c
om
pl
ex
)
- 20-
to the Ag:Ab:Cl complex. In the presence of magnesium ions, C2 binds to 
C4b and is cleaved by Cls to C2Ä (released) and C2b. C4b2b is a C3 
convertase enzyme, cleaving C3 to C3a and C3b through a proteolytic site 
on C2b. C3a, an anaphylatoxin, is released into the circulation and C3b 
binds to the Ag:Ab:C14b2b complex and cleaves complement component C5 to 
its active form, resulting in the activation of the terminal attack 
cascade and the formation of C5b-9b, (the terminal attack complex), 
which is extremely hydrophobic and inserts into the lipid bilayer of 
cells and causes lysis.
In the alternative pathway, factor B (BF) is activated by antigens 
particularly those carrying complex polysaccharides on their surface 
such as bacteria, as well as large insoluble immune complexes and IgA 
carrying immune complexes. Factor D cleaves factor B forming Ba 
(released) and Bb which binds to C3b. Properdin stabilizes this C3 
convertase and the terminal attack pathway is activated. A positive 
feedback loop, controlled by Factors I and H, is set up as C3 is part of 
its own C3 convertase. In the classical pathway, Cl is controlled by Cl 
esterase inhibitor and C4 is inactivated by C4 binding protein and 
factor I which cleaves C4b to C4c and C4d (for general references on the 
complement system see Dias da Silva 1986; Schur 1985).
Both pathways act together to clear immune complexes from the body, 
the alternative pathway being essential for the solubilization of immune 
complexes while the classical pathway is essential for the prevention of 
precipitation of immune complexes, (Webb and Whaley 1986; Schifferli 
1986a). To facilitate the clearance of immune complexes from the 
circulation, C3b and C4b bind to a receptor, CR1, which is found in 
large numbers on erythrocytes so that immune complexes can be 
transported to the liver where the fixed macrophage system removes them.
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This prevents interaction of immune complexes with endothelium and 
reduces local inflammation and tissue damage from the activation of 
complement. C3b also plays a role in opsonization, coating immune 
complexes which facilitates binding to macrophages which carry a C3b 
receptor (Bianco et al. 1975).
1.10.2 COMPLEMENT DEFICIENCIES.
Deficiencies of most of the complement proteins are seen in the 
general population with approximately equal numbers of males and females 
affected. C2 deficiency is the most common with about 1% of Caucasoids 
heterozygous for C2 deficiency (Glass et al. 1976). Individuals with 
complete deficiencies of one of the early complement components Cl, C2, 
or C4 often present with a lupus-like disease but usually lack the 
characteristic LE cell, antinuclear antibodies or Ig and C3 deposits in 
the skin, which are seen in lupus. Deficiencies of components C5 to C8 
result in an increased susceptibility to bacterial infections, in 
particular to the bacterium Neisseria, while complete lack of C3 causes 
predisposition to extremely severe, recurrent diseases usually caused by 
bacterial infection. Complement component C9 deficiency has been seen 
in many people but does not appear to predispose individuals to any 
particular disease. Factor P (properdin) deficiency results in high 
susceptibility to meningococcal meningitis. Complement deficiencies are 
reviewed by Schur (1986) and Agnello (1986). Complete deficiency of 
factor B has not been reported indicating that it may be lethal, but 
silent alleles have been reported in some families (Suciu-Foca et al.
1980; Tokunaga et al. 1984; Bertrams and Mauff, 1985).
- 2 2 -
The early complement components C2, C4, and 3F are encoded by genes 
in the class III region of the MHC, and are therefore important in 
disease studies because of the association of the MHC class I and II 
genes with diseases such as IDDM (Svejgard 1980) and because of the 
linkage disequilibrium between genes in the MHC. Due to the linkage 
disequilibrium it is often difficult to pinpoint the locus conferring 
the greatest risk in diseases such as SLE where associations are 
sometimes weak. However, in the case of SLE where deficiencies of 
complement components Clq, Clr, and Cls are associated with a lupus-like 
disease (Schur 1986; Agnello 1986) and are not encoded by genes in the 
MHC and where acquired deficiencies of C4 and C2 (eg. from Cl esterase 
inhibitor deficiency) (Frank et al. 1976) also result in a lupus-like 
disease, it would appear that low levels of complement could predispose 
an individual to SLE. This could happen in several ways. For example, 
a complement deficient individual may not be able to eliminate a 
pathogen from the body fast enough so that it causes a chronic illness 
or else the subject may not be able to process immune complexes and 
these could be deposited causing the tissue damage seen in lupus.
Figure 1.3 taken from Webb and Whaley (1986) shows possible 
pathways to immune complex disease. An increase in circulating immune 
complexes could result from inherited complement deficiencies, non 
functional complement allotypes, inhibitors of complement activation, 
complement depletion or low levels of CR1 (the C3b/C4b receptor), 
therefore increasing the chances of the formation of insoluble immune 
complexes and precipitation and the development of immune complex
disease.
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1.10.3 COMPLEMENT COMPONENT C4.
Complement component C4 is encoded by two genes in the MHC, C4A and 
C4B (O'Neill et al. 1978), which arose through gene duplication (White 
et al. 1985) and which show considerable polymorphism with at least 13 
C4A and 21 C4B alleles detectable by agarose gel electrophoresis of 
desialized C4 followed by immunofixation (Mauff et al. 1983), making C4 
one of the most polymorphic serum proteins in Caucasoids. More 
polymorphism is evident at the DNA level with a few reported RFLPs 
already subdividing some of the known C4 alleles (Whitehead et al.
1984). Only one RFLP specific for a C4 allele, (C4A*6), has been 
reported (Palsdottir et al. 1983). In addition to the variation in C4 
generated by the large number of alleles at each locus, there can be 
duplication of C4A or C4B loci on some haplotypes (Bruun-Peterson et al. 
1982; Raum et al. 1984; Uring-Lambert et al. 1984), and null alleles of 
both C4A and C4B have been observed.
C4 is synthesized in a proenzyme form, about 200 kDa in size and 
1722 amino acids in length, which is cleaved to produce a protein 
comprised of three polypeptide chains a (95 kDa), ß (75 kDa), and y (30 
kDa) linked by disulphide bonds (Schreiber and Mulier-Eberhard 1974;
Reid and Porter 1981). The a chain of C4A is about 96 kDa in size while 
that of C4B is 94 kDa, however they have been shown to be identical in 
length suggesting that conformational changes are responsible for the 
observed size differences (Roos et al. 1982). Sequencing has shown that 
there are only 15 nucleotides which are different between the C4A and 
C4B proteins (Belt et al. 1985), twelve of which are located close to 
the internal thiolester bond and are responsible for the different
alleles observed and their functional heterogeneity. These base changes
- 25-
FIGURE 1.4 A POSSIBLE MECHANISM FOR DELETION OF THE C4A GENE.
IX
C4A'
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result in amino acid substitutions, six are believed to be isotypic and 
four allotypic. C4A gene products show less haemolytic activity than 
those of the C4B gene, with C4A*6 on certain haplotypes showing the 
least haemolytic activity of all (O'Neill et al. 1980; Teisberg et al. 
1980). Dodds et al. (1985) have shown that the C5 convertase formed 
with C4A*6 is less active which explains the lower haemolytic activity 
of C4A*6.
Homozygous C4A deficiency is not common in the general population, 
estimated to be present in about 1% of individuals while homozygous C4B 
deficiency is more prevalent at the 5% level (O'Neill et al. 1978). 
Complete C4 deficiency is rare and is usually associated with SLE 
(Agnello 1986). In about 50% of cases, C4 null alleles are believed to 
have arisen through deletions (Schneider et al. 1986), which are 
probably due to unequal crossing over, resulting in one chromosome 
having a deletion in a C4 gene (Raum et al. 1984; Schneider et al. 1986) 
(Figure 1.4), but in other cases transcriptional or translational 
defects are believed responsible. It has also been suggested that a C4 
gene could be converted to code for the product at the alternate locus, 
therefore only C4A or C4B alleles would be observed (Palsdottir et al. 
1987). In one family, C4 deficiency has been associated with a gene 
which is not linked to the MHC (Muir et al. 1984). The deficiency was 
incomplete and appeared to be autosomal dominant.
1.10.4 COMPLEMENT COMPONENT C2.
Complement component C2 is encoded by a single gene in the MHC 
which shows 39% amino acid sequence homology (Campbell 1987) and similar 
organization to that of Factor B, (the equivalent of C2 in the
- 2 7 -
alternative pathway), indicating they probably arose through gene 
duplication. The C2 gene encodes a 102 kDa glycoprotein (Kerr and Porter 
1978), which is 732 amino acids in length. C2 is a serine protease but 
shares an uncommon feature with BF in being much longer than the 
majority of serine proteases. C2 does not show such extensive 
polymorphism as C4 with 4 alleles detectable with isoelectric focussing 
followed by a haemolytic overlay, but like C4, greater variation is 
seen at the DNA level (Bentley et al. 1985; Cross et al. 1985).
Southern blot analysis of the C2 gene has shown no major 
rearrangments or deletions in individuals who are C2 deficient (Cole et 
al. 1985). The lack of detectable mRNA in these people led Cole and his 
colleagues to propose that a transcriptional or pretranslational defect 
leads to C2 deficiency. C2 deficiency is stongly associated with the 
MHC haplotype A25.B18.BF*S.C4A*4.C4B*2.DR2(Dw2) with about 67% of C2 
deficient individuals carring this extended haplotype (Hauptmann et al. 
1982). This makes it difficult to say whether the complement deficiency 
or another gene (or genes) on the haplotype are important in the 
pathogenesis of SLE.
1.11 STRUCTURE AND FUNCTION OF THE T-CELL RECEPTOR.
Another group of genes which could be involved in SLE are those 
encoding the T-cell antigen receptor. The TCR recognizes foreign 
antigen in association with the HLA antigens and a defect in the TCR 
could conceivably lead to autoimmunity.
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1.11.1 THE aß RECEPTOR.
The T-cell antigen receptor (TCR) is a polymorphic heterodimer 
responsible in part for discrimination between self and nonself (Yague 
st al. 1985), conferring clonal variability in T-cell recognition of 
antigen/MHC complexes (Dembic et al. 1986). The TCR has a protein 
structure similar to other members of the immunoglobulin superfamily 
with the characteristic immunoglobulin homology unit and both constant 
and variable domains (Hunkarpillar and Hood, 1986). There are two types 
of T-cell receptor, the first is comprised of an acidic a and a basic ß 
polypeptide chain linked with a disulphide bond. The a chain is about 
45 kDa in size while the ß chain is about 40 kDa (Allison et al. 1982; 
Haskins et al. 1983; Meuer et al. 1983a; Meuer et al. 1983b). The aß 
receptor is found on the surface of the majority of T-cells and is MHC 
restricted in activity - that is, it requires compatible or self MHC 
protein to react. The aß receptor on the T-helper subset of lymphocytes 
recognizes antigen in association with an MHC class II protein presented 
on the surface of antigen presenting ceils such as macrophages (Epplen 
1987). Another T-helper cell surface protein, CD4, is also involved in 
this recognition process, possibly increasing the affinity between the 
T-cell and the antigen presenting cell by binding to the MHC class II 
molecule (Epplen et al. 1987). A third T-cell protein, CD3, comprised 
of three polypeptide chains y, 5 and e, (Borst et al. 1983), is 
noncovalently associated with the T-cell receptor and is thought to 
transmit a signal into the cell which triggers T-cell activation (Weiss 
and Stobo 1984; Oettgen et al. 1985; Samelson et al. 1985). T-cytotoxic
Usually
cells also carry the aß receptor butArecognize antigen in association 
with the MHC class I molecule (Epplen 1987). The T-cytotoxic cell
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protein, CD8, is thought to be involved in the recognition of the MHC 
protein and CD3 is believed to transmit an activation signal across the 
cell membrane.
1.11.2 THE y6 RECEPTOR.
The second type of T-cell receptor is comprised of a y and a 
proposed 6 polypeptide chain (Brenner et al. 1986; Moingeon et al. 1986) 
with the y polypeptide chain about 55kDa in size and the putative 5 
chain about 40kDa (Brenner et al. 1986; Littman et al. 1987). This 
receptor is expressed early in T-cell maturation which takes place in 
the thymus. In adults, the y6 receptor is found mainly on the least 
mature T-cells in the thymus, (Fowlkes et al. 1985), and on the 
CD3+CD4“CD8~ subset of peripheral T-cells, (about 2% of T-cells), 
(Brenner et al. 1986; Borst et al. 1987), with both a disulphide and 
non-disulphide linked form of the y6 receptor having been observed 
(Brenner et al. 1987; Borst et al. 1987). Unlike the aß receptor 
carrying cells, T-cells with the y & receptor are not MHC restricted in 
their cytotoxic activity (Borst et al. 1987; Brenner et al. 1987). This 
y6 receptor is associated with the CD3 protein complex which has been 
shown to be involved in signal transduction and activation of Tcr-Y<$ 
lymphocytes (Weiss et al. 1986; Krangel et al. 1987).
1.11.3 T-CELL RECEPTOR GENES.
The genes for the TCR-a, TCR-ß and TCR-y polypeptide chains have 
been localized and characterized , the gene maps to chromosome 7 
(Caccia et al. 1984) at 7q32-35 (Lebeau et al. 1987; Morton et al.
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1985), while the Y. gene is believed to be at 7pl5 (Murre et al. 1985). 
The TCR-a gene is found on chromosome 14 at 14qll-12 (Caccia et al.
1985; Collins et al. 1985). cDNA clones believed to encode the TCR-<5 
protein have recently been isolated (Hata et al. 1987; Band et al.
1987), and the gene is believed to lie just upstream of the TCR-a gene 
cluster (Takihara et al. 1987).
1.11.3.1 TCR-8 GENE ORGANIZATION.
There is a high degree of similarity between the immunoglobulin 
genes and those encoding the T-cell receptor. Like the immunoglobulin 
genes, the TCR genes are encoded by variable (V), joining (J), and 
constant (C) gene segments, and in the case of TCR-3 there is also a 
diversity (D) gene region (Figure 1.5). The TCR-3 gene was the first 
isolated and therefore is the best characterized TCR gene. Of all the 
TCR genes it is the one most like that of the immunoglobulins. There 
are between 60 and 100 TCR-3 variable genes (Concannon et al. 1986a; 
Kimura et al. 1986) with each variable region gene comprised of two 
exons, one for the leader sequence and one for the protein variable 
domain (Siu et al. 1984). The 3' ends of the V region genes are very 
diverse (Concannon et al. 1986b) and it has been shown that some V 
region genes are utilized more often than others (Behlke et al. 1985:
Sim and Augustin, 1985). Between 25-30% of the variable genes are 
thought to be pseudogenes, with maybe 5% or less V region genes actually 
used (Concannon et al. 1986a). The diversity and joining region genes 
are organized into two tandemly linked clusters each associated with a 
single constant region gene, with this organization probably arising
through gene duplication (Toyonaga et al. 1985). The D-J-C region
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covers about 24kb of DNA with six J region genes in each cluster and the 
two C regions about lOkb apart (Toyonaga et al. 1985; Mak et al. 1986). 
The two C regions are composed of four exons each, and shew similar 
sequence and genomic organization, the first two exons encode the 
extracellular domains, the third the transmembrane domain and the fourth 
the cytoplasmic carboxy terminal domain and the 3' untranslated region. 
The 95 bp 3' to the first exon have been shown to be highly conserved 
among C region genes, but the other intron sequences are not (Toyonaga 
et al. 1985). Rearrangements between the V, D, and J gene segments 
occur with the use of recombination signals similar to those seen in the 
immunoglobulin genes (Early et al. 1980; Tonegawa 1983). These are 
immediately adjacent to the V, D, and J coding sequences and comprise a 
highly conserved heptamer followed by a variable spacer and then an AT 
rich nanomer (Toyonaga et al. 1985; Clark et al. 1984; Siu et al. 1984). 
The spacer in between the heptamer and the nanomer is either 12 or 23 bp 
in length, the 12 bp spacer is found 5’ to the D-ß and J-ß genes and the 
23 bp spacers are found 3' to the V-ß and D-ß genes. Early and his 
colleagues showed that a short spacer is always involved in 
recombination with a long spacer in the immunoglobulin genes (Early et 
al. 1980) . Therefore, the arrangement of spacers seen in the TCR genes 
allows optional use of the D and J gene segments.
1.11.3.2 TCR-a GENE ORGANIZATION.
Unlike the TCR-ß gene, the TCR-a gene does not appear to contain 
diversity gene segments but does have a large number of V genes, 
estimated to be from 50 (Yoshikai et al. 1986) to more than 100 (Klein 
et al. 1987). The V region genes can be divided into closely related
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cross-hybridizing families (Yoshikai et al. 1986). Like the TCR-3 V 
genes, the TCR-a V genes are composed of two exons, the first a signal 
peptide and the second encoding the variable protein domain (Yoshikai et 
al. 1985). It has been observed that the coding sequences of the 
joining regions are several codons longer than those of TCR-8 and the 
immunoglobulins and there are many more of them, (Yoshikai et al. 1985) 
covering an area of about 70kb of DNA and separated by about lkb. The 
first J region gene is found about 4kb upstream of the single constant 
TCR-q gene. Recombination signals like those seen in the TCR-8 gene are 
located next to the variable and joining gene segments (Yoshikai et al. 
1985; Baer et al. 1986). The C region genes are comprised of four 
exons, the first two encoding the extracellular domains, the third the 
transmembrane and cytoplasmic tail domains and the fourth the 3' 
untranslated region. The unusual feature of the poly A tail being 
almost entirely encoded by one exon is also seen in the MHC genes (Baer 
et al. 1986; Yoshikai et al. 1985).
1.11.3.3 TCR-Y GENE ORGANIZATION.
The TCR-y gene locus contains at least 9 variable regions covering 
an area of about 54 kb, which can be divided into two groups on their 
DNA homology, one group with 8 members, the other with one (LeFranc et 
al. 1986a). Of the former group, 4 of the 8 have been shown to be 
pseudogenes (LeFranc et al. 1986a). Recombination signals like those in 
the immunoglobulin and other TCR genes have been observed 3' to the 
variable gene segments and 5' to joining segments (LeFranc et al.
1986a). There are two constant genes, about 16kb apart, each associated 
with several joining regions (LeFranc and Rabbitts 1985). The CY1 gene
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ha s three exons but Cy 2 has 4 exons as the second exon has been 
duplicated and both copies have lost the codon for the cysteine residue 
which is thought to be involved in forming the disulphide bond between 
the y and 6 polypeptide chains (LeFranc et al. 1986b; Pelicci et al. 
1987). This explains the two forms of the y<5 TCR which have been seen, 
with use of the Cy 1 gene resulting in the disulphide linked heterodimer 
and use of the Cy2 gene in the non-disulphide linked form (Krangel et 
al. 1987; Littman et al. 1987).
1.11.4 DIVERSITY OF THE T-CELL RECEPTOR.
Diversity in the T-cell receptor is generated by flexibility in the 
joining position of the V, (D), J and C regions when they are rearranged 
as well as the many possible combinations of gene segments. In 
addition, random nucleotides can be added during joining of the V, J, 
(and D) gene segments, (N-region diversity), a phenomenon also seen in 
the rearrangements of the heavy chain immunoglobulin genes (Alt and 
Baltimore 1982). However, unlike the immunoglobulin genes which can 
also generate variablility by somatic hypermutation, TCR genes do not 
use somatic mutation, probably because T cells are first selected for 
nonreactivity against self antigens before leaving the thymus, and 
further somatic mutation after this could result in self reactive 
clones.
1.12 AIMS OF THESIS.
No definite susceptibility gene has yet been found in SLE despite 
some intensive research. Associations with the MHC class I and II
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antigens have been conflicting, and the role of complement C2 and C4 
deficiencies is not clear because of linkage disequilibrium with the HLA 
genes in the MHC. Many serological disorders are seen in lupus, but the 
cause of the autoantibodies remains elusive. Part of the problem in 
studying SLE is the extreme clinical diversity seen in the patients, 
which may be due to different genetic influences. It has been proposed 
the SLE is due to several factors: environmental, such as a virus; 
genetic predisposition, (one or more genes); and accelerating factors, 
such as estrogen (Alarcon-Segovia 1984).
Molecular genetic techniques now make it possible to analyse more 
closely the genetic susceptibility to SLE. Restriction fragment length 
polymorphisms (RFLPs) can be examined to look for unusual RFLPs in 
patients which do not occur in healthy individuals, or an increase in a 
particular RFLP which may reflect linkage disequilibrium with a 
susceptibility gene or locus. Genes for the MHC class II antigens have 
been cloned, so their contribution to SLE can now be studied at the DNA 
level. Many RFLPs in the HLA-D genes have been reported and DNA-DR 
typing is now possible also (Kohonen-Corish and Serjeantson 1986a). 
T-cell antigen receptor genes have been recently isolated, which permits 
examination of these genes, the products of which play an important role 
in the immune response.
This thesis firstly examines RFLPs in the class II DR, DQ and DP 
MHC genes, and applies the technique of DNA-DR typing to SLE patients, 
for whom serological DR typing is not always reliable (Chapter 3). The 
contribution of the class III complement components C2 and C4 to the 
pathogenesis of SLE is examined in three ethnic groups to look at the 
role of these complement deficiencies in SLE, and to compare the 
contribution of the class II and III genes to SLE, which has been a
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problem in the past due to linkage disequilibrium (Chapter 4). T-cell 
receptor genes (a,ß and y) have been examined by RFL? analysis to look 
for unusual rearrangments or unusual clonality in these genes in 
patients with SLE (Chapter 5). Finally, in Chapter 6, Gm phenotypes, 
LCAs, RF and complement component C3 are studied in relation to 3LE, and 
discriminant analysis of all the experimental data is performed to 
search for clinical subsets of SLE and to look for posssible genetic 
combinations which could result in susceptibility to SLE.
In conjunction with this study on SLE, other related connective 
tissue diseases have also been examined to look for susceptibility genes 
in these diseases.
CHAPTER TWO
METHODS
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2.1 INTRODUCTION.
The following methods describe the basic techniques used in the 
work of this thesis. Specific details of particular studies are 
included in the appropriate chapter.
2.1.1 PATIENTS AND CONTROLS.
Patients with SLE and related connective tissue diseases came from 
Sydney where they were reviewed by Dr. Paul Gatenby (Clinical 
Immunologist, Royal Prince Alfred Hospital). Patients with SLE were 
positive for four or more of the American Rheumatism Association Revised 
Criteria for SLE (Tan et al. 1982). Patients with the connective tissue 
diseases scleroderma (progressive systemic sclerosis or PSS), CREST, 
linear scleroderma, Primary Sjogren's syndrome, polymyositis (Pm), 
dermatomyositis (Dm), polymyositis/dermatomyositis (Pm/Dm), mixed 
connective tissue disease (MCTD), and undifferentiated connective tissue 
disease (UNCTD) were also studied. Patients with scleroderma were 
diagnosed according to the ARA preliminary criteria described by Masi et 
al. (1980), while diagnosis of the CREST subset of patients, 
characterized by anti-centromere antibodies, followed guidelines by 
Steen et al. (1984). The few patients studied with linear scleroderma 
were typical of the description by Falanga et al. (1986). Clinical 
features of polymyositis and dermatomyositis described by Bohan and 
Peter (1975) were used in the diagnosis of these patients. Patients 
with undifferentiated connective tissue disease included those with
predominantly musculoskeletal features where a definite diagnosis could
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no t be made (Le Roy et al. 1980), while classic mixed connective tissue 
disease has been described by Sharp et al. (1972). Patients with 
Primary Sjogren's syndrome were diagnosed following guidelines by Fox et 
al. (1986).
In the analysis of experimental results, the following disease 
groups were combined because of low patient numbers: CREST, scleroderma 
and linear scleroderma; Pm, Dm and Pm/Dm; MCTD and UNCTD.
Controls comprised healthy unrelated blood donors from the Woden 
Valley Hospital 31ood Bank in Canberra as well as healthy laboratory 
workers.
2.2 HLA-A, -B, -C, AND -DR SEROLOGICAL TYPING.
HLA-A, -B, -C, and -DR serological typing was performed using the 
standard complement dependent microcytotoxicity test. Heparinized blood 
(50ml) from the SLE and CTD patients was taken in Sydney with informed 
consent and transhipped overnight to Canberra. Heparinized blood (20ml) 
was taken from the controls, with informed consent, and was taken 
immediately to the Canberra laboratory where HLA typing was performed.
Whole blood was centrifuged at 2000 rpm for 10 min and the buffy 
coat layer of white cells harvested. This was diluted 1:2 with 
phosphate buffered saline (PBS; 2% by volume of 0.2M phosphate buffer pH
7.2 in 0.9% NaCl), underlaid with Ficoll-Paque (Pharmacia), and then 
centrifuged at 2000 rpm for 20 min. The white cells were harvested and 
washed with 10% fetal calf serum (FCS) (Flow Laboratories) in PBS, and 
then the platelets were removed with a 20% sucrose gradient at 1000 rpm 
for 10 min. The cells were washed again in 10% FCS in PBS and then the 
T-cells were separated by rosetting with AET treated sheep red blood 
cells (SRBC), (see below for preparation of AET treated SRBC). The
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lymphocytes were suspended in 3 ml 10% FCS in PBS, and 3 ml of 1% AET 
treated SRBC were added. The white cell/SRBC mix was incubated at 37^C 
for 10 min, centrifuged at 2000 rpm for 10 seconds and then incubated at 
4^C for at least 30 min, after which the cells were underlaid with 
Ficoll-Paque and centrifuged for 20 min at 2000 rpm. The non-rosetting 
cells could then be harvested leaving the rosetting T-cells in the 
bottom of the testtube with the SRBC.
2.2.1 T-CELLS.
T-cells were separated from the SRBC by incubation at 37^C for 10 
min with 0.83% ammonium chloride in distilled water, which lyses red 
blood cells. The T-cells were centrifuged down and were then washed 
twice with 10% FCS in PBS, counted and diluted to a concentration of 
2x10^ cells/ml.
2.2.2 NON-ROSETTING CELLS.
The non-rosetting cells were harvested, washed, and resuspended in 
10% FCS in PBS (2ml) and were then treated with 1% iron filings in PBS 
(2 ml) and a further cycle of AET SRBC (2 ml), incubating firstly at 
37^C for ten minutes, centrifuging at 2000rpm for 10 seconds and then 
incubating at 4°C for at least 30 minutes to remove monocytes. The 
B-cells were isolated over a Ficoll-Paque gradient, centrifuging at 2000 
rpm for 20 minutes. The 3-cells were then washed twice in 10% FCS in 
PBS, counted and diluted to 2xl06 cells/ml.
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2.2.3 TISSUE TYPING.
T- and B-cells were loaded onto locally prepared trays, with 60 
wells each, which contained l]il of antisera in each well, covered in 
parraffin oil (Sigma). These trays were stored at -20°C until they were 
used. T- or B-cells (lyl per well) were loaded onto the trays which 
were then incubated at about 22°C for 30 min for the HLA-A, -B, and -C 
typing and 60 min for the HLA-DR typing. Rabbit complement from Pel 
Freeze (5yl) was then added and the HLA-A, -B, and -C trays were 
incubated for a further 60 min and the HLA-DR trays for two hours. The 
cells were stained with a 5% eosin yellow dye (lul/well) and were fixed 
with formalin (2]il/well). The trays were then placed at 4°C overnight 
to allow the cells to settle and were read the next day with an inverted 
light microscope. Most of the antisera used was obtained locally from 
Canberra, or regionally (from Australia). Some of the patients were 
typed with antisera from the Third Asia-Oceania Histocompatibility 
Workshop.
2.2.4 AET TREATMENT OF SHEEP RED BLOOD CELLS.
Sheep red blood cells were treated with 2-aminoethylisothioronium 
bromide hydrobromide (AET, from Sigma) by a modified method of 
Pellegrino et al. (1975). Sheep blood was collected into Alsevers 
solution and the RBC were then washed five times with normal saline. 
Packed SRBC (2ml) were mixed with 10ml of 2% AET in distilled water, pH 
8.0, and incubated for 15 minutes at 37^C, inverting the testtube gently 
every five minutes to mix the cells. The AET treated SRBC were then 
washed five times in normal saline. The AET SRBC were stored at 4^C for 
up to two weeks after which time they were discarded. A 1% solution of
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the AET SRBC in FCS was used for rosetting.
2.3 DNA EXTRACTION, DIGESTION, AND SOUTHERN BLOTS.
2.3.1 DNA EXTRACTION.
Genomic DNA was extracted from huffy coat white cells harvested 
after the first Ficoll-Paque gradient during KLA typing. The huffy coat 
was frozen at -20°C until DNA was extracted. The huffy coat was washed 
three times with 120^5' resuspended in 4ml of the same buffer, and 
incubated overnight at 37°C with 200lil 10% SDS and 400]ll Proteinase K 
from Sigma (10 mg/ml). The suspension was extracted twice with an equal 
volume of Tris pH 8.0 equilibrated phenol-.chloroform: iso amyl alcohol 
(25:24:1), and then twice with an equal volume of chloroform:isoamyl 
alcohol (24:1). The DNA was then ethanol precipitated overnight at -2Q^C 
with 5M NaCl. The precipitated DNA was centrifuged down, air dried and 
resuspended in T^o^l to a concentration of about 0.3 mg/ml
2.3.2 DNA DIGESTION.
The following procedure was used in the digestion of DNA samples:
30tll (lOlig) DNA 
5ul lOx core buffer 
xfil restriction enzyme 
x|il distilled water to 50vil.
Core buffers were made according to manufacturers recommendations at ten 
times the digestion concentration and were stored at -2Q^C in small
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aliquots. The restriction enzymes used were BamHI (Boehringer- 
Mannheim); Bglll (Pharmacia); EcoRI (Boehringer-Mannheim); EcoRV 
(Boehringer-*Mannheim); TaqI (Biolabs); and PvuII (Pharmacia). All 
digests were performed at 37^C overnight with the exception of TaqI 
digests which were done at 65°C for 2 hours.
Digestions were stopped with 2.5]il 0.5M EDTA and the DNA ethanol 
precipated with 2M NaOAc (5]il 2M NaOAc, llOyl ethanol) and placed in dry 
ice for about 30 min. (The digested DNA was sometimes precipitated at 
-20^C overnight or longer) . The DNA was centrifuged down and air dried 
for about 30 min and was then resuspended in 16\!l of T^o^l* Ficoll/dye 
buffer containing bromophenol blue and xylene cyanol (Maniatis et al. 
1982) was added, the samples heated to 65QC for 5 min and then placed on 
ice and loaded onto a gel, which was submerged in buffer. The DNA was 
fractionated on a 0.8% agarose gel in TAE buffer, (0.04M Tris-Acetate, 
0.001M EDTA pH 8.0), using submarine apparatus (Pharmacia, GNA-200).
Gels were 20cm by 20cm and 7mm thick, with 22 wells which held about 
25yl of solution. The DNA was run out of the wells at 90V for about 30 
min and the voltage was then set at 20V overnight. The bromophenol blue 
dye had usually migrated about 11cm when electrophoresis was stopped.
The gels were stained with ethidium bromide for about 20 minutes and 
photographed under UV light with a red filter using a Polaroid camera.
2.3.3 SOUTHERN BLOTS.
The gels were blotted by the method of Southern, (1975) or Reed and 
Mann (1986). With Southern's method, the gels were washed at room 
temperature by gentle shaking for 25 min with 0.25M HCl to depurinate 
the DNA, for 40 min with 0.4N NaOH,0.6M NaCl to denature the DNA and 
then for 40 min with 1.5M NaCl,0.5M Tris pH7.5 to neutralise. The gels
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were blotted onto GeneScreen Plus membranes (New England Nuclear) with 
lOxSSC overnight (lxSSC= 150mM NaCl, 15mM trisodium citrate). The 
membranes were rinsed in 0.4M NAOH for 30 secs and 2xSSC,0.2M Tris pH 
7.5 for 30 secs and allowed to air dry completely. With Reed and Mann's 
method, the gels were washed in 0.25M HC1 for 25 min and were then 
blotted onto Genescreen Plus membranes with 0,4M NaOH overnight. The 
filters were then rinsed in 2xSSC,0.2M Tris pH 7.5 for 30 secs and 
allowed to air dry completely.
2.4 PREPARATION AND NICK TRANSLATION OF THE PROBES.
cDNA probes were prepared following the SDS method described by 
Maniatis et al. (1982). Probes were purified by a CsCl gradient 
(Maniatis et al. 1982).
Probes were nick translated using the Amersham nick translation 
kit, following the manufacturers recommendations. The following 
reaction mix was used:
0.25 to lyg of probe
lOlil nucleotide buffer
3yl to 12hl a-32P dATP or a-32P dCTP
5]il enzyme
x]il distilled water to 50vil
A maximum of lyg of DNA was nick translated in a particular reaction 
mix, with 3ul of radioactive label used per 0.25ug of DNA. The whole 
plasmid containing the probe was used in the nick translation. The 
reaction mixture was mixed well before being incubated at 15^C for 60 
minutes, after which time 2.5]il of 0.5M EDTA was added to stop the 
reaction. The labelled probe was separated from the unincorporated
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radioactive label by passing the reaction mix through a 5ml column of 
Ultrogel (AcA54, LKB) with T10E1* The iabeii-ed P^obe was collected in 
an eppendorf. If the incorporation of the radioactive label was too 
low, the probe was discarded.
2.5 HYBRIDIZATIONS.
Hybridizations were performed following the method of Nasmyth 
(1982) with a few modifications. Filters were placed in plastic freezer 
bags (2 per bag, DNA side out) and were prehybridized in 15ml of 
prehybridization solution for at least 30 min at room temperature. The 
prehybridization solution was prepared in the following way. Distilled 
water (6.8ml or 0.46 total volume) was boiled for ten minutes with 
sonicated salmon sperm DNA (50yg/ml), and was then chilled on ice after 
which 8.1ml of Nasmyth solution was added. The tube was inverted to mix 
the solution and was then added to the bag with the filters making sure 
that the filters were completely wet and there were no air bubbles. 
Nasmyth solution contained 1.1M NaCl, 0.333M Na2HP04 ' EDTA pH
6.2, 1.85% sodium lauroyl sarcosine and 18.5% dextran sulphate. Prior 
to hybridization, any excess prehybridization solution was squeezed out 
of the bag. Hybridizations were carried out in a solution prepared the 
same way but containing lxlOd cpm/ug of labelled probe which was
boiled with the water and salmon sperm DNA. For every lOOcm^ of filter, 
10ml of solution was used with 0.lyg of probe. The hybridization fluid 
was sometimes reused for a second set of filters, with the whole 
hybridization solution boiled for 10 minutes, cooled briefly on ice, and 
then put into the hybridization bag which was sealed after all the air 
bubbles were removed. Hybridizations were carried out at 65^C for 22 to 
44 hours in a shaking water bath.
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Filters were washed at room temperature for 5 min in 2xSSC,0.1%
SDS; at 65°C for 30 min in lxSSC,Q.l% SDS; and at 65°C for 30 min in 
Q.5xSSC,0.1% SDS. The filters were then usually at 5 to 10 cps but if 
not they were given a second wash in the 0.5xSSC,0.1% SDS buffer at 65°C 
for 15 to 30 min. Filters were allowed to air dry (not completely) for 
5 to 10 min and were then wrapped in Glad Wrap. Autoradiography was 
carried out using Fuji Xray film and Lightning Plus intensifying screens 
(Du Pont) in casettes at -70^C for 3 to 7 days. The films were 
developed with an automatic film developer.
2.5.1 REHYBRIDIZATIONS.
The GeneScreen Plus membranes were reused several times with 
excellent results. Probes were stripped from membranes according to 
manufacturers recommendations. The filters were washed in 0.4M NaOH at 
42°C for 30 minutes with a shaking water bath, and then in 0.1xSSC,0.1% 
SDS, 0.2M Tris pH7.5 at 42^C for 30 minutes. Membranes were then air 
dried for five to ten minutes. The membranes were reused with 
prehybridizing and hybridizing carried out as before.
2.6 C4 ALLOTYPING.
C4 typing was performed by the method of Awdeh and Alper (1980) and 
as described by Blake and Radford (1984).
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2.6.1 MATERIALS AND METHOD.
1. 0.2M EDTA pH 7.2: Na2EDTA 37.22g
Na4EDTA 38.40g
Distilled water to 1L
This solution was stored frozen at -20°C, with a working aliquot kept at 
4^C for no longer than one week.
2. Dialysis stock solution: NaH2PC>4 * 2^2°
NaHP04 •H2°
NaEDTA
41.8g 
33. lg
12.5g
Distilled water to 1L
The pH of this solution was about 6.8. This stock solution was diluted 
1:5 with distilled water, with one litre of the diluted dialysis 
solution was for each dialysis. The stock solution was kept no longer 
than one week.
3. Tank buffer: Tris 22.60 g
Glycine 28.10 g
Na barbiturate 6.55 g
Barbituric acid 1.035g
Distilled water to 1L 
pH 8.8
4. Gel solution: Seakem ME (EEO 0.16-0.19) agarose 0.75g
Tank buffer 16.0 ml
0.2 M EDTA 1.6 ml
Distilled water 22.4 ml
The gel solution was boiled until the agarose was completely dissolved 
and then poured into the gel mould which was made as follows. A piece 
of Gel 3ond (24.3cm x 12.5cm) (FMC Marine Colloids Division) was put on 
a glass plate with a little water on the hydrophobic side to bind it to
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the plate. A second glass plate (preferably siliconized) was placed on 
top of the Gel Bond using a lmm silicone gasket to separate the two 
plates. The plates were held together using bulldog clips. When the 
gel was set it was wrapped in Glad Wrap and placed at 4°C overnight. 
Samples (lOvil of plasma) were desialized with neuraminidase (2y.l) from 
Clostridium perfringens (Type VI, Sigma, St. Louis, MO, USA) by placing 
them on cellophane which had been boiled for at least 6 hours to develop 
hydrophobic properties. The cellophane was placed on top of thin 
towelling which had been soaked in the dialysis buffer. One end of the 
towel was in the buffer, while the other end was hanging over the edge 
of the container so that the dialysis buffer could move through the 
towel. Dialysis was carried out at 4°C overnight.
Excess water was removed from the gel where the samples were to be 
loaded using a piece of of Whatman No.l and ehe sample applicator strip 
(made from a piece of Gel Bond with slots 8-10mm long, 0.75mm wide and 
2mm apart) was placed on the gel. Desialized plasma samples (10]il) were 
loaded into the wells and allowed to soak in for about 30 min before the 
applicator strip was removed and electrophoresis was started.
Haemoglobin was used as a marker to check how far the samples were 
moving down the gel. Samples were electrophoresed using LKB 2117 
multiphor equipment, with the current running from the cathode to the 
anode. The gels were electrophoresed for 4 to 5 hours at 80 mA at 6°C, 
and were then overlaid with anti-C4 antiserum (Silenus, Australia) for 1 
hour at room temperature under a glass dish to prevent dessication. The 
gels were then washed gently with tap water, squashed for 10 min and 
soaked in 0.9M saline overnight. The gels were washed again, pressed 
and air dried and stained with Coomassie Brilliant Blue. The gels were 
destained with the same solvent as used in the stain (9 parts methanol,
2 parts glacial acetic acid, 9 parts distilled water).
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2.6.2 HAEMOLYTIC OVERLAY.
A haemolytic assay was performed when C4A and C4B alleles 
overlapped or when it was difficult to assign unusual alleles.
1. Complement Fixation Diluent (CFD). This was made with Oxoid 
complement fixation test diluent tablets (Code BR16). This makes a 
veronal buffered saline solution, pH 7.2.
2. Antibody coated sheep red blood cells. SRBC (10ml) collected into 
Alsevers solution was washed three times with PBS and the packed SRBC 
then made up to a 10% solution. For 1ml of 10% SRBC, 1ml EDTA-PBS 
(0.01M EDTA pH 7.2 in PBS) and 10]il rabbit anti-sheep antibody 
(Wellcome) was added. The SRBC were then incubated at 4^C for 10 
minutes, washed once with EDTA-saline and twice with CFD. The SRBC were 
then reconstituted to a 10% solution in CFD.
After electrophoresis, a border was made around the edge of the gel 
with strips of Whatman (5MM), and overlay containing 7.5ml 2xCFD, 7.5ml 
2% agarose, 750ul antibody coated SRBC, and 750]il C4 deficient serum 
from guinea pigs, was poured evenly over the surface of the gel. The 
gel was then placed at 37°C for 15 to 30 minutes to allow haemolysis.
C4 types were assigned according to the recommendations of Mauff et 
al. (1983). C4 gels were read independently by myself and another 
person.
2.7 C2 ALLOTYPING.
C2 phenotyping was performed as described by Blake and Radford
(1984).
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2.7.1 MATERIALS AND METHOD.
1. Acrylamide stock solution:
Acrylamide 3.35g
N,N-methylene-bis-acrylamide 0.90g 
Taurine 16.68g
Distilled water to 500 mis.
The solution was filtered and stored at 4^C.
2. Gel solution:
Acrylamide stock solution 26.5ml
Ampholyte (LKB ampholine) pH 5-7. 1.5ml
Riboflavin (lmg/100ml) 7.0ml
3. Iodine solution: Potassium Iodide 8.30g
Iodine 0.25g
0.5M phosphate buffer pH 6.0 40.0ml
Distilled water to 100 ml
4. Complement fixation diluent (CFD) and antibody coated SRBC were made 
as described for C4 allotyping.
5. Haemolytic overlay: 2 x CFD 7.50ml
2% agarose 7.50ml
10% antibody coated SRBC 0.75ml 
C2 deficient serum 0.20ml
A gel mould was made from a 1mm thick glass plate 16.5cm x 21.5cm 
and another glass plate 3mm thick, 19cm x 21.5cm. The plates were 
separated by a 1mm thick silicone gasket which was positioned about 
0.5cm from the edge of the glass plates (the two long sides and one of
the short sides). The plates were clamped together with bulldog clips
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and the mould was stood up vertically with the open end uppermost. The 
gel solution was degassed with a vacuum pump and then poured into the 
mould. The gel was left to polymerize under a fluorescent light for 3 
to 4 hours.
Strips of 20mm x 5mm Whatmann 3MM chromatography paper were placed 
at the anodal end of the gel and 20ul of plasma was applied to each 
strip. The gel was isoelectrofocussed using the apparatus described by 
Awdeh (1968), inverting the gel and placing it over carbon rod 
electrodes so it was in continuous contact with the electrodes. The gel 
was isoelectrofocussed at 4^C for about 18hrs with power at 1.5 watts 
per gel, and a maximum voltage of 1000 volts per gel with the initial 
current at 6mA per gel which dropped to about 2mA per gel when the gel 
was focussed. Gels were soaked in the iodine solution for 30 min at 
room temperature and then in lxCFD for 30 min also at room temperature.
A barrier was formed around the edge of the gel using strips of 5MM 
Whatmann chromatography paper and the haemolytic overlay solution was 
poured over the surface of the gel. The gel was then placed in a sealed 
container to prevent dessication and incubated at 4^C for about 60 min, 
and then at 37°C for 2 to 4 hours until bands of haemolysis appeared.
The gel was read by myself and another person.
2.8 C2 DEFICIENCY ASSAY.
The C2 deficiency assay was performed by the radial diffusion assay 
according to the method described by Lachmann and Hobart (1978). Normal 
human serum, was warmed to 37^C and 50ul of the yeast preparation 
(Lachmann and Hobart 1978) was added. The serum was then shaken at 37^C 
for 45 min and centrifuged to remove the yeast. Antibody coated SRBC 
(lml) were diluted to 10ml with lxCFD and warmed to 37^C when one ml of
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the yeast treated serum was added. The mixture was stirred at 37^C for 
70 sec and then 0.2ml of suramin (Antrypol, B.P. Bayer 205) at 50 mg/ml 
was added. This was shaken gently at 37 ^ C for five min and the SRBC 
were then spun down and washed three times with IxCFD. The SRBC were 
then resuspended in 1ml CFD. C2 was destroyed by incubating the SRBC in 
CFD/sucrose (9%) at 37^C for 90min. The red blood cells were washed in 
CFD/sucrose twice after this treatment. A gel was made by mixing the 
following:
7.5ml 2% agarose (56^C)
7.5ml 2x CFD/18% sucrose
100111 C2 reagent (Lachmann and Hobart 1978)
1.0ml Treated SRBC
which was then poured onto a glass slide (12cm x 12cm) which had been 
warned to about 37°C. When the gel was set, holes 2 mm in diameter were 
cut in the gel which were filled with 6ul of test sera at the following 
dilutions: 1:1, 1:4, and 1:8. The gels were incubated overnight at 4^C 
and then placed at 37°C the next day for one to two hours. Clear rings 
of lysis were then visible and were measured against a control who was 
known to have either 100% or 50% levels of C2.
2.9 C3 TYPING.
C3 typing was carried out following the method of Teisberg et al.
(1970).
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2.9.1 MATERIALS ÄND METHOD.
1. Gel buffer: 0.0230M NaBarbitol
Q.0037M Barbitone
0.Q009M CaLactate
Distilled water to 30 ml (gives pH 8.65)
2. Bridge buffer: 0.0610M NaBarbitol
Q.0106M Barbitone
0.0018M CaLactate
Distilled water to 1L (gives pH 8.65)
A gel was made by mixing 0.3g agarose and 30ml gel buffer and boiling to 
melt the agarose. This was then poured onto the surface of a warm glass 
plate (17.2cm x 15.2cm) and allowed to set underneath a glass dish to 
prevent dessication. Wells were cut about 2cm from the cathodal end of 
the gel using a plastic template, and were blotted to take up any 
moisture from the slots. Plasma (5ul) was loaded into the wells, and 
plasma + bromophenol was used as a marker in one well and a control of 
known C3 type FS was also used in one well. Gels were electrcphoresed 
for about 10 min at 25mA, and the wells were then sealed with some left 
over gel solution and the gel electrophoresed at 480V for 2 to 3 hours. 
Cooling plate electrophoresis equipment was used.
The gels were stained according to Johansson et al. (1972). The 
gels were immersed in saturated picric acid:glacial acetic acid (5:1) 
for 15 minutes to fix the protein. The gels were then rinsed in running 
tap water for 2-3 minutes. They were then covered with a sheet of wet 
Whatmann, (No. 1), and several sheets of paper towelling and blotted 
with a 2-3kg weight for 10 minutes. The gels were air dried with a fan 
until the agarose became clear and were then stained with Coomassie Blue 
(0.2%) in methanol: glacial acetic acid: distilled water (9:2:9) which
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was filtered before use. The gels were destained in 2.5% acetic acid, 
2.5% Teepoi in water. The gels were read independently by myself and 
another person.
2.10 TESTING FOR LYMPHOCYTOTOXINS.
Lymphocytotoxins against both B- and T- cells were examined using 
the complement dependent microcytotoxicity test as described for the 
HLA-A, -B, -C, and -DR serological typing. B- and T-cells were isolated 
from healthy controls of known HLA type in the same way as for tissue 
typing, and were tested against SLE sera. The trays were incubated at 
both 4^C and 15^C initially to see which temperature gave the best 
result. The lymphocytotoxins were identified equally well at both 
temperatures so the experiments were then carried out at 15°C. The 
trays were read in the same way as for normal tissue typing.
2.11 STATISTICAL ANALYSIS.
Significance was tested for by the chi square statistic (Armitage 
1971) using 2x2 contingency tables. When any number in a 2x2 cell fell 
below 5, Fisher's exact probablity was calculated (Armitage 1971). 
Statistical methods specific for particular parts of this thesis are 
outlined in the appropriate chapter.
CHAPTER THREE
DR GENOTYPING IN SLE AND OTHER MHC CLASS IIRFLPS
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3.1 INTRODUCTION.
3.1.1 HLA-DR TYPING IN SLE.
Serological HLA-DR typing is notoriously difficult in patients with 
SLE due to multiple autoantibodies including anti-lymphocyte antibodies 
(Terasaki et al. 1970) and low levels of circulating B—lymphocytes 
(Gladman et al. 1979), which are often of poor viability (Stastny 1978). 
Difficulties in HLA-DR typing are further exacerbated when patients 
receive immunosupressive therapy (Hokland et al. 1981; Snyder and Unanue 
1982). In published reports of HLA-DR profiles in SLE patients, 
technical problems in HLA-DR typing have seldom been discussed, although 
one leading histocompatibility laboratory failed to achieve HLA-DR 
typing in as many as 21% of patients tested (Gladman et al. 1979).
When a high proportion of any series cannot be DR typed, there is 
potential for bias in that some HLA-DR antigens may not be as 
confidently typed as others. This phenomenon may well contribute to the 
conflicting findings regarding the particular HLA-DR antigens at risk in 
SLE. HLA-DR2 has been implicated in SLE in some studies of Caucasoids 
(Reinertsen et al. 1978; Reveille et al. 1985) but not in others 
(Scherak et al. 1979; Celada et al. 1979). Similarly, HLA-DR3 has often 
been associated with an increased risk for SLE (Reinertsen et al. 1978; 
Reveille et al.1985) but not consistently (Ahearn et al. 1982).
Unequivocal HLA-DR genotypes can now be established by the 
application of recombinant DNA techniques in healthy individuals 
(Owerbach et al. 1983; Spielman et al. 1984) as well as in patients with 
chronic myelocytic leukaemia (Hui et al. 1985) or with the form of
combined immunodeficiency syndrome (Marcadet et al. 1985) where HLA-DR
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antigens are not expressed. For instance, using the restriction 
endonuclease TaqI and a DRß chain gene probe, each serological DR type 
from DR1 to DRwlO, with the exception of DR3 and DRw6, gives a unique 
and characteristic fragment pattern after hybridization (Kohonen-Corish 
and Serjeantson 1986a; Kohonen-Corish et al. 1986). DR3 and DRw6 show 
similar restriction fragment length polymorphisms (RFLPs) and these two 
DR types are differentiated by their linkage disequilibrium 
relationships with DQa (Spielman et al. 1984; Trcwsdale et al. 1985) and 
DQß (Kohonen-Corish and Serjeantson 1986a) TaqI fragments. By using 
DRß, DQa, and DQß gene probes with TaqI digested DNA, some DR types can 
be subdivided by RFLP patterns that correlate with HLA-D, including DR2 
(Dw2, Dwl2, and Dw"AZHn) and DRw6 (Dw9, Dwl8, and Dwl9). Further, some 
DR types such as DR3, DR5, and DR7 show greater heterogeneity at the 
genomic level than serologically which is useful in studies of HLA 
related diseases and also in population studies.
HLA-DR and -DQ RFLPs have been extensively described in various 
populations in Asia-Oceania (Kohonen-Corish and Serjeantson 1986b; 
Kohonen-Corish et al. 1988) which gives the opportunity to examine HLA- 
DR profiles in SLE in other - populations as well as in Caucasoids, and 
also to see if there are any common RFLP patterns in SLE patients of 
different ethnicities. Studies of HLA-DR profiles in Japanese SLE 
patients have been conflicting as they are in Caucasoid populations.
The HLA-DR2 antigen frequency was increased in SLE patients in one study 
(Hashimoto et al. 1985), but in another, there was an increase of DR4 
(Sakurami et al. 1982). In a third study, HLA-DR4 was decreased in
frequency (Kameda et al. 1982).
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3.1.2 HLA-DR AND HLA-DQ IN CONNECTIVE TISSUE DISEASES.
Few HLA-DR studies have been performed on the lupus like connective 
tissue diseases and similar problems could be expected in HLA-DR typing 
these patients as are seen in SLE. Scleroderma has been associated with 
HLA-DR5 in some studies (Gladman et al. 1981; Briggs et al. 1986) and 
showed a non-significant increase in a third (Mollenhauer et al. 1984), 
but no associations were seen in two other studies (Lynch et al. 1982; 
Niks et al. 1982). It has been suggested that HLA-DR5 is also increased 
in the CREST form of scleroderma (Briggs et al. 1986). One study with 
12 patients with polymyositis reported an increase in HLA-DR3 (Hirsch et 
al. 1980) while primary Sjogren's syndrome has shown associations with 
HLA-DR3 and DQw2 (Wilson et al. 1984). Harley and colleagues (1986) 
have reported an interactive effect between DQwl and DQw2 in Sjogren's 
syndrome patients. Because of the nature of these connective tissue 
diseases and the immunosuppressive therapy that many patients receive, 
HLA-DR typing in these diseases could have been affected as it has been 
in SLE.
3.1.3 HLA-DQ AND HLA-DP GENES IN SLE.
Few studies of SLE have examined the role of the MHC DQ genes in 
the disease. One large study by Ahearn et al. (1982) with 60 white SLE 
patients showed an increase in DQwl compared with controls from the 
Eighth International Histocompatibility Workshop (p<.G05), but the 
increase was not significant when local controls were used. The authors 
suggested that the HLA genes were not the primary susceptibility genes 
but could have had some effect on disease expression. Isolation of the
- 57-
DQa (Schenning et al. 1984) and DQß (Long et al. 1982) genes allows more 
detailed analysis of these genes in relation to SLE. Although many DQa 
and DQß RFLPs show linkage to DR types, some can be used in disease 
analysis, and, as is the case for insulin dependent diabetes mellitus, 
may show closer disease associations than the DR genes (Todd et al.
1987).
There have been no published reports investigating the HLA-DP genes 
in SLE. Until recently, primed lymphocyte typing was the only method 
available to study the DP antigens (Shaw et al. 1980), but monoclonal 
antibodies are now becoming available. A major study of serological DP 
typing has only just been undertaken as part of the Tenth International 
Histocompatibility Workshop. Since the DPa and DPß genes have been 
isolated, a few studies on RFLPs in the DP region have been published 
with some promising results in the area of DNA-DP typing (Hyldig-Nielsen 
et al. 1987; Bodmer et al. 1987).
3.1.4 AIMS.
The present study examines potential bias in serological HLA-DR 
typing of SLE patients by probing TaqI digests of genomic DNA with 
probes of HLA-DRß, DQa, and DQß chain genes to establish HLA-DR 
genotypes in Caucasoid patients. These results are compared with DR 
phenotypes determined by conventional tissue typing techniques. The 
HLA-DR antigen profile as determined by DNA-typing is compared with that 
in appropriate control populations. In addition, HLA-DR profiles in 
Japanese SLE patients are examined by DNA-DR typing. Patients with 
various lupus like CTDs have also been DNA-DR typed and their antigen
profiles are presented.
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HLA-DQ types have been assigned by DNA typing so that DQ 
distributions can be examined in SLE and the connective tissue diseases. 
Further, The HLA-DPß genes have been analysed by RFLP studies in both 
the SLE and CTD patients.
3.2 MATERIALS AND METHODS.
3.2.1 PATIENTS AND CONTROLS.
Caucasoid patients with SLE and the connective tissue diseases 
scleroderma, CREST, primary Sjogren's syndrome,
polymyositis/dermatomyositis (Pm/Dm), mixed connective tissue disease 
(MCTD), and undifferentiated connective tissue disease (UNCTD) were 
reviewed in Sydney by Dr. P. Gatenby and blood was sent overnight to 
Canberra where serological HLA class I and II typing was performed. 
Buffy coat white cells were separated and stored frozen at -20°C until 
DNA was extracted.
Caucasoid controls comprised 39 random blood bank donors from 
Canberra and 30 healthy laboratory personel.
Japanese SLE patients were reviewed by Dr. S. Naito and were 
-examined serologically for HLA class I and II antigens as part of the 
Third Asia Oceania Histocompatibility Workshop (Naito et al. 1986). 
Buffy coats from the patients and controls were sent frozen in dry ice 
to Canberra where DNA was extracted for DNA-DR analysis.
3.2.2 SEROLOGICAL HLA CLASS I AND II TYPING.
All the Caucasoid patients were HLA-A, -B, and -C typed and a
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random subset of these were also HLA-DR typed serologically as described 
in Chapter 2. The blood bank controls and some of the laboratory 
personel were HLA-A, -B, -C, and -DR typed serologically while the 
remaining controls were typed only for HLA class I antigens.
The Japanese patients and controls were typed for HLA-A, -B, -C, 
and -DR antigens in Japan by Dr. S. Naito.
3.2.3 DNA-DR TYPING.
Genomic DNA was prepared from the patients and controls and was 
then digested with TaqI and transferred to GeneScreen Plus membranes as 
described in Chapter 2. The filters were hybridized with probes for
DRß, DQa, and DQß following the protocol in Chapter 2. DRß/Taql RFLP
associations with DR antigens have been described (Kohonen-Corish and 
Serjeantson 1986a; Serjeantson et al. 1986) and the most common 
Caucasoid RFLP DRß/Taql patterns and their corresponding DR types are 
summarised in Table 3.1. DQa/TaqI RFLPs (Trowsdale et al. 1985) and 
DQß/Taql RFLPs (Kohonen-Corish and Serjeantson 1986a) correspond with DR 
types due to linkage disequilibrium, and the DQ and DR associations are 
presented in Table 3.2. DQß/BamHI RFLPs also correlate with DR types
(Owerbach et al. 1983) and the 3.7kb and 12kb fragments can be used in
subsetting some DR types (Kim et al. 1985) and these are also shown in 
Table 3.2.
3.2.4 OTHER HLA CLASS II HYBRIDIZATIONS.
SLE and CTD patients were examined for DRa and DPß RFLPs following 
the methods described in Chapter 2.
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TABLE 3.3 SOURCE AND DESCRIPTION OF PROBES.
PROBE DESCRIPTION REFERENCE SOURCE
DRa llOObp 
in pBR322
Stetler et al. 1982 Dr. H. Erlich, 
Cetus Corporation
DRß 1300bp 
in pBR322
Lonq et al. 1982 D r . B . Mach, 
University of Geneva
DQa 500bp 
in pBR322
Schenninq et al. 1984 D r . D . Larhammar, 
University of Uppsala
DQg 1250bp 
in pBR322
Lonq et al. 1982 D r . B . Mach, 
University of Geneva
DPß 50,100,and 
700bp
Gustafsson et al. 1984 D r . D . Larhammar, 
University of Uppsala
TABLE 3.4 PROBE/ENZYME COMBINATIONS USED.
PROBE ENZYME REFERENCE
DRa Bglll Stetler et al. 1982
ScoRV Erlich and Stetler 1984
DRß TaqI Kohonen-Corish and Serjeantson 1986a
DQa TaqI Trowsdale et al. 1985
DQß TaqI
BamHI
Kohonen-Corish and Serjeantson 
Owerbach et al. 1983
1986a
DPß Bglll
EcoRV
Kohonen-Corish 1987 
Kohonen-Corish 1987
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FIGURE 3.1: DRß hybridization of TaqI digested DNA from SLE patients.
DR types are indicated at the top of each lane.
DR 4,7  1,9 1,4 5 , -  5 ,8  3s ,4 2,5 3s,6l 7,8 1,2 6s,4
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3.2.5 PROBES.
The probes used in this study are shown in Table 3.3, and the 
probe/restriction enzyme combinations are given in Table 3.4.
3.3 RESULTS.
3.3.1 DNA-DR TYPING.
An autoradiograph of genomic DNA from SLE patients digested with 
TaqI and probed with DRß is shown in Figure 3.1. The results clearly 
show the DR types of the patients, with the characteristic DNA fragments 
associated with each DR type. Only HLA-DR3 and -w6 cannot be 
distiguished by DRß/TaqI hybridizations, but their linkage relationships 
with DQa and DQß can be used to differentiate between them and to assign 
Dw types. Hybridizations of TaqI digested DNA probed with DQa or DQß 
are shown in Figures 3.2 and 3.3 respectively. The DRw6 subtype DRwl3 
has either a 6.8 (Dwl8) or 6.2kb (Dwl9) DQa/TaqI fragment while DRwl4 
(Dw9) has an alternative 2.9kb fragment; DR3 has a characteristic 5.0kb 
TaqI/DQa fragment which it shares with DR5. These linkage relationships 
have already been described by Trowsdale et al. (1985), who assigned 
slightly different sizes to the DNA fragments. Similarly, DRw6 positive 
cells have either a 5.5kb (Dwl9) or 3.0kb (Dwl8) DQß/TaqI fragment which 
is absent from DR3 positive cells (Kohonen-Corish et al. 1986a). DR2 
can also be subdivided by its linkage relationships with DQa and DQß 
TaqI RFLPs, such that Dw2 has a 6.2kb DQa/'Taql fragment and a 3.0kb 
DQß/Taql RFLP while Dwl2 has a 6.8kb DQa/TaqI fragment and the 
monomorphic DQß/Taql fragments. The Dw"AZH" specificity in Caucasoids
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FIGURE 3.2: a. DQa hybridization of TaqI digested DNA.
b. DQß hybridization of TaqI digested DNA.
c. DQß hybridization of BamHI digested DNA.
a. DQa/Taql b. DQß/Taql
-III
- 5.7
- 5.0
- 2.9
c. DQß/BamHI
-  6.7
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has a 6.2kb DQa/TaqI and a 5.5kb DQß/Taql fragment. One variant of DR2 
does not have the usual DRß/Taql RFLPs associated with DR2 but instead 
has four fragments, 15kb, 4.4kb, 2.2kb, and 1.7kb in size. This DR2 
pattern has also been seen in the Tenth International Histocompatibility 
Workshop cell line called KAS011 (Dr. S. Serjeantson, personal 
communication). This DR2 variant was seen both in the Caucasoids and 
Japanese examined here, but was not common.
3.3.2 RELIABILITY OF SEROLOGICAL DR TYPING IN SLE.
A sample of 39 of the total 69 controls typed at the DNA level as 
well as by traditional serological techniques showed excellent 
correlation (r=0.99, p<.01) between DNA-DR typing and serological DR 
antigen assignment. One error occurred, in the non-assignment of a DR5 
antigen. The excellent correspondence between DRß chain RFLPs and HLA- 
DR types in controls confirms the reliability of DNA typing and the 
suitability of applying this technique in SLE patients. There were no 
TaqI DRß fragments seen in the patients that did not occur in the 
controls.
The correlation of serological DR assignment with DNA-DR assignment 
in SLE patients is shown in Table 3.5. It can be seen that 35% of DR 
antigens in SLE patients could not be assigned at all. The success of 
serological antigen assignment was non-random with DR2 and DR3 more 
readily typed than DR5 and DRw6(wl3). These differences were 
statistically significant. The chi-square value for ease of typing DR2 
compared with DRwl3 was 6.8 (p <.Q1) and compared with DR5 was 
6.0 (p <.05).
Similarly DR3 was significantly more readily assigned than DR5 or
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TABLE 3.5 CORRELATION OF SEROLOGICAL DR TYPING WITH 
DNA-DR TYPING IN SLE.
DNA-DR
Assignment
Serological DR antigen assignment 
Correlation with DR type (%).
Antigen Number Agree Disagree No result
DR1 10 60.0 20.0 20.0
DR2 9 77.8 22.2
DR3 27 77.8 3.7 18.5
DR4 16 56.3 43.6
DR5 7 14.3 28.6 57.1
DRw 13 11 18.2 18.2 63.6
DRw 14 1 0.0 100.0 0.0
DR7 10 60.0 40.0
DRw8 0 - - -
DRw9 1 0.0 100.0
DRw 10 0 - - -
Total 92 56.5 8.7 34.8
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TABLE 3.6 DR GENE FREQUENCIES IN CAUCASOID SLE ÄND CTD PATIENTS 
COMPARED WITH CONTROLS.
FREQUENCY
CONTROLS SLE PSS/CREST SJOGREN’S PM/DM MCTD/UNCTD
DNA-DR
TYPE N % N % N % N % N % N %
DR1 8 5.8 15 9.1 9 16. la 0 3 10.0 5 13.2
DR2 (Dw2) 22 15.9 23 14.0 5 8.9 4 28.6 4 13.3 5 13.2
(Dwl2) 2 1.4 0 0 0 0 0
(DwKASOll) 0 1 0.6 1 1.8 1 7.1 0 0
DR3 18 13.0 39 __ _ *23.8 4 7.1 6 42.9C 8 26.7 4 10.5
DR4 32 23.2 25 15.2 7 12.5 1 7.1 6 20.0 7 18.4
DR 5 11 8.0 17 10.4 17
XXoCO 0 2 6.7 4 10.5
DRw 13 14 10.1 15 9.1 4 7.1 0 0 d 4 10.5
DRw 14 7 5.1 4 2.4 1 1.8 0 0 4 10.5
DR7 19 13.8 24 14.6 4 7.1 1 7.1 5 16.7 3 7.9
DRw8 3 2.2 1 0.6 2 3.6 1 7.1 2 6.7 0
DRw9 1 0.7 0 2 3.6 0 0 1 2.6
DRw 10 1 0.7 0 0 0 0 1 2.6
Number 69 82 28 7 15 19
Tested
*  X2=4.6, p<.05 1 a X2=5.3 , P< .05
b X2=16.0, p<.001 c X2=8.5 , P<:.005
d X2=5.2, p<.05
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DRwl3 at the 1% level. Some errors in antigen identification did occur, 
as shown in Table 3.5, but no systematic error emerged.
3.3.3 HLA-DR IN THE CAUCASOID SLE PATIENTS.
The frequencies of DNA-DR types in SLE compared with controls are 
shown in Table 3.6. The frequencies are markedly similar between SLE 
patients and controls, apart from DR3 which is increased in the SLE 
patients. This is statistically significant with a X^ value of 4.6 
(p C.05) and relative risk of 1.5. The chi-square value has not been 
corrected for the number of antigens tested due to a priori hypothesis 
(Arnett et al. 1984) of an increase in DR3 antigen frequency in SLE.
3.3.4 HLA-DR IN CONNECTIVE TISSUE DISEASES.
HLA-DR distributions for the CTD patients are also shown in Table
3.6. A significant increase in DR5 compared to controls was seen in the
PSS/CREST group (X^=16.2, p<.001), which was also seen when both patient
groups were analysed individually, with X^=ll.l (p<.001) in the 13
scleroderma patients and X^=9.4 (p<.Q05)in the 15 CREST patients. DR1
was also significantly increased in the PSS/CREST group (X^=5.3, p<.05).
The Sjogren’s syndrome patients had a significant increase in HLA-DR3
(X^=8.5, p<.005), but only 7 patients with primary Sjogren's syndrome
were examined. The only other significant change in DR distributions in
the CTD patients was a decrease in DRw6 in the Pm/Dm disease group
(X^=5.2, p<.05), with none of the fifteen patients positive for either 
1
of the DRw6 splits, DRwl3 or DRwl4.
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3.3.5 HLA-DQ IN THE CAUCASOID SLE ÄND CTD PATIENTS.
The SLE and CTD patients were examined for HLA-DQ types which were 
assigned according to linkage disequilibrium relationships with HLA-DR.
As shown in Table 3.7, the SLE patients showed no significant 
differences compared with the controls in DQ distributions, with the 
increased frequency of DQw2 in the SLE disease group only approaching 
significance (X2=3.1, p>.05)
DQw2 showed an increased frequency in the Pm/Dm patients (X2=3.9, 
p<.05), but this is not significant when corrected for the number of 
antigens tested for. The PSS/CREST patients had an increase in 
DQw3/TA10+ (X2=13.4, p<.001), but when corrected for the number of 
antigens tested, the X2 value only approached significance (X2=3.3,
P> • 05) .
3.3.6 DQß/BamHI RFLPs IN THE SLE AND CTD PATIENTS.
The DQß/BamHI RFLPs show associations with serological DR 
specificities (Owerbach et al. 1983) and can be used as an adjunct to 
the Taql/DRß, /DQa, and /DQß RFLPs in DNA-DR typing. HLA-DR4/DQw3 cells 
can also be subdivided according to sizes of DQß/BamHI fragments, such 
that TA10 positive cells have a 3.7kb fragment and TAlQ-negative cells 
have instead a 12kb fragment (Kim et al. 1985) . There was a similar 
level of DR4-positive, TAlO-positive or DR4-positive, TAlO-negative 
cells in the SLE and CTD patients as in the controls. None of the other 
DQß/BamHI RFLPs showed an increase in any of the SLE or CTD patients
with the RFLPs correlating with expected DR types.
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3.3.7 HLA-DRa/Bqlll RFLPs IN SLE AND THE CTD PATIENTS.
As described by Stetler et al. (1982), DNA digested with 3glII 
gives four RFLPs, 4.5kb, 4.4kb, 3.9kb and 0.7kb in size, with the 3.9kb 
and 0.7kb fragments invariably occurring together. These DR types show 
linkage with HLA haplotypes (Serjeantson et al. 1986). The 4.5kb 
fragment occurs on the B18.DR3 haplotype while the 4.4kb RFLP is seen in 
B8.DR3 positive cells as well as DRwl3 (Dwl8) positive cells. The 3.9kb 
and 0.7kb fragments are associated with DR1, DRwlQ and Bw57.DR7 positive 
haplotypes. These same associations are seen in the SLE and CTD 
patients studied here with no unexpected occurrences. No other 
DRa/Bglll RFLPs were seen in the SLE or CTD patients.
3.3.8 HLA-DP IN SLE AND THE CONNECTIVE TISSUE DISEASES.
The DPß gene in SLE and CTD patients was examined by RFLP analysis 
with the restriction enzymes Bglll and EcoRV. Two allelic fragments are 
observed with Bglll, approximately 20kb and 2.8kb in size, (Stetler et 
al. 1982), while EcoRV also gives two polymorphic fragments about 12kb 
and 8kb long, (Erlich and Stetler 1984). The DPß/Bglll phenotype and 
allele frequencies are shown- in Table 3.8. No significant differences 
were seen between the controls and SLE or CTD patients in phenotype or 
allele frequencies and all phenotype distributions were in Hardy- 
Weinberg equilibrium. DPß/EcoRV allele frequencies and phenotype 
distributions in the controls and patients are given in Table 3.9. The 
SLE and CTD patients did not differ from the controls in frequencies of 
the DPß/EcoRV RFLPs. A recent report (Hyldig-Hielsen et al. 1987) shows
that these DP RFLPs correlate with functional DP epitopes, with the
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BglII/2.8kb and EcoRV/8kb fragments found in DPw2 and DPw4 ceils, and 
the BglII/19kb and EcoRV/12kb fragments seen in DPwl, w3, w5, and w6 
positive cells.
3.3.9 HLA-DR AND HLA-DQ IN JAPANESE PATIENTS WITH SLE.
A significant number of the Japanese SLE patients could not be DR 
typed serologically and DNA-DR typing proved very useful as it had been 
in Caucasoids. DRß/Taql RFLPs in Japanese were the same as those seen 
in Caucasoids, with the exception of one DR5 associated RFLP and one 
rare DR4 variant pattern. The DR5 pattern occurs in Micronesians from 
Nauru and has been designated DR5*Nauru (Kohonen-Corish and Serjeantson 
1986b). Instead of the usual 12kb and 6.0kb DRß/Taql fragments seen in 
most DR5 positive Caucasoids, DR5*Nauru has a lOkb and a 4.4kb fragment. 
While DR5 in Caucasoids is associated with a 5.0kb DQa/TaqI fragment, 
DR5*Nauru in the Japanese is associated with either a 5.0kb or 6.2kb 
fragment. The DQa and DQß RFLP associations with other DR types were 
essentially the same in the Japanese as Caucasoids except for DRw8 which 
usually had a 6.8kb DQa/TaqI fragment rather than the 6.2kb fragment 
which is seen in Caucaoids. The DR and DQ RFLP patterns in Japanese 
compared with other populations in Asia-Oceania have been reported 
(Kohonen-Corish et al. 1988).
Table 3.10 gives DNA-DR frequencies in the Japanese SLE patients 
and controls. DR3 and DR7 were rare in the Japanese which is compatible 
with serological studies in this population. No significant differences 
were seen in the DR distributions between the SLE patients and controls 
with the increase in DR2 only approaching significance (X^=3.0, p>.05). 
However, when DR2 was subdivided into RFLP types corresponding to HLA-D
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TABLE 3.10 DNA-DR FREQUENCIES IN JAPANESE SLE PATIENTS
AND CONTROLS.
DNA-DR TYPE
FREQUENCY
CONTROLS (n=39) SLE (n=40)
N % N %
DR1 7 9.0 3 3.8
DR2 (Dw2) 6 7.7 16* 20.0
(Dwl2) 7 9.0 6 7.5
(KAS011) 2 2.6 3 3.8
DR3 1 1.3 2 2.5
DR4 16 20.5 14 17.5
DR5 3 3.8 4 5.0
DRw 13 6 7.7 3 3.8
DRw 14 3 3.8 3 3.8
DR7 0 0
DRw8 11 14.1 13 16.3
DRw9 15 19.2 13 16.3
DRw 10 1 1.3 0
* X^=5.0, p<.05
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specificities Dw2, Dwl2 and Dw,,KAS011" , Dw2 was significantly increased 
(X2=5.0, p<.05) in patients compared with controls.
KLA-DQ distributions were very similar between the Japanese SLE 
patients and controls, with DQwl present in 41.0% of controls and 42.5% 
of patients, DQw2 seen in only 1.3% of controls and 2.5% of patients, 
and DQw3 present in 57.7% of controls and 55.0% of the SLE patients. 
Only one TAlO-positive individual (an SLE patient) was seen in the 
Japanese studied here.
3.4 DISCUSSION.
3.4.1 DNA-DR TYPING IN SLE.
This study demonstrates an important application of DNA-DR typing 
techniques in an HLA associated disease where HLA-DR phenotypes cannot 
always be assigned using conventional tissue typing procedures. In SLE, 
investigations of HLA-D specificities using mixed lymphocyte cultures 
have proved technically unsuccessful (Arnett et al. 1984) due to poor 
viability of patient lymphocytes. Serological HLA-DR typing is 
similarly difficult in SLE patients. The situation is further 
exacerbated in patients undergoing corticosteroid therapy, due to 
decreased antigenic expression (Hokland et al. 1981; Snyder and Unanue 
1982). In a study of white SLE patients (Gladman et al. 1979), one 
fifth could not be HLA-DR typed and in the current series, HLA-DR 
antigen assignment was not possible in one third of the SLE patients. 
This high failure rate has the potential to introduce bias into studies 
of HLA-DR antigens at risk for SLE, and there is also the potential for 
a systematic error in incorrect assignment of HLA-DR antigens. In a
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series of SLE patients described by Ahearn et al. 1982, HLA-DR 
determinations were performed in duplicate and an unspecified proportion 
of patients was necessarily recalled when duplicated DR typings were 
discrepant.
In the current study, HLA-DR antigen assignment on serological 
results was attempted in 46 patients and 43% of the 92 antigens were 
either not detected or were designated incorrectly when compared with 
the DNA-DR typing results. This serious error rate can be compared with 
that in a healthy control series typed with the same HLA-DR antisera, 
where only 1% of the DR antigens were assigned incorrectly.
Given the high error rate in HLA-DR typing in SLE patients, the 
question remains as to whether the apparently conflicting results in the 
literature regarding the correlation of DR2 (Reinertsen et al. 1978; 
Reveille et al. 1985) and DR3 (Scherak et al. 1979; Celada et al. 1979) 
with SLE can be attributed to technical errors. In the current series, 
HLA-DR2 was correctly identified more often than any other antigen 
except DR3 and significantly more so than DRwl3 and DR5; that is, the 
frequency of DR2 was overestimated when using serological typings. In 
earlier studies, this problem may have been exacerbated by mistyping.
The definition of DRw6 has been difficult even in healthy individuals 
(Schreuder et al. 1984) and was first described in 1977 during the 
Seventh International Histocompatibility Workshop (Bodmer et al. 1978) 
using multispecific sera, HLA-DR2 + w6 and HLA-DR3 + w6. In the Eighth 
Histocompatibility Workshop in 1980, again, no monospecific sera could 
be defined and DRw6 was defined by DR3 + w6 sera. Thus, in DR3 positive 
indivduals, HLA-DRw6 has proved particularly difficult to assign, in 
this as well as in earlier studies.
Technical problems are not of course the only factors contributing
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to the conflicting reports regarding the association of DR2 or DR3 with 
SLE. If HLA-DR3 is not the primary susceptibility locus but is linked 
on chromosome 6 to the disease promoting genes, then different linkage 
disequilibrium relationships in different populations could account for 
the conflicting findings. Also, since SLE is a heterogeneous disorder, 
lack of clinical uniformity between different studies could account for 
discrepant reports in DR antigen frequencies. For instance, it has been 
claimed that the haplotype HLA-A1.B8.DR3 relates to more severe disease 
with higher titres of anti-DNA antibodies and HLA-B7.DR2 with milder 
disease (Christiansen et al. 1983; Griffing et al. 1980). However, in 
this study where unequivocal HLA-DR typings were available for all 
patients tested, HLA-DR3 was clearly and significantly associated with 
an increased risk for SLE and HLA-DR2 was not.
3.4.2 HLA-DQ IN SLE.
The increase in DQw2 frequency in the Caucasoid SLE patients is a 
consequence of the linkage disequilibrium between DQw2 and DR3. DQw2 
RFLPs, when in linkage with DR7 did not increase in frequency in SLE 
patients. Ahearn et al. (1982) have reported an increase in DQwl in 
SLE, but in their study DR2 was increased, so linkage disequlibrium may 
again be responsible. As the authors noted, the increase in DR2 was 
more significant than the increase in DQwl. It was also reported 
(Ahearn et al. 1982) that DQwl positive patients had an increase in nRNP 
while those with DQw2 had an increase in anti-Ro antibodies, so it is 
possible that DQ antigens are segregating with different clinical 
subsets of SLE. This correlation between HLA class II RFLPs and
clinical subsets of SLE is investigated further in Chapter 6.
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3.4.3 HLA-DR AND HLA-DQ IN THE CONNECTIVE TISSUE DISEASES.
HLA-DR5 was increased in the CREST and PSS patients studied here 
which is in agreement with other studies of these diseases (Gladman et 
al. 1981; Briggs et al. 1986). DR1 was also increased in the CREST/PSS 
patients. Whether these are the primary susceptibility genes or are 
linked to the disease promoting locus cannot be determined and 
comparisons between different ethnic groups would be of value, as was 
shown here for SLE. PSS has shown associations with null genes at the 
complement component C4 loci and DR1 is linked to C4B*Q0 on certain 
haplotypes. DR5, however, is not linked to genes encoding complement 
deficiencies.
While an association was seen between DQw3 and the connective 
tissue diseases CREST and scleroderma, this may be because of linkage 
disequilibrium with the DR antigens, in particular with DR5 which was 
significantly increased.
Earlier studies have shown DR3 and DQw2 to be increased in patients 
with primary Sjogren's syndrome (Wilson et al. 1984), and with the small 
numbers of patients studied here, the same increases were seen. The 
association of DQw2 may be secondary to the DR3 increase due to linkage 
disequilibrium.
The only other connective tissue disease with a significant change 
in DR or DQ distributions was the polymyositis/dermatomyositis group 
where none of the 15 patients were positive for DRwl3 or DRwl4. This 
could have been an effect of the small patient numbers. DR3 was 
increased in one study of 12 polymyositis patients (Kirsch et al. 1980)
and a similar trend was seen in the current study.
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3.4.4 HLA-DP RFLPs IN THE SLE AND CTD PATIENTS.
From the RFLPs examined in the DP genes, using Bglll and EcoRV, 
there does not appear to be any association with SLE or the connective 
tisssue diseases studied here. With the recent advances in DNA-DP 
typing, it should now be possible to correlate functional variation in 
HLA-DP with SLE and the CTDs.
3.4.5 DR TYPING IN JAPANESE SLE PATIENTS.
The Japanese SLE patients here showed a significant increase in 
DR2(Dw2) RFLPs. This is in accord with the previous findings of an 
increase in DR2 (Hashimoto et al. 1985). There was no decrease in DR4 
as observed by Kameda et al. (1982) in Japanese SLE patients. Since the 
increased risk for SLE is associated with DR2(Dw2) in Japanese and with 
DR3 in Caucasoids, it would seem that HLA-DR is not the primary disease- 
promoting gene but is in linkage disequilibrium with a disease 
susceptibility locus.
3.5 CONCLUSION.
In this study, DNA-DR typing has shown errors in serological DR 
typing of Caucasoid SLE patients which is partially systematic. This 
could cause inflation in the estimate of DR2 antigen frequencies. The 
practical application of recombinant DNA techniques in HLA-DR typing has 
shown HLA-DR3, but not HLA-DR2, to be significantly associated with an 
increased risk for SLE in Caucasoids. No association was seen between
SLE and the DQ antigens, nor with DP RFLPs in the Caucasoid patients.
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DNA-DR typing has also been useful in the study of Japanese 
patients with SLE, revealing an increase in Dw2 in the patients. DQ 
does not appear to be associated with SLE in the Japanese.
An increase in DR5 in the CREST/PSS patients with DNA-DR typing 
supports earlier serological observations, but the patient numbers in 
the other CTDs examined are too small to make definite conclusions. No 
strong associations were seen between the connective tissue diseases and 
DQ or DP genes.
CHAPTER FOUR
COMPLEMENT AND SLE
4.1 INTRODUCTION.
Complete deficiencies of complement components C4 and C2 have 
clearly been associated with SLE in several studies (reviewed by Agnello 
1986; Atkinson 1986). Homozygous C2 deficiency is the most common 
complete deficiency of complement and was the first complement 
deficiency associated with SLE. Of the published cases of homozygous C2 
deficiency, about 75% of the individuals suffer from SLE or an immune 
complex mediated illness such as glomerulonephritis. Complete 
deficiency of C4 is rare as this requires four null or defective genes, 
but of the 15 reported individuals with complete C4 deficiency, eight 
had SLE and another three had an an SLE like disease. Partial C4 
deficiency has also been implicated in SLE in some studies (Fielder et 
al. 1983; Reveille et al. 1985), as has partial deficiency of C2 (Glass 
et al. 1976), although one study (Christiansen et al. 1983) reported no 
increase in C2 deficiency in their patient series. However, because of 
the linkage disequilibrium between the MHC class I and II genes, the 
importance of partial C2 and C4 deficiencies in the pathogenesis of SLE 
has been difficult to determine.
While complete deficiency of C4 or C2 could understandably lead to 
an immune complex disease, the mechanism of partial deficiency is less 
clear when an individual may, for example, have three functional C4 
alleles and only one null allele. The situation becomes more confusing 
when considering the many healthy people who have partial deficiencies 
of C2 or C4. In fact, the first reported case of complete C2 deficiency 
was seen in an immunologist who donated some blood for a complement 
fixing experiment which didn't work (Silverstein 1960).
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It is now becoming evident that C4A and C4B alleles have different 
biological properties, which was initially seen when C4B alleles showed 
greater haemolytic activity than C4A alleles. This has become the basis 
for differentiating between overlapping C4A and C4B alleles when C4 
allotyping (Awdeh and Alper 1980). C4B has now been shown to react more 
quickly than C4A with hydroxyl groups which are found in abundance on 
the surface of red blood cells (Isenman and Young 1984; Law et al.
1984). The relative importance of C4A and C4B null alleles in SLE is 
not clear with two previous studies of SLE and complement component C4 
showing an increase of C4A and C4B in familial SLE (Fielder et al. 1983; 
Reveille et al. 1985), while another study by Christiansen et al. (1983) 
indicating that only C4A*Q0 was increased in lupus. A recent study of 
DR3-negative SLE patients has shown an increase in C4B*Q0 (Batchelor et 
al. 1987).
One problem with studying C4 deficiencies in SLE is that it is 
sometimes difficult to assign null alleles by gel electrophoresis 
results, as this is dependant on differences in staining intensity 
between the C4A and C4B alleles. This becomes impossible when an 
individual is both heterozygous C4A and C4B deficient, as the C4A:C4B 
density ratio remains 1:1. Examination of serum C4 levels to look for 
C4 deficiencies is net always reliable because of the wide range in 
different people (Schur 1986). To attempt to solve this problem, 
studies have been made at the genomic level to search for RFLPs that 
will detect C4 null alleles.
Several investigators have reported a TaqI RFLP with a 21-CH probe 
which detects null alleles on the two haplotypes A1.B8.DR3.C4A*Q0 and 
318.DR3.C4B*Q0 (White et al. 1984; Carroll et al. 1985; Garlepp et al.
1986). A 3.2kb fragment is absent in individuals homozygous for these
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haplotypes due to a large deletion encompassing either the C4A or C4B 
gene and the 21-OHA gene. However in individuals heterozygous for one 
of these haplotypes, differences in density between the 3.2kb band and 
other RFLPs are required to detect the null allele and this is not 
always a reliable method. One RFLP has been reported to identify 
individuals with a deleted C4A gene (Carroll et al. 1985) with a 15kb 
Hindlll fragment lost and an 8.5kb fragment gained when the probe pAT-A 
(Belt et al. 1985) is used. However not all C4 deficiencies are 
believed to have arisen through deletions. Schneider et al. (1986) 
estimate that 50% of C4A or C4B null alleles are the result of large 
deletions in the C4 genes that also include part of one of the 21-OH 
genes which flank the C4 genes. The basis of the remaining 50% of null 
alleles is not known, and at the moment cannot be detected by RFLPs.
One possibility put forward by Palsdottir et al. (1987) is that of gene 
conversion so that a chromosome could end up with two C4A or two C4B 
genes.
In addition to the problems of assigning C4 null genes, linkage 
disequilibrium within the MHC makes it difficult to determine what gene 
is the most important in contributing to SLE. For example, in 
Caucasoids, DR3 has been reported to be increased in SLE (Reinertsen et 
al. 1978; Reveille et al. 1985) as have C4A and C4B null'alleles 
(Fielder et al. 1983: Reveille et al. 1985; Christiansen et al. 1983). 
However, C4A*Q0 is in linkage disequilibrium with the haplotype 
A1.B8.DR3, while C4B*Q0 is found on the B18.DR3 haplotype. Thus it has 
been difficult to distinguish between the class II and class III genes 
as the primary susceptibility gene in SLE.
One way of overcoming linkage disequilibrium effects is to examine 
SLE patients of different ethnicities. The class I and II HLA antigens
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and class III complement allotypes vary in frequency between various 
ethnic groups, and also show different linkage disequilibrium 
relationships. For example, while DR3 is common in Caucasoids, it is 
rare in Japanese. Similarly, the haplotype A24.B52.DR2 is rare in 
Caucasoids but common in Japanese. Different ethnic groups can be 
examined to look for a common susceptibility locus which crosses ethnic 
boundaries. To avoid the problems of assigning C4 alleles, gene 
frequencies can be estimated by statistical techniques, for example by 
the maximum likelihood method, with iteration of the null allele 
frequencies to obtain the best fit to Hardy-Weinberg equilibrium of the 
observed phenotype distributions.
4.1.1 AIMS.
The contribution of deficiencies of the early complement 
components, C2 and C4, to the pathogenesis of SLE have been investigated 
by examining C4 allelic distributions in SLE patients in three distinct 
ethnic groups, Caucasoid, Chinese and Japanese, and by C2 functional 
assays in these three different populations. C2 phenotypes in Caucasoid 
SLE patients were also examined. C4 phenotyping, C2 functional assays 
and C2 phenotyping have also been done in some CTD groups, to look for 
any associations of these diseases with C2 and C4. The contribution of 
C4 to lupus is compared with that of HLA-DR.
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4.2 MATERIALS ÄND METHODS.
4.2.1 PATIENTS AND CONTROLS.
Japanese and Chinese SLE patients were examined for HLA antigen 
distributions as part of the Third Asia Oceania Histocompatibility 
Workshop (Naito et al. 1986) as were healthy Japanese and Hong Kong 
Chinese. The Japanese patients were reviewed by Dr. S. Naito, and the 
Hong Hong Chinese by Dr. B. Hawkins. Plasma was stored at - 70°C within 
a few hours of collection and forwarded in dry ice to Canberra.
Caucasoid patients with SLE and the related diseases scleroderma, CREST, 
Sjogren's syndrome, polymyositis (Pm) and/or dermatomyositis (Dm), mixed 
connective tissue disease (MCTD) and undifferentiated connective tissue 
disease (UNCTD) have been described in Chapters 2 and 3. Sterile blood 
was transported overnight to Canberra where EDTA plasma was separated 
and stored at - 70°C. Caucasoid controls came from the Canberra Blood 
Bank and EDTA plasma samples were stored at -70°C within a few hours of 
collection.
4.2.2 C4 TYPING.
C4 allotyping was performed on patients and controls following the 
method of Awden and Alper (1980) as described in Chapter 2. Haemolytic 
overlays were carried out when C4A and C4B alleles overlapped or when it 
was difficult to distinguish between C4A and C4B alleles. Caucasoid 
controls were typed by Mrs. P. Ranford while the Caucasoid patients and 
all the Japanese and Chinese were typed by myself. The C4 gels were 
read independently by at least one other person.
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4.2.3 STATISTICAL ANALYSIS.
Differences in C4A and C4B phenotype distributions between patients 
and controls were tested by the chi-square statistic with continuity 
correction. If any number in a ceil of a 2x2 contingency table fell 
below 5, the exact probability was calculated (Armitage 1971). 
Frequencies of the common haplotypes C4A*3.B*1 and C4A*4.B*2 were 
calculated according to Mittal et al. (1973) and the nonrandom 
association of C4A and C4B alleles was measured by the disequilibrium 
statistic delta. (Mittal et al. 1973). The significance of delta was 
tested by chi-square.
4.2.4 ESTIMATION OF NULL ALLELE FREQUENCIES.
Partial deficiency of either C4A or C4B can sometimes be inferred 
by differential density of C4A and C4B bands on an agarose gel, (for 
example Figure 4.1a, lanes 1 and 4), but an individual heterozygous for 
both null alleles cannot be detected by this technique as the C4A:C4B 
ratio densities remains 1:1 (Figure 4.1b, lane 3). The population 
frequencies can be determined however, by statistical techniques. Gene 
frequencies were estimated using the maximum likelihood method, with 
iteration of the null allele frequencies to obtain the best fit of 
observed phenotype distributions to Hardy-Weinberg equilibrium. 
Sjogren's syndrome and Pm/Dm could not be examined by this method 
because of small patient numbers.
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4.2.5 LOGISTIC REGRESSION.
Logistic regression was used to compare the contribution of C4A or 
C4B deficiency with DR3 to lupus. The SPSSX statistical package was 
used with the loglinear function (SPSSX Users Guide 1986). Individuals 
with SLE were designated as either homozygous for C4A*Q0, heterozygous 
for C4A*Q0 (determined by density differences between C4A and C4B), 
heterozygous for two C4A alleles (definitely not C4A deficient) or 
undetermined (because the C4A:C4B density ratio was 1:1). C4B 
phenotypes were assigned in the same way. The Caucasoid SLE patients 
were compared with Caucasoid control haplotype data analysed in the 
Ninth International Histocompatibility Workshop (Baur et al. 1984). 
These haplotypes were obtained from family studies. The published 
haplotype frequencies were used to calculate the numbers of individuals 
with and without C4A*Q0 (both homozygous and heterozygous C4A*Q0), the 
number of those with and without DR3 (homozygous or heterozygous for 
DR3) and the joint occurence of these alleles. Similarly, the C4B*Q0, 
DR3 data was calculated from the haplotype frequencies.
4.2.6 HYBRIDIZATIONS.
DNA from selected individuals was digested with TaqI and probed 
with a C4 cDNA probe following the methods described in Chapter 2. The 
950bp probe pC4ALl (Whitehead et al. 1984) was kindly provided by Dr.
A.S. Whitehead.
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4.2.7 C2 TYPING.
Caucasoid patients with SLE or a connective tissue disease were C2 
typed by isoelectric focussing on polyacrylamide gels, following the 
method of Awdeh (1968), as described in Chapter 2. C2 gels were read 
independently by another person.
4.2.8 C2 FUNCTIONAL ASSAYS.
C2 functional assays were performed on Caucasoid, Japanese, and 
Chinese SLE patients, Caucasoid CTD patients and controls, according to 
Lachmann and Hobart (1978), as described in Chapter 2. The C2 assays of 
the patients were compared with two controls known to have 50% and 100% 
C2 levels, and were designated as having either 100% C2 (same amount of 
haemolysis as the 100% control), 50% C2 (same amount of haemolysis as 
the 50% control), 0% (no haemolysis at all) or 75% (between 50% and 100% 
haemolysis level). The C2 assay results were checked independently by 
another person.
4.3 RESULTS.
4.3.1 C4 IN CAUCASOID, JAPANESE, AND CHINESE SLE PATIENTS 
AND IN CAUCASOID CTD PATIENTS.
Figure 4.1 is a photo of a typical C4 gel stained with Coomassie 
Blue. Each gene product is represented by a set of three bands and 
phenotypes are indicated by the position of the leading band. C4A 
alleles are generally more acidic compared to C4B, but there is an
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FIGURE 4.1 a. Photograph of a C4 gel stained with Coomassie blue showing 
null alleles. Lane 1: C4A*3,Q0 C4B*1,1; Lane 2: C4A*Q0,Q0 
C4B*1; Lane 3: C4A*3 C4B*1; Lane 4: C4A*3,3 C4B*12;
Lane 5: C4A*4 C4B*1,2; Lane 6: C4A*3 C4B*Q0,Q0;
Lane 7: C4A*3 C4B*1.
b. Photograph of a C4 gel showing the slow C4B variant seen 
in Chinese. Lane 1: C4A*4,6 C4B*1,2; Lane 2: C4A*3,6 
C4B*1,1; Lane 3: C4A*3 C4B*1; Lane 4: C4A*3 C4B*1;
Lane 5: C4A*4 C4B*1,2; Lane 6: C4A*3 048*1,2,96;
Lane 7: C4A*3 C4B*1; Lane 8: C4A*4 C4B*1,2;
Lane 9: C4A*4 C4B*1,2,96; Lane 10: C4A*3 C4B*1,96.
a.
1 2 3 4 5 6 7 8 9 10
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overlapping zone and haemolytic assays are required to differentiate 
between C4A and C4B gene products when they lie in this area.
Table 4.1 shows the C4A gene frequency distributions in Caucasoid, 
Japanese and Chinese SLE patients and controls. C4A*3 was the most 
common allele in all populations with frequencies ranging between 45% in 
Japanese SLE patients to 69% in Caucasoid controls. The Japanese showed 
the least genetic variability, with C4A*5 and C4A*12 absent and very few 
instances of C4A*2 and C4A*6. Table 4.1 shows that although the C4A 
null gene (C4A*Q0) reached appreciable frequencies in all populations, 
there was a systematic two to three fold increase in frequency in each 
patient group with pC.Ol in the Caucasoids (X^=13.5) and Japanese 
(X^=13.7), and p<.05 in the Chinese (X^-5.3). There was a compensatory 
decrease in C4A*3 that reached statistical significance in the Japanese 
(X^=10.5, pC.Ol) and Chinese (X^=9.5, pC.Ol). No patient group showed 
an increase in the less haemolytically active C4A*6 allele compared with 
controls.
Table 4.2 shows C4B gene frequency distributions. In all 
populations the most common allele was C4B*1, although C4B*2 reached 
frequencies of 41% in Chinese controls. Once again, the Japanese showed 
the most restricted range of genetic variation. In the Japanese, C4B*3 
and C4B*12 were absent and C4B*4 was rare. The frequency of C4B null 
alleles ranged from 13% in Chinese to 20% in Caucasoid controls, with no 
increase in SLE patients.
An unusual C4B allele was seen in the Chinese, the most cathodal or 
basic C4B allele yen described, (shown in Figure 4.1b, lanes 6,9 and 10) 
(Dunckley and Hawkins 1986) . The variant is functional as evidenced by 
the haemolytic overlay technique and has been designated C4B*96 
according to guidelines devised by the IV International Workshop for
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Genetics of Complement (Mauff et al. 1983). C4B*96 was not described in
the study of complement allotypes in Orientals in the IXth International 
Histocompatibility Workshop. C4B*96 was higher in frequency in the 
Cantonese SLE patients compared with normal controls with 7 of 77 (9.1%) 
of the SLE patients having the C4B*96 allele compared with 2 of 76 
(2.6%) of controls (0.05<p<0.1). The C4B*96 allele appears to be on a 
chromosome with a duplicated C4B locus with all individuals positive for 
C4B*96 also C4B*1 positive, and in three of the nine occurences of 
C4B*96, C4B*1 and C4B*2 alleles were both present. Significant linkage 
disequilibrium was seen in the Cantonese between C4B*96 and HLA-B13. 
Seven of nine (77.5%) were positive for C4B*96 and HLA-B13 (X^=22.Q, 
pCO.OOl). C4B*96 was also seen in two Chinese SLE patients, now 
resident in Sydney, both of whom also carried C4B*1 and C4B*2 and were 
HLA-B13 positive.
Table 4.3 shows C4A gene frequency distributions in the connective 
tissue disease patients compared with controls. C4A*3 was the most 
common allele in the patient groups studied followed by C4A*4. The 
C4A*Q0 allele was increased in the MCTD/UNCTD group (X^=6.4, p<.05) and 
was due to an increase of apparent C4A,C4B homozygosity in the 
MCTD/UNCTD patients (there were no C4A or C4B null homozygotes).
Although all patients appeared to be homozygous at the C4A locus, some 
could have been carriers for both C4A*Q0 and C4B*Q0 alleles.
Table 4.4 shows C4B gene frequencies in the CTD patients and 
controls. A similar distribution is seen between the patient groups and 
the controls with C4B*1 and C4B*2 comprising 70 to 77% of the C4B 
alleles in the CREST/PSS and MCTD/UNCTD disease groups. Apart from the 
C4B*Q0 allele, the other C4B alleles were rare in these disease groups.
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Table 4.3 C4A GENE FREQUENCIES IN CONNECTIVE
TISSUE DISEASE PATIENTS AND CONTROLS.
Controls PSS/CREST MCTD/UNCTD
Allele
n=197 n=33 n=20
GFa SEb GF SE GF SE
C4A*2 0.040 0.010 0 .000 0.026 0.025
C4A*3 0.685 0.032 0.657 0.078 0.536 0.098
C4A*4 0.069 0.013 0.100 0.038 0.083 0.044
C4A*5 0.003 0.003 0 .000 0 .0 0 0
C4A*6 0.031 0.009 0.046 0.026 0 .0 0 0
C4A*12 0.005 0.004 0 .0 00 0 .0 0 0
C4A*Q0 0.169 0.029 0.197 0.073 0.355* 0.096
a GF=Gene frequency b SE=Standard error 
* pC.Ol
Table 4.4 C4B GENE FREQUENCIES IN CONNECTIVE
TISSUE DISEASE PATIENTS AND CONTROLS.
Controls PSS/CREST MCTD/UNCTD
Allele
n=197 n=33 n=20
GFa !5Eb GF SE GF !BE
C4B* 1 0.668 0.032 0.630 0.078 0.638 0.010
C4B*2 0.112 0.016 0.144 0.045 0.079 0.043
C4B*3 0.018 0.007 0.015 0.015 0.027 0.026
C4B*4 0.003 0.003 0.000 0.000
C4B*5 0.005 0.004 0.000 0.027 0.026
C4B*Q0 0.195 0.030 0.211 0.073 0.205 0.092
a GF=Gene frequency b SE=Standard error
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Table 4.5 gives C4A,C4B and C4A.C4B phenotype distributions in 
Caucasoid SLE patients and controls. Individuals typing as apparent 
homozygotes for C4A or C4B alleles may in fact be carriers of null 
alleles for C4A or C4B, so phenotypes such as C4B 1-1 and C4B 1-QO are 
pooled. There is an increased frequency of C4A*Q0 homozygosity in SLE 
patients compared with controls (X^=5.1, p<.05), with the C4A*Q0 allele 
occuring in conjunction with C4B*1, C4B*2 or C4B*3. There is no 
increase in C4B*Q0 homozygosity in patients. The frequency of C4A*3-4 
is decreased in SLE patients although not significantly (X^=3.7, 
p(corr)=.06). This is accompanied by a small increase in 
C4A*4-4,4-QO (X^=2.6, p=.l). [p(corr)=p(corrected)].
The distribution of C4 phenotypes in Japanese SLE patients and 
controls is given in Table 4.6. There is a significant increase in the 
frequency of C4A null homozygosity in patients (X^=4.3, p<.05) but no 
increase in C4B null homozygosity. The C4A*Q0 allele occurs in 
conjunction with 048*1, C4B*2 or C4B*5 in Japanese as shown in Table 
4.6, so no secondary distortion in C4B phenotypes was evident in the SLE 
patients.
Table 4.7 shows the C4A and C4B phenotype distributions in the 
Chinese SLE patients and controls. The most common phenotype is 
C4A*3-3,3-Q0 with the C4A*3 allele linked with several different C4B 
alleles. The frequency of C4A*3-4 is decreased in SLE patients, 
although not significantly (X^=3.4, p(corr)=.Q6). This would be 
compensated for if some of the apparent C4A.C4B homozygotes were 
carriers for the C4A and C4B null alleles.
Linkage relationships between C4A*3 and C4B*1 and between C4A*4 and 
C4B*2 in the three populations for patient and control groups are shown 
in Table 4.8. C4A*4 and C4B*2 are in significant linkage disequilibrium
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Table 4.8 C4A,C4B LINKAGE RELATIONSHIPS IN SLE PATIENTS 
AND CONTROLS IN THREE ETHNIC GROUPS.
C4 HAPLOTYPE
DISEASE
C4A* 3 . B* 1 C4A*4. B*2
ETHNICITY STATUS HFa Ab HF A
Caucasoid SLE
Control
0.379
0.459
0.013
0.026
0.040
0.060
0.036**
0.052**
Japanese SLE
Control
0.340
0.414
0.095*
0.095*
0.123
0.139
0.094**
0.112**
Chinese SLE
Control
0.229
0.319
0.031
0.094**
0.147
0.126
0.091**
0.064**
a HF= haplotype frequency 
b A= disequilibrium statistic delta
* .01<p<.05 ** p<.01
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in all groups while C4A*3 and C4B*1 are linked only in Chinese controls 
and in the Japanese groups. The linkage disequilibrium value was 
significant for the haplotype C4A*3.B*2 in the Chinese patients (X~=3.9, 
p<.05) and controls (X^=5.2, p<.05) but was not a common haplotype in 
the Caucasoids or Japanese.
The numbers of patients in the CTD groups were too small to look at 
C4A,C4B phenotype distributions however the Pm/Dm patients showed an 
increase in C4A*4,B*2 with 5/19 (26%) positive for these two alleles 
compared to 21/197 (11%) of the controls (X^=2.7, p(corr)=.l). Two of 
the five Pm/Dm patients with C4A*4 and C4B*2 were apparent homozygotes 
for these two alleles compared to 1/21 controls (X^=4.9, p<.05).
One family was studied with twin sisters, one with lupus and the 
other healthy. The two children and husband of the SLE twin were also 
available for study (Figure 4.2). Both twins were identical at the HLA 
class I and II loci and both had undetectable levels of C4. However, 
from the children it was clear that the genes for C4 were present in the 
SLE twin. DNA from the twins was also examined with a C4 cDNA probe and 
this confirmed that the C4 genes were present in both twins. The twins 
also presented with 50% C2 levels so it appears that another factor such 
as Cl esterase inhibitor deficiency is causing the low C4 and C2 levels 
seen in these twin sisters.
4.3,2 C4A DEFICIENCY VERSUS HLA-DR3 IN SLE.
The relative contribution of DR3 and C4A deficiency to SLE in 
Caucasoids was analysed by logistic regression. Both complete and 
partial C4A deficiencies were compared with DR3. Patients and controls 
were divided into the four groups shown in Table 4.9 as described in the
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Table 4.9 C4A*Q0 AND DR3 IN CAUCASOID SLE PATIENTS
AND CONTROLS.
C4A TYPE
SLE CONTROLS
DR3 + DR3- DR3 + DR3-
Two C4A null alleles 6 0 5 2
One C4A null allele 16 8 56 51
No C4A null alleles 9 14 31 207
Undetermined 6 19 26 124
Total 37 41 118 384
Table 4.10 COMPLETE C4A DEFICIENCY VERSUS DR3.
VARIABLES IN MODEL X2
(GOF)**
DF* P
C4A*Q0-Q0+ 4.6 2 0.098
C4A*Q0-Q0, DR3 4.3' 1 0.038
DR3 14.6 2 0.001
* DF= degrees of freedom ** GOF= goodness of fit 
+ C4A*Q0-Q0= complete C4A deficiencY
Table 4.11 PARTIAL C4A DEFICIENCY VERSUS DR3.
VARIABLES IN MODEL X2
(GOF)**
DF* P
C4A*QQ-x+ 3.5 2 0.173
C4A*Q0-x, DR3 3.4 1 0.066
DR3 8.2 2 0.017
* DF= degrees of freedom ** GOF= goodness of fit
+ C4A*Q0-x= partial C4A deficiency
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methods section. Table 4.10 gives the chi-square values which indicate 
the goodness of fit of the model for estimating the probability of an 
individual having SLE or being healthy, so the higher the chi-square 
value, the worse the fit. As can be seen in Table 4.10, when C4A alone 
was included, X2=4.6, p=.098. When DR3 was included with C4A, the X^ 
value was significant, suggesting that DR3 was not contributing to the 
disease, and when DR3 alone was considered, the chi-square value was 
highly significant (p=.0Ql) showing that the use of DR3 alone did not 
give a satisfactory model to account for the disease, and could not be 
the primary factor contributing to SLE when compared with complete C4A 
deficiency.
The logistic regression results comparing partial C4A deficiency 
and DR3 are shown in Table 4.11. When C4A was used alone, X^=3.5, and 
p=.173, which indicated that the use of partial C4A deficiency alone 
gave a well fitting model and so accounted for the disease. When both 
partial C4A deficiency and DR3 were included in the logistic regression, 
the chi square value for goodness of fit approached significance and 
when DR3 alone was used, the chi square value was significant (p=.017) 
suggesting that DR3 did not give a satisfactory model and so was not 
accounting for the disease. Therefore, partial C4A deficiency was more 
important than DR3 in contributing to the pathogenesis of SLE.
4.3.3 C4B DEFICIENCY VERSUS DR3 IN SLE.
Patients and controls were divided into the four groups shown in 
Table 4.12, as was done for the C4A analysis. Table 4.13 gives the 
logistic regression results comparing DR3 and complete C4B deficiency. 
When C4B was used alone, X2=14.6, p=.Q01, showing that complete C4B
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Table 4.12 C4B*QQ AND DR3 IN CAUCASOID SLE PATIENTS
AND CONTROLS.
SLE CONTROLS
C4B TYPE DR3 + DR3- DR3 + DR3-
Two C4B null alleles 0 2 2 9
One C4B null allele 3 7 26 100
No C4B null alleles 21 13 42 111
Undetermined 12 22 47 170
Total 36 44 117 390
Table 4.13 COMPLETE C4B DEFICIENCY VERSUS DR3.
VARIABLES IN MODEL X2 DF* P
(GOF)**
C4B*Q0-Q0+ 14.6 2 0.001
C4B*Q0-Q0, DR3 2.1 1 0.147
DR3 2.1 2 0.347
* DF= degrees of freedom ** GOF= goodness of fit 
+ C4B*Q0-Q0= complete C4B deficiency
Table 4.14 PARTIAL C4B DEFICIENCY VERSUS DR3.
VARIABLES IN MODEL X2
(GOF)*’
*DF P
C4B*Q0-x+ 14.4 2 0.001
C4B*Q0-x, DR3 1.4 1 0.237
DR3 7.3 2 0.026
* DF= degrees of freedom ** GOF= goodness of fit
+ C4B*Q0-x= partial C4B deficiency
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deficiency did not give a model which accounted for the disease.
However, when DR3 was analysed, the chi-square value for goodness of fit 
was not significant suggesting that DR3 (or the linked C4A null gene) 
gave a satisfactory model to account for SLE. When both DR3 and C4B 
deficiency were included together, there was little change in the chi 
square value compared with DR3 alone, implying that complete C4B 
deficiency has little effect on the pathogenesis of the disease.
Logistic regression results comparing the contribution of partial 
C4B deficiency and DR3 are given in Table 4.14. When C4B alone was 
included, X^=14.4, p=.001, indicating that use of partial deficiency of 
C4B alone did not give a good model which accounted for lupus. When DR3 
alone was examined, the chi square value was still significant, although 
not as high as when C4B alone was used, so DR3 (or the linked C4A*Q0 
gene) accounted for some, but not all, the disease. When both DR3 and 
partial C4B deficiency were included, the X^ value was not significant, 
showing that together these variables gave a satisfactory model which 
accounted for the disease. This can be explained by examining the raw 
data (Table 4.12). It can be seen in Table 4.12 that 30% of the SLE 
patients have one C4B null allele and are DR3 positive compared to 20.6% 
of the controls, which is not significantly different. However, the 
number of individuals with no C4B null alleles (C4B definite 
heterozygotes) and with DR3 is much higher in the patient group than the 
controls, (47.7% as opposed to 27.5%), which is significant (X^=11.3, 
pC.001). These C4B heterozygotes have either two different C4B alleles 
or the same two C4B alleles and carry one C4A null allele. So in the 
logistic regression, when looking at partial C4B deficiency (Table 
4.14), DR3 accounts for some of the disease (due to linkage 
disequilibrium with C4A*Q0), while C4B, (due to many of the C4B
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FIGURE 4.2 Photo of a C2 radial diffusion assay showing
100% and 50% C2 actvity.
Dilution 1:1 1:4 1:8
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heterczygotes carrying C4A null alleles), appears to account for the 
rest cf the disease.
Therefore, this logistic regression analysis comparing the 
contributution of C4B deficiency and DR3 to lupus actually appears to 
support C4A deficiency as playing the major role.
Logistic analysis examining C4A*Q0, C4B*Q0 and DR3 together could 
not be carried out because of the way in which the null allleles were 
defined. For example, a person with partial deficiency of C4A must by 
our criteria of definition have two functional C4B alleles.
4.3.4 C2 DEFICIENCY IN CAUCASOID, JAPANESE AND CHINESE SLE PATIENTS AND 
CAUCASOID CTD PATIENTS.
Figure 4.3 shows a photo of a C2 haemolytic assay. Assays were 
performed with undiluted and diluted plasma as indicated and rings cf 
lysis can clearly be seen around the wells. These can be measured by 
eye or with a ruler to determine the C2 levels in the plasma. Because 
the normal range of C2 levels is narrow, C2 levels which are below 
normal can easily be detected (Raum et al. 1980).
Table 4.15 gives C2 levels in the Caucasoid SLE and CTD patients 
Loto lev&ls wece
and controls. HotoroaygouG C2 dcfigieney was seen in 23% of the 
Caucasoid SLE patients studied here but not in any of the 40 controls 
(X^=9.1, pC.01) (Table 4.15). A report by Glass et al. (1976) shows 
that heterozygous C2 deficiency is only seen in 1% of Caucasoids in the 
general population, so the level seen in the SLE patients studied here 
is significantly above this. Heterozygous C2 deficiency was also seen 
in four of fifty (8%) of the Japanese SLE patients and six of fifty 
(12%) of the Hong Kong Chinese SLE patients. Some of the Caucasoid
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Table 4.15 C2 LEVELS IN CAUCASOID SLE AND CONNECTIVE TISSUE DISEASE PATIENTS.
CONTROLS SLE PSS/CREST SJOGREN'S PM/DM MCTD/UNCTD
C2 level N % N % N % N % N % N %
0% 0 0 0 0 0 0
50% 0 19 22.9 2 5.9 0 1 5.3 2 12.5
75% 0 2 2.4 2 5.9 0 0 0
100% 40 100.0 62 74.7 30 88.2 7 100.0 18 94.7 14 87.5
Number
Tested
40 83 34 7 19 16
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Table 4.16 C2 PHENOTYPE DISTRIBUTIONS IN CAUCASOID SLE AND 
CONNECTIVE TISSUE DISEASE PATIENTS.
SLE PSS/CREST SJOGREN' PM/DM MCTD/UNCTD
C2
Phenotype N % N % N % N % N %
C2-1 39 95.1 14 93.3 3 100.0 5 100.0 7 87.5
C2-1,2 2 4.9 1 6.7 0 0 1 12.5
Number
tested
41 15 3 5 8
Table 4.17 C2 LEVELS IN RELATION TO HLA-B18 AND DR2. 
IN SLE AND CTD PATIENTS.
C2
LEVEL
HLA HAPLOTYPE
B18 ,DRx* Bx+,DR2 B18,DR2 Bx,DRx
SLE CTD SLE CTD SLE CTD SLE CTD
N % N % N % N % N % N % N % N %
50% 0 2 2.5 4 4.8 1 1.3 1 1.2 1 1.3 14 17.1 1 1.3
75% 0 0 0 0 0 0 2 2.4 2 2.5
100% 2 2.4 6 7.5 16 19.5 11 13 .8 1 1.2 2 2.5 42 51.2 53 66.3
Total 2 8 20 12 2 3 58 83
* DRx= not DR2 + Bx= not B18
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patients had C2 levels somewhere between 50% and 100% of normal 
(designated as 75%) which is probably a consequence of the disease.
The CTD patients did not show any significant increases in C2 
deficiency although 50% levels were seen in 13% of the MCTD/UNCTD 
disease group (Table 4.15). However the sample sizes are small 
(particularly in the Sjogren's and MCTD/UNCTD groups) and a larger 
patient series will need to be studied to obtain an accurate picture of 
the role of C2 deficiency in these connective tissue diseases.
Homozygous C2 deficiency was seen in only two patients, both 
Lebanese, one with SLE and the other with a connective tissue disease, 
but currently under review. The SLE patient came from a first cousin 
marriage and was tissue typed as HLA A2,-, B18,-, DR5,-, while the 
latter patient was not homozygous at the HLA class I loci being typed as 
HLA A24,-, B18,w49, DR5,-. Both patients also showed very low levels of 
C4, although the C4 genes were present as indicated by hybridizing DNA 
from these patients with a C4 cDNA probe, and there is the possibility 
that the C2 deficiency, could have been caused by some other factor, 
such as Cl esterase inhibitor deficiency.
The C2 phenotyping results are shown in Table 4.16. No unusual 
distributions were seen, with C2*l (formerly known as C2*C) the most 
common allele in all the patient groups. There were a few individuals 
with C2*l,2 (C2*C,B) but no rare C2 alleles were seen.
C2 levels were examined in relation to the HLA antigens B18 and DR2 
because of the known linkage disequilibrium between C2 deficiency and 
the haplotype HLA A25.B18,BF*S.C4A*4.C4B*2.DR2(Dw2) (Fu et al. 1975; 
Hauptmann et al. 1982). However, no association was seen between C2 
deficiency and B18 or DR2 in the SLE patients studied here as shown in
Table 4.17. However, when C2 levels were examined according to KLA-DR
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TABLE 4.18 C2 LEVELS IN RELATION TO HLA-DR TYPE IN SLE AND CTD PATIENTS.
C2 LEVEL
DR TYPE
50% C2 75% C2 100% C2
SLE CTD SLE CTD SLE CTD
N % N % N % N % N % N %
HLA-DR1 7 36.8 1 20.0 0 1 33.3 7 11.3 15 20.8
HLA-DR2 5 26.3 2 40.0 0 1 33.3 17 27.4 13 18.1
HLA-DR3 3 15.8 0 1 50.0 0 31 50.0 27 37.5
HLA-DR4 5 26.3 3 60.0 0 2 66.7 15 24.2 19 26.4
HLA-DR5 4 21.1 2 40.0 1 50.0 0 11 17.7 19 26.4
HLA-DR7 5 26.3 0 1 50.0 1 33.3 14 22.5 11 15.3
HLA-DRW8 0 0 0 0 1 1.6 6 8.3
HLA-DRw9 0 0 0 0 0 3 4.2
HLA-DRwlO 0 0 0 0 0 1 1.4
HLA-DRW13 3 15.8 0 1 50.0 0 10 16.6 6 8.3
HLA-DRW14 2 10.5 0 0 0 2 3.2 5 6.9
Total 19 5 2 3 62 72
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type, HLA-DR1 appeared to be associated with partial C2 deficiency in 
the SLE patients, but this was not statistically significant when 
corrected for the number of antigens tested for. (Table 4.18). A 
negative association was seen with HLA-DR3 and partial C2 deficiency.
The CTD patients did not show any association between partial C2 
deficiency and HLA-DR.
C2 levels were crosstabulated with the number of C4A or C4B alleles 
present to see if there was any association between low C2 and and low 
C4 levels. Uko et al. (1986) have reported that the serum concentration 
of C4 can be correlated with the number of C4 alleles, so C2 levels were 
examined according to whether individuals were C4A or C4B null 
homozygotes, C4A or C4B heterozygotes, C4A or C4B null heterozygotes, 
or, C4A or C4B undetermined heterozygotes or homozygotes. C4A and C4B 
null heterozygotes were assigned according to density differences 
between the C4A and C4B alleles. No association was seen between C2 
levels and the number of C4 alleles indicating that low C2 levels 
probably do not correlate with low C4 levels. Three of the 19 SLE 
patients with 50% C2 levels also had very low C4 levels that made C4 
allotyping impossible, but whether these low C2 and low C4 levels are 
associated could not be determined.
4.4 DISCUSSION.
4.4.1 SIGNIFICANCE OF C4A*Q0 IN SLE PATIENTS.
This study of C4 distributions in three ethnic groups has shown a 
systematic increase in the frequency of C4A null alleles in SLE 
patients. This increased C4A null gene frequency is due not only to an
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excess of C4A null homozygotes, but also to an increase in C4A null 
carriers in the patient groups. C4A null homozygosity was significantly 
increased in Caucasoid and Japanese patients while the number of C4A 
null carriers or apparent homozygotes was increased in Caucasoid and 
Chinese patients. Thus complete and partial deficiencies of C4A are 
implicated in SLE, significantly increasing the C4A*Q0 gene frequency in 
SLE patients from three ethnic groups.
Although partial complement deficiency has been implicated 
previously in the predisposition to SLE in Caucasoids (Fielder et al. 
1983) the relative importance of C4A and C4B null alleles as disease 
determinants remains controversial (Christiansen et al. 1983). In 
addition, because the C4 alleles are in strong linkage disequilibrium 
with the HLA alleles, with C4A*Q0 carried on the HLA-A1.B8.DR3 haplotype 
and C4B*Q0 on the HLA-B18.DR3 haplotype (Christiansen et al. 1983; 
Revielle et al. 1985) it has been difficult to distinguish between the 
HLA class II and class III genes as the primary factors involved in 
predisposition to SLE.
HLA-DR associations with SLE do tend to differ between and within 
different ethnic groups, suggesting that HLA-DR antigens may not be the 
causative factors in SLE. For instance, in Caucasoid SLE patients, 
increased frequencies of both HLA-DR3 (Celada et al. 1979; Dunckley et 
al. 1986) and HLA-DR2 have been reported (Reinertsen et al. 1978;
Gladman et al. 1979; Reveille et al. 1985), while in Japanese HLA-DR2 
was increased in one study, (Hashimoto et al. 1985), but not in another 
where the only significant change in DR distributions was a decrease in 
DR4 (Kameda et al. 1982). A recent study of SLE in Hong Kong Chinese 
has shown an increase in HLA-DR2 (Hawkins et al. 1987). These different
HLA-DR associations suggest MHC-linked determinants rather than HLA-DR
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antigens, are involved in the pathogenesis of SLE. In addition to the 
ethnic study, logistic regression analysis here has clearly shown that 
both complete and partial C4A deficiency are more important than DR3 in 
contributing to SLE. C4B deficiency (either complete or partial) is not 
implicated in the pathogenesis of SLE in this study. This is supported 
by a recent study looking at C4 in white and black Americans which also 
showed an increase in C4A*Q0 but not C4B*Q0 in SLE patients in both 
ethnic groups (p<.05) (Howard et ai. 1986). In addition, Green et al. 
(1986) using the empirical logistic method, presented results indicating 
that the association between C4A*Q0 and SLE is primary while that of DR3 
and SLE is secondary. A recent study by Kemp et al. (1987) used 
Southern blotting to look at the C4 genes in SLE and found a high 
proportion of patients with deletions in the C4A gene.
The reason for the association of SLE with C4A*Q0 and not C4B*Q0 
may reflect the different functional properties of C4A and C4B. C4 is 
activated through cleavage of the internal thiolester bond, and it is 
able to acylate hydroxyl, amino or other nucleophilic groups of 
proteins, carbohydrates or other antigenic molecules. C4A has been 
shown to bind more readily to amino groups in contrast to C4B which 
binds more readily to hydroxyl groups (Isenman and Young 1984; Law et 
al. 1984). Thus C4A may be more efficient than C4B in denaturing the 
protein immune complexes which characterize SLE. A study by Schifferli 
et al. (1986b) supports this by showing that C4A is 1.7 fold more 
efficient than C4B in preventing immune precipitation, and threfore 
plays an important role in prevention of immune complex precipitation 
and the clearance of immune complexes. Therefore, a decrease in serum 
C4B would have less impact than a decrease in serum C4A. Partial C4A
deficiency could be accentuated because C4A competes with C4B as a
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substrate for Cl, and C4B would be in 2 fold excess over C4A, therefore 
even less C4A would be activated (Atkinson 1986). In addition, Sim and 
Law, (1985), in the study of hydralazine induced SLE, have shown that 
hydralazine binds to C4A more efficiently than C4B thereby inactivating 
it which is consistent with the proposal that the lack of C4A is more 
important than C4B in determining susceptibility to SLE.
If this proposition is correct, complete and partial C4A 
deficiencies should be genetic determinants of SLE not only in 
Caucasoids but also in other ethnic groups. This study has confirmed an 
increase in frequency of C4A null alleles in Caucasoid SLE patients and 
has shown a similar increase in Chinese and Japanese SLE patients also. 
Since only one third of the SLE patients have complete or partial 
deficiency of C4A, this cannot be the only determinant of SLE.
No increase of the C4A*6 allele was seen in the Caucasoid, Japanese 
or Chinese SLE patients. C4A*6 can have less in vitro haemolytic 
activity than the other C4 alleles because a less active C5 convertase 
is formed (Dodds et al. 1985). However, if the reaction of the C4A 
protein with amino nucleophiles is the initial, important step in 
clearing protein immune complexes, a lower level of C5 convertase 
activity may not seriously affect in vivo function.
4.4.2 C2 IN SLE.
There was an increased frequency of partially C2 deficient 
individuals in the SLE patients of Caucasoid, Japanese and Chinese 
origin which is in accord with other studies which have associated C2 
deficiency with SLE (Glass et al. 1976; Schur 1982). The classical
complement pathway is essential for the prevention of precipitation of
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immune complexes (Webb and Whaley 1986) so lack of C2 would probably 
result in less efficient processing of immune complexes, more immune 
complexes precipitating and therefore becoming harder to solubilize, and 
increased deposition of immune complexes in the tissues where they could 
cause damage. Further local tissue damage would also result if the 
complement system was activated by the deposited immune complexes.
The lack of association between C2 deficiency and HLA-B18 or DR2 
seen here is in contrast to other studies which have reported a high 
degree of linkage between the extended hapiocype HLA 
A25.B18.BF*S.C4A*4.C4B*2.DR2(Dw2) and C2 deficiency (Hauptmann et al. 
1982; Schur 1982). A report by Christiansen et al. (1982) indicated 
that their lupus patients, like those here, did not show an association 
between C2 deficiency and the extended haplotype above. Six of the 39 
SLE patients were HLA B18 positive, but not C4A*4.C4B*2.BF*S positive 
suggesting they were not C2 deficient. Three of the 13 B18 positive 
controls (from a total of 176 controls) were C4A*4.C4B*2.BF*S positive. 
It is possible that some of the C2 deficiencies seen here are acquired 
as a result of the disease and are not due to a defective or null gene, 
and therefore would not be expected to show linkage to genes in the MHC. 
While nearly 40% of indivduals with homozygous C2 deficiency develop SLE 
(Agnello et al. 1986), partial inherited deficiency of C2 may not be so 
detrimental.
4.4.3 C4 AND C2 IN CONNECTIVE TISSUE DISEASES.
In contrast to the SLE patients, none of the CTD patient groups 
showed an increase in C4A*Q0 frequency apart from the MCTD/UNCTD 
patients but only 4 MCTD and 15 UNCTD patients were studied. A study of
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patients with scleroderma (Briggs et al. (1986), has shown a significant 
increase in C4A*Q0 in the patients, however no association was seen 
here. The Pm/Dm patients showed an increased frequency of C4A*4 and 
C4B*2 which are known to be in linkage disequilibrium on the extended 
haplotype HLA-A25.B18.BF*S.C2*Q0.DR2(Dw2) (Hauptmann et al. 1982). 
However, the Pm/Dm patients did not show an increase in C2 deficiencies 
(Table 4.9) indicating that the C4A*4 and 048*2 alleles may not be 
carried on the same chromosome. Alternatively, it is possible that the 
C4A*4 and C4B*2 alleles are markers for some other gene which is in 
linkage disequilibrium with them. The C4B null gene did not appear to 
be a risk factor for the CTDs studied here. Mollenhauer et al. (1984) 
in a report of patients with scleroderma showed an increased frequency 
of C4B*Q0 homozygotes in their patient group, but this was not seen in 
the scleroderma patients here.
A role for C2 deficiency was not supported in the connective tissue 
diseases studied here as the CTD patients did not show any significant 
increases in C2 deficiency unlike the SLE patients.
4.5 CONCLUSION.
SLE is a clinically heterogeneous autoimmune disorder and this 
study suggests that there is genetic heterogeneity in its aetiology. 
However, one important genetic determinant of SLE in Caucasoid, Japanese 
and Chinese populations is complete or partial deficiency of complement 
component C4A. In addition, logistic regression in Caucasoids has shown 
that both complete and partial C4A deficiency is more important than DR3 
in contributing to lupus. Partial C2 deficiency was increased in the 
SLE patients studied here, but this may be a consequence of the disease
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and not an inherited genetic defect. While exacerbating the disease, 
partial C2 deficiency may not be as serious as C4A deficiency.
From the small numbers in this study, it would appear that 
deficiencies of complement components C2 and C4 do not play a major role 
in the pathogenesis of PSS, CREST, Pm/Dm, MCTD, UNCTD, or Sjogren's 
syndrome.
CHAPTER FIVE
THE T-CELL RECEPTOR INSLE
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5.1 INTRODUCTION.
The T-cell antigen receptor is responsible for recognizing foreign 
antigens either in association with the MHC class I antigens, (the aß 
receptor in association with CD8 on T-cytotoxic cells), or class II HLA- 
D antigens, (the aß receptor found on T-helper cells in association with 
CD4). The foreign antigen is firstly processed by cells such as B-cells 
or antigen presenting cells, (Grey and Chestnut 1985; Germain 1986;
Mills 1986), and is then presented on the cell surface in association 
with the HLA class I or II proteins (Babbitt et al. 1986; Phillips et 
al. 1986), where it is recognized by the T-cell receptor. The T-cell is 
then activated and can further stimulate the immune response (T-helper 
cell) by stimulating 3-cell activation resulting in antibody class 
switching (IgM to IgG) and immune MmemorY,,. Alternatively, cytotoxic T- 
cells or killer T-cells can be activated to kill cells carrying the 
foreign antigen. If the T-cell receptor was defective and was reactive 
with self antigens or was not MHC restricted, an immune response to self 
antigens may be initiated which could result in autoantibodies. Another 
possibility is that the TCR may fail to recognize foreign antigen such 
as a virus which could lead to a persistent infection.
5.1.1 THE T-CELL RECEPTOR IN AUTOIMMUNITY.
A possible role for the TCR genes in SLE is suggested by studies of 
NZW mice and their offspring. In 1985, Kotzin et al. showed with RFLP 
analysis that the NZW mouse had a deletion of 8.8 kb in the TCR-ß gene 
encompassing the Cßl, Jß2 and Dß2 loci. This has been shown to start in 
the first 167 bp of the first C gene and extend to the homologous area
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of the second C gene (Noonan et al. 1986). This reduces the potential 
diversity of the T-ceil receptor and even though all the aß TCR's in NZW 
mice must be derived from a single set of TCR-ß genes they are 
phenotypically normal. A subsequent paper, (Yanagi et al. 1986), 
analysed the contribution of the TCR-8 deletion to the autoimmunity seen 
in (NZW x NZB)F1 offspring, which develop a lupus like disease. The 
(NZW x NZB)F1 hybrids were crossed with NZ3 mice and the offspring 
showed a high association between autoantibody formation and circulating 
retroviral gp70 immune complexes and the TCR-ß deletion or a locus 
closely linked to it. The appearance of SLE in the FI offspring 
suggests a combinatorial or interactive role for at least two loci, one 
of which may encode the TCR-ß chain and the other, as shown in (NZB x 
FI) backcrosses, an MHC-linked gene (Kotzin and Palmer 1987).
5.1.2 AIMS.
This chapter examines RFLPs associated with the T-cell receptor 
a,j3, and x  chain genes in SLE and associated connective tissue diseases, 
to search for unusual gene rearrangements. In addition, possible 
interaction of the TCR RFLPs with HLA-DR and -DQ RFLPs in SLE is 
examined•
5.2 METHODS.
5.2.1 PATIENTS AND CONTROLS.
Caucasoid patients with SLE and the connective tissue diseases 
Sjogren's syndrome, scleroderma, linear scleroderma, CREST, Pm/Dm, mixed
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connective tissue disease and undifferentiated connective tissue disease 
were studied. Controls comprised healthy blood bank donors and 
laboratory personnel.
5.2.2 PROBES.
The TCR-a cDNA clone pY14 (llOObp) (Yanagi et al. 1985) which 
encodes a complete TCR-a protein was used. The TCR-ß cDNA clone (770 
bp) contains the J and C region (Yoshikai et al. 1984), and the TCR-y 
cDNA clone contains the V,J, and C-yl region (Dr. T. Mak, personal 
communication). The three probes were provided by Dr. T. Mak.
5.2.3 RESTRICTION ENZYMES.
The following TCR probe and restriction enzyme combinations were 
examined in patients and controls to find useful RFLPs for this study.
A. TCR-a. Bglll digested DNA revealed no RFLPs in 80 patients while 
EcoRI did show two polymorphic fragments in 20 patients of approximate 
size 17kb and 9kb, but EcoRI was not a reliable enzyme and therefore was 
not used. EcoRV digested DNA showed two useful RFLPs and DNA was 
readily digested to completion with this enzyme. So et al. (1987) 
reported that TaqI digested DNA was polymorphic with the TCR-a probe and 
this was also seen in our patients. EcoRV and TaqI appeared to be the 
most useful enzymes with the TCR-a probe and were used in this study.
B . TCR-ß . It has been observed that DNA digested with Bglll is 
polymorphic with TCR-0 (Robinson and Kindt 1985; Berliner et al. 1985) 
and this restriction enzyme was used here. EcoRI digested DNA showed a 
RFLP in only one patient out of twenty and therefore was not used.
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FIGURE 5.1 a. TCR0 hybridization of Bglll digested DNA
b. TORY hybridization of PvuII digested DNA
c. TCRy hybridization of TaqI digested DNA.
a. TCRß/Bgl l l
- 10.0  
"  9.2
- 2.0
- 1.0
b. TCRT/P vuII c. TCRT/Taql
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C. TCR-Y. While EcoRV digested DNA did show two polymorhic fragments 
approximately 23 and 24 kb in size, this enzyme was not used because of 
the difficulty in distinguishing between the two fragments. DNA 
digested with Bglll showed no RFLPs in 20 patients or 7 controls. The 
following enzymes showed no polymorphisms in a small number of controls: 
Avail (5 controls), Hindlll (4), MspI (4), and PstI (6), but PvuII 
digested DNA revealed three RFLPs in 7 controls and was used in this 
study. TCR-Y was also polymorphic with TaqI as seen initially in 40 
patients and was used in this study in addition to PvuII.
5.3 RESULTS.
5.3.1 TCR-a, -3, and -y RFLPS.
Figure 5.1 shows polymorphic fragments observed with TCR-ß and -y 
cDNA probes. The TCR-ß/BglII polymorphism of allelic lO.Okb and 9.2kb 
fragments has been described previously (Robinson and Kindt 1985). Two 
constant fragments were also evident, approximately 2.0kb and l.Qkb in 
size. For TCR-y, as reported by Dunckley et al. (1988), PvuII generated 
an informative polymorphism with three allelic fragments 20kb, 17kb and 
15kb in size and two constant fragments of 9.4kb and 3.5kb. TCR-y was 
also polymorphic when hybridized with TaqI digests of genomic DNA, with 
a 3.3kb fragment either present or absent. Seven non-polymorphic 
fragments were also present in the TCR-y/TaqI hybridization, with 
fragments about 6.8kb, 4.3kb and 3.0kb hybridizing strongly and 
fragments approximately 6.2kb, 2.2kb, 1.3kb, and 0.8kb hybridizing less 
strongly. Figure 5.2 shows the RFLPs observed with the TCR-Qt probe. 
EcoRV digests were informative with allelic fragments of 1.7kb and
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FIGURE 5.2 a. TCRa hybridization of EcoRV digested DNA.
b. TCRa hybridization of TaqI digested DNA.
a. TCRa/EcoRV b. TCRa/Taql
—  - 7.0
- 1.4
- 0.4
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1.6kb, as well as an unlinked 9.4kb polymorphic fragment (Dunckley et 
al. 1988). In addition, constant fragments approximately 23kb, 19kb, 
14kb, 8.5kb, 5.5kb and 2.5kb in size were observed. TCR-a is also 
polymorphic with TaqI (So et al. 1987) with allelic fragments of 7.0kb 
and 2.0kb due to changes in restriction sites in the constant TCR-a gene 
and a 1.4kb fragment either present or absent due to a TCR-a variable 
gene restriction site polymorphism. In this study, an additional 
polymorphic fragment was seen, approximately Q.4kb in size. Eight non- 
polymorphic fragments are also evident in the TCR-a/TaqI hybridization.
5.3.2 TCR-ß IN THE SLE AND CTD PATIENTS.
Table 5.1 shows the TCR-ß/BglII phenotype and allele frequencies in 
the patient groups and controls. The SLE patients showed no significant 
differences from the controls in their phenotype distributions (X2=0.54, 
p=.8) or allelic frequencies (X^=0.54) of the lO.Okb and 9.2kb 
fragments. The CTD patients did show a difference in phenotype and 
allele distributions, with all patient groups showing a trend towards an 
increase of the lO.Okb fragment with a significant increase in the 
MCTD/UNCTD disease group (p(corr)=.05). However, the patient numbers in 
the individual CTD groups are small and a larger patient series would be 
needed to verify this increase. Interestingly, when all the CTD 
patients were combined, the increase in the lO.Okb fragment was 
significant (X^=6.5, p=.01).
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5.3.3 TCR-y IN THE SLE ÄND CTD PATIENTS.
Table 5.2 gives phenotype distributions and allele frequencies for 
the TCR-y/PvuII RFLPs. There were no differences seen in the allele 
{x^-1.9) and phenotype (X^=3.53, p=.06) distributions between the SLE 
patients and the controls. Similarly, the CTD groups did not show any 
significant differences from the controls in allele and phenotype 
distributions either in the individual disease groups or when combined, 
with all phenotype distributions in Hardy-Weinberg equilibrium. 
Distribution of the 3.3kb TCR-y/Taq I RFLP in patients and controls is 
shown in Table 5.3. The 3.3kb fragment was present at a similar 
frequency in both the controls and SLE patients. Of the connective 
tissue diseases, only the MCTD/UNCTD group showed a significant increase 
in the presence of this fragment (p<.05). This was due to an increase 
in the UNCTD disease group with 7/13 patients (53.8%) (p<.Q5) having 
this fragment. No linkage disequilibrium was seen between the 
TCR-y/Taql 3.3kb fragment and the TCRy/PvuII 20kb fragment (X^=1.3, 
p(corr)=0.2), or the TCRy /Pv u II 17kb fragment (X^=0.0, p(corr)=1.0), or 
the TCRy/PvuII 15kb fragment (X^=2.9, p(corr)=.09).
5.3.4 TCR-Gt IN THE SLE AND CTD PATIENTS.
Phenotype and allele frequencies of the TCR-a/EcoRV RFLPs in 
patients and controls are given in Table 5.4. The SLE patients showed 
no significant differences when compared with the controls in their 
phenotype (X^O.29, p=0.9) or allele frequencies (X^=0.23). The CTD 
groups also showed similar phenotype and allelic distributions as the 
controls and no significant differences were seen even when the CTD
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TABLE 5.3 FREQUENCY OF THE TCR-y/Tagl 3.3kb FRAGMENT IN SLE AND CTD 
PATIENTS AND CONTROLS.
Controls SLE PSS/CREST Pm/Dm MCTD/UNCTD
Phenotype N % N % N % N % N %
TCR-y/Taql 
3.3 kb
9 15.3 16 23.9 8 30.8 2 15.4 8* 47.1
Number
tested
59 67 26 13 17
*p<.05
TABLE 5.4 TCR-a/EcoRV PHENOTYPES IN SLE AND CTD PATIENTS 
COMPARED WITH CONTROLS.
Controls SLE PSS/CREST Pm/Dm MCTD/UNCTD Sjogren's
Phenotype N . % N % N % N % N % N %
1.7/1.7 2 4.8 4 7.1 2 10.0 0 1 6.3 0
1.7/1.6 16 38.1 22 39.3 6 30.0 6 60.0 5 31.3 3 60.0
1.6/1.6 24 57.1 30 53.6 12 60.0 4 40.0 10 62.5 2 40.0
Unlinked 
9.4kb RFLP
6 14.3 8 14.3 1 5.0 2 20.0 1 6.3 1 20.0
Allele
frequency
1.7 kb 0.238 0.263 0 .250 0.300 0.219 0.300
1.6 kb 0.762 0.732 0.750 0.700 0.781 0.700
Number
tested
42 56 20 10 16 5
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TABLE 5.5 TCR-g/Taal PHENOTYPES IN SLE ÄND CTD PATIENTS 
COMPARED WITH CONTROLS.
Phenotype
Controls SLE PSS/CREST Pm/Dm MCTD/UNCTD
N % N % N % N % N %
7.0/7.0 4 10.8 3 10.0 1 14.3 1 20.0 1 25.0
7.0/2.0 14 37.8 15 50.0 6 85.7 2 40.0 3 75.0
2.0/2.0 19 51.4 12 40.0 0 2 40.0 0
Allele
frequency
7.0 kb 0.297 0.350 0.571 0.400 0.625
2.0 kb 0.703 0.650 0.429 0.600 0.375
Number 37 30 7 5 4
tested
TABLE 5.6 FREQUENCY OF THE TCR-a/TaqI 1.4kb FRAGMENT IN SLE AND
PATIENTS COMPARED WITH CONTROLS.
Controls SLE PSS/CREST Pm/Dm MCTD/UNCTD
Phenotype N % N % N % N % N %
TCR-TaqI 19 54.3 9 42.9 2 22.2 4 66.6 2 100.0
1.4 kb
Number 35 21 9 6 2
tested
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patients were combined. Table 5.5 shows the allele and phenotype 
frequencies of the TCR-a/TaqI RFLPs in the SLE and CTD patients and 
controls. Again, no significant differences were seen in the phenotype 
(X^=1.03, p=0.6) and allele (X^=0.37) distributions between the SLE 
patients and controls. Likewise, the phenotype and allelic 
distributions of the TCR-a/TaqI RFLPs were similar between the CTD 
patients (in the individual disease groups and when combined) and the 
controls. Distribution of the TCR-a/TaqI 1.4kb fragment is shown in 
Table 5.6. The 1.4kb fragment was present at a similar level in the SLE 
patients and controls. The patient numbers in the CTD groups studied 
here were low, but no significant differences were seen between the CTD 
groups and the controls in the distribution of the 1.4kb fragment.
There was no linkage disequilibrium between the TCR-a/EcoRV 1.7kb 
fragment and the TCR-a/TaqI 7.0kb (X^=0.18, p(corr)=Q.6) or 2.0kb 
(X^=3.2, p(corr)=0.7) fragments. Chi-square values for linkage 
disequilibrium between the TCR-a/EcoRV 1.6kb fragment and the TCR-a/TaqI 
fragments could not be calculated because all individuals included in 
the linkage disequilibrium analysis were positive for the EcoRV 1.6kb 
fragment. (Some patients were negative for the EcoRV 1.6kb fragment, 
but were not included in the analysis because TaqI results were not 
available).
5.3.5 TCR RFLPS AND HLA-DR PHENOTYPES.
TCR phenotypes were examined according to DR phenotypes of the SLE 
patients as shown in Table 5.7. The phenotypes DR2,x, DR2,3, and DR3,y 
were tested because of the reported associations between SLE and DR2 and 
DR3. DR phenotypes were assigned by DNA typing as described in
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TABLE 5.7 TCR PHENOTYPES AND HLA-DR IN SLE.
TCR phenotype
DR phenotype
2,X*C 2,3 3, Y+ X,Y
N % N % N % N %
TCR-a/EcoRV v£>iid
1.7/1.7 1 14.3 1 14.3 1 5.9 0 0.0
1.7/1.6 3 42.9 1 14.3 6 35.3 6 40.0
1.6/1.6 3 42.9 5 71.4 10 58.8 9 60.0
Total 7 7 17 15
TCR-ß/BglII (n=56)
10.0/10.0 3 50.0 1 20.0 5 25.0 8 32.0
10.0/9.2 2 33.3 3 60.0 8 40.0 13 52.0
9.2/9.2 1 16.7 1 20.0 7 35.0 4 16.0
Total 6 5 20 25
TCR-Y/PvuII (n=79)
20/20 1 7.7 0 0.0 1 4.0 1 3.1
20/17 3 23.1 1 11.1 8 32.0 6 18.8
20/15 1 7.7 2 22.2 0 0.0 6 18.8
17/17 2 15.4 2 22.2 8 32.0 11 34.4
17/15 6 46.2 3 33.3 6 24.0 6 18.8
15/15 0 0.0 1 11.1 2 8.0 2 6.2
Total 13 9 25 32
X : not DR2 Y: not DR3
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Chapter 3. No significant differences were seen in T-ceil receptor 
phenotype distributions or allele frequencies between the different DR 
phenotypes examined, but patient numbers with some of the selected DR 
phenotypes were small, in particular DR2,x and DR2,3, (allele 
frequencies not shown).
Table 5.8 shows the allelic frequencies of TCR RFLPs in relation to 
the HLA-DR and HLA-DQ associated RFLPs of the SLE patients. No 
significant associations were seen between any of the TCR RFLPs and the 
HLA-DR or -DQ RFLPs. Possible DR,TCR and DQ,TCR interactions were 
examined according to presence or absence of a given DR or DQ type 
(described in Chapter 3) and presence or absence of a given TCR RFLP.
The 1.6kb TCR-a/EcoRV fragment and HLA-DRw6 were positively associated 
(X^=4.31, p<.05), but when corrected for the number of statistical tests 
made, this was no longer statistically significant.
5.4 DISCUSSION.
5.4.1 THE T-CELL RECEPTOR IN SLE.
This study has shown that there are no major deletions or 
rearrangements in the T-cell receptor a, §_ or i  chain genes in SLE 
patients. Major rearrangements or unusual clonality in TCR genes should 
be detected with almost any common-cutter restriction enzyme, but no 
novel RFLPs were seen in patients that were not seen in controls. 
Similarly, any major deletions in the TCR genes would be evident in 
altered restriction fragment sizes, or, if the gene was deleted in its 
entirety, by increased apparent homozygosity for RFLP patterns in the 
patient series. Minor deletions or alterations in the TCR genes are
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less easily detected in Southern blot analysis, but linkage 
disequilibrium between polymorphic restriction enzyme sites and possible 
defects in TCR genes would be expected. Neither TCR-a, -ß nor -y RFLPs 
were associated with SLE in this study. This is in accord with two 
earlier studies, both with 14 SLE patients, (Fronek et al. 1986, 
Goldstein et al. 1987) which showed that that TCR-ß RFLPs in patients 
were similar in distribution to those seen in controls. In contrast, a 
study of rheumatoid arthritis patients showed clonal TCR-ß 
rearrangements in synovial fluid T-cells that were readily detected with 
a TCR-ß constant region cDNA probe (Savill et al. 1987).
Evidence for TCR-ß gene involvement in murine SLE models is 
conflicting. A study of the MRL-lpr/lpr mouse strain which develops an 
SLE-like autoimmune disease has shown TCR V-ß gene expression to be 
significantly skewed in favour of certain V-ß genes suggesting a 
possible role for the TCR variable genes in autoimmunity and SLE (Singer 
et al. 1986) . A recent study of SWR x NZB mice has shown I-A6 and TCR-ß 
or closely linked genes are associated with the development of lupus 
nephritis in the FI offspring (Ghatak et al. 1987). While Yanagi et al 
(1986) found an association between the TCR-ß deletion and SLE in the
(NZW x NZB)FI mouse, Kotzin and Palmer (1987) in their NZB x (NZW x
NZB)Fl backcross studies concluded that lupus-like disease is largely 
associated, although not absolutely, with heterozygosity at an MHC- 
linked locus, rather chan with the TCR-ß deletion. NZW mice have been 
shown to have multiple RFLPs in their TCR-a variable region genes 
compared with NZB and non-autoimmune mouse strains, (Kotzin and Palmer, 
1987) as well as an unusual MHC haplotype, H-2Z (Klein 1975) so it is
possible that there are other loci, as yet undetected, which show
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unusual rearrangements in the NZW mice and that these are contributing 
to the iupus-like disease seen in the NZW x NZB offspring.
The observations reported here discount an important role for 
inherited differences in TCR-y, TCR-a and TCR-ß genes in contributing to 
SLE in man since phenotype and allelic distributions are normal and 
there is no significant increase in any HLA-DR,TCR genic combination, 
nor any T-cell receptor phenotype distribution differences in the HLA-DR 
phenotypes DR2,x, DR2,3, or DR3,y.
5.4.2 THE T-CELL RECEPTOR IN CONNECTIVE TISSUE DISEASES.
Similarly, the TCR-y and TCR-a genes do not appear to play a role 
in the connective tissue diseases studied here with only one significant 
difference seen, an increase in the TCR-y/TaqI 3.3 kb fragment in the 
UNCTD patients, but the number of patients was small (13) so this 
association may not be seen in a larger patient series. The CTD 
patients did show an increase in the lO.Okb TCR-ß/BglII fragment which 
was significant when all the connective tissue disease patients were 
grouped together. A larger patient series would be required to examine 
the possible involvement of the TCR-ß gene in predisposing to these 
connective tissue diseases.
5.4.3 FUTURE T-CELL RECEPTOR RESEARCH.
A possible role for the TCR-y gene in autoimmunity is suggested by 
a study which showed a higher level of X  gene expression in autoreactive 
T-helper cells compared with antigen specific T-helper cells which show 
a low level of expression (Zauderer et al. 1986). Future study of the
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possible role of TCR genes in the pathogenesis of SLE or associated 
connective tissue diseases may need to examine T-lymphocyte subsets for 
novel TCR gene arrangements and unusual clonality. The study by Savill 
et al. (1987) which showed clonal TCR-8 gene rearrangements in 
rheumatoid arthritis examined cells from a specific tissue, the 
synovium, which would presumably contain T-cell subsets of particular 
antigenic reactivity. This shows the value of looking at particular 
subsets of cells. Studies with TCR variable region probes may also 
prove useful in the study of SLE but the study on rhematoid arthritis by 
Savill was done with a probe from the constant region of the TCR-ß gene 
which shows that this should be sufficient to detect unusual 
rearrangemnts or clonality in SLE also.
CHAPTER SIX
DISCRIMINANT ANALYSIS IN SLE
AND OTHER IMMUNOLOGICAL VARIABLES.
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6.1 INTRODUCTION.
SLE is an extremely heterogeneous disease which can present 
clinically in many different ways and in differing degrees of severity. 
Diagnosis of SLE depends on the presence of a minimum of four, out of a 
total of 20, clinical and laboratory criteria, as established by the 
American Rheumatism Association (Tan et al. 1982), so it is possible for 
two given patients to be diagnosed with lupus and yet have no 
overlapping clinical or laboratory features. Attempts at clinical 
subsetting of SLE patients, aimed at improved patient treatment and 
management, have been made (Urowitz 1977; Provost 1979). However, the 
reproducibility of the proposed clinical and serological subsets is poor 
(American Rheumatism Association 1983), with patients sometimes shifting 
from one subset to another during the disease process. A useful 
approach to defining disease subsets in lupus is that of attempting to 
define genetic subsets. This approach was paramount in defining subsets 
of diabetes, with Type 1 (juvenile onset diabetes) clearly MHC 
associated and Type 2 (adult onset diabetes) not MHC associated 
(Cudworth et al. 1975).
A further difficulty in defining distinct clinical entities is that 
SLE patients share some features, including the production of a large 
array of autoantibodies, with other connective tissue diseases such as 
CREST, scleroderma, Sjogren's syndrome, dermatomyositis and 
polymyositis. Once again, the genetic approach may be useful, for 
example Whittingham et al. (1983a) found a strong association between 
anti-SS-A (La) and HLA-B8 in Sjogren's syndrome.
One method of looking for genetic associations in SLE is to use 
discriminant analysis on a large patient group which can be subdivided,
- 140-
for example by the classification criteria, to see what factors may be 
important in the susceptibility to certain clinical features. With 
discriminant analysis, it is also possible to analyse a large number of 
variables and assess their relative importance to the disease. Further, 
it is possible to search for the genetic and clinical features that help 
discriminate SLE from other connective tissue diseases.
Although this study has focussed on the role of the MHC and the 
T-cell receptor genes in the pathogenesis of lupus, other candidate 
genes include the immunoglobulins (Whittingnam et al. 1983b) and 
complement component C3 (McLean et al. 1980). Additional features that 
may or may not be under genetic control, include the presence or absence 
of lymphocytotoxic antibodies (LCAs) and rheumatoid factor (RF). This 
chapter describes the distribution of Gm allotypes, C3 phenotypes, LCAs 
and RF in SLE and CTD patients. These factors are then included along 
with other genetic and clinical features in discriminant analysis of SLE 
and other CTDs.
6.1.1 THE IMMUNOGLOBULINS.
Immunoglobulins (Igs) or antibodies are secreted from B-cells in 
response to foreign antigen and can be one of five classes: IgM, IgG, 
IgA, IgE, or IgD. They are comprised of four polypeptide chains, two 
heavy and two light. There are two classes of light genes, kappa (k ) 
and lambda (X). Polymorphisms of the immunoglobulins can be detected 
serologically, with those of the IgG heavy chain known as Gm allotypes, 
and those of K called Km. The Gm allotypes are commonly inherited as 
haplotypes which are highly conserved within a given population, but 
which vary between different ethnic groups. Several studies have looked
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at Gm and Km phenotypes in SLE with conflicting results. For example, 
both Schur et al. (1985) and Whittingham et al. (1983b) showed an 
increase in Gm heterozygosity in SLE while Stenszky et al. (1986) found 
no increase of Gm heterozygotes in their SLE patients. Evidence for an 
interactive effect between Gm and HLA types in SLE has been presented by 
some researchers (Whittingham et al. 1983; Stenszky et al. 1986) but not 
all (Schur et al. 1985). It has also been suggested that HLA-B8 and Gm 
homozygotes have an increased risk for renal involvement in SLE 
(Stenszky et al. 1987). This supports the proposal that different 
clinical subsets of lupus may have different genetic associations.
6.1.2 COMPLEMENT COMPONENT C3.
Complement component C3 is activated by both the classical and 
alternative complement pathways and therefore has a central role in 
complement activity. A decrease in the serum concentration of C3 is 
seen in active SLE, and deposition of C3 has been observed in the 
kidneys. C3 levels usually return to normal with remission of the 
disease. Little polymorphism has been observed in C3 (Alper and Propp 
1968), with 99% of individuals positive for one or two alleles, 03^ and 
C3*S (Wyatt 1984). A few rare alleles have been reported with a 
frequency of less than 1%. No major functional differences have been 
seen between C3*F and C3*S, but Arvilommi et al. (1974) suggested that 
the C3*F allele may have greater affinity for the monocyte C3b receptor 
than C3*S . One report has shown an increased incidence of C3*F in
patients with onset of SLE during childhood (McLean et al. 1980).
- 142-
6.1.3 LYMPHOCYOTOXIC ANTIBODIES.
Lymphocytotoxic antibodies against both B- and T-cells have been 
seen in the sera of SLE patients (Mittal et al. 1970; Stastny and Ziff 
1970; Terasaki et al. 1970) as well as in people with acute viral 
infections (Huang et al. 1973). These LCAs may be responsible for the 
lymphopenia seen in some SLE patients (Winfield et al. 1975b) and have 
also been associated with several other clinical features (Butler et al 
1972) .
6.1.4 RHEUMATOID FACTOR.
The anti-IgG antibody known as rheumatoid factor (RF) was initially 
seen in patients with rheumatoid arthritis, and has now also been seen 
in several other connective tissue diseases. RF can be induced by 
antigens cross reactive with IgG, polyclonal B cell activators or by 
aggregated IgG, for example in immune complexes (Fong et al. 1985) . RF 
is present in 70 to 90% of rheumatoid arthritis patients, but is usually 
present at a much lower frequency (20%) in SLE patients. Whether these 
antibodies play a role in the pathogenesis of SLE or other connective 
tissue diseases is not' known.
6.1.5 AIMS.
Gm allotyping and C3 phenotyping were performed on SLE and CTD 
patients to look for associations of Gm or C3 with these diseases. 
Lymphocytotoxic activity against B- and T-cells and rheumatoid factor 
activity were also examined in the SLE and CTD patients. Discriminant
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analysis using the MHC class II RFLP results, C4 and C2 data, T-cell 
receptor RFLPs, Gm allotypes, LCAs and RF data, C3 phenotypes and other 
serological markers was performed to determine factors distinguishing 
SLE from the related CTDs. The SLE patients were also examined to look 
for clinical subsets that could be defined by the laboratory results.
6.2 METHODS.
6.2.1 PATIENTS AND CONTROLS.
The SLE patients and the control series have been described in 
Chapters 2 and 3. Patients with PSS, CREST, linear scleroderma, 
Sjogren's, Pm/Dm, MCTD, and UNCTD were also examined.
6.2.2 Gm TYPING.
Gm and Km typing was performed on plasma samples from SLE and CTD 
patients and controls by Dr. D. Propert (Royal Melbourne Institute of 
Technology, Melbourne).
6.2.3 C3 TYPING.
SLE and CTD patients were C3 typed as described in Chapter 2 
following the method of Teisberg (1970).
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6.2.4 LYMPHOCYTQTOXIC ANTIBODY SCREENING.
This was performed as described in Chapter 2. Patient sera was 
screened with both B- and T-ceils from healthy individuals of known HLA 
type. The trays were read as for tissue typing, and the positive scores 
summed and then divided by the total number of target cells, to give a 
quantitative score ranging from 1.0 to 8.0.
6.2.5 RHEUMATOID FACTOR SCREENING.
Rheumatoid factor was tested for using the Rheuma-Wellcotest latex 
suspension (Wellcome). Agglutination reactions were scored from one to 
four, with four being the greatest reaction.
6.2.6 STATISTICS.
The computer statistic package SPSSX was used in the statistical 
analysis, (SPSSX User's guide 1986). Discriminant analysis (following 
Rao 1973) and factor analysis was performed.
6.3 RESULTS.
6.3.1 GM AND KM ALLQTYPING.
Table 6.1 gives Gm phenotyping results in SLE and CTD patients 
compared with the controls. The SLE patients did not differ from the 
controls in their distributions of Gm types, with a similar number of 
heterozygotes and homozygotes in the patients and controls.
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TABLE 6.1 GM PHENOTYPES IN SLE AND CTD PATIENTS COMPARED WITH CONTROLS.
Gm phenotype
CON SLE PSS/CREST SJOGREN'S PM/DM MCTD/UNCTD
N % N % N % N % N % N %
1 5 6.8 3 3.6 4 11.8 1 14.3 0 0
1; 23 0 1 1.2 1 2.9 0 0 0
1,2 5 6.8 2 2.4 3 8.8 0 2 14.3 3 15.8
1,2;23 0 1 1.2 0 0 0 0
1,3;5,10 11 15.1 8 9.6 2 5.9 1 14.3 2 14.3 1 5.3
1,3;23;5,10 10 13.7 15 18.1 3 8.8 1 14.3 1 7.1 3 15.8
1,2,3;5,10 3 4.1 6 7.2 1 2.9 0 2 14.3 1 5.3
1,2,3;23;5,10 9 12.3 11 13.3 0* 1 14.3 1 7.1 1 5.3
3;5,10 5 6.8 4 4.8 2 5.9 1 14.3 0 2 10.5
3;23;5,10 24 32.9 31 37.3 17 50.0 2 28.6 6 42.9 7 36.8
1; 10 0 1 1.2 1 2.9 0 0 0
1;5,10 1 1.4 0 0 0 0 1 5.1
Number 73 83 34 7 14 19
tested
* p=.03
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TABLE 6.2__KM1 ALLOTYPING IN SLE AND CTD PATIENTS AND CONTROLS.
CON SLE PSS/CREST SJOGREN'S PM/DM MCTD/UNCTD
Km phenotype N % N % N % N % N % N %
Kml positive 17 23.3 18 21.4 8 22.9 2 28.6 2 13.3 4 20.0
Kml negative 56 76.7 66 78.6 27 77.1 5 71.4 13 86.7 16 80.0
Number
tested
73 84 35 7 15 20
TABLE 6.3 C3 PHENOTYPE AND ALLELE FREQUENCIES IN SLE ÄND CTD PATIENTS.
SLE PSS/CREST SJOGREN *S PM/DM MCTD/UNCTD
Phenotype N % N % N % N % N %
C3F,F 3 3.5 1 2.8 0 0 1 5.0
C3F, S 27 31.4 10 27.8 2 28.6 3 20.0 4 20.0
C3S, S 56 65.1 25 69.4 5 71.4 12 80.0 15 75.0
Number
tested
86 36 7 15 20
Allele
C3*F 0 ,.192 0.167 0.143 0.100 0.150
C3*S 0 ,.808 0.833 0.857 0.900 0.850
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The four connective tissue disease groups ail showed similar 
distributions of Gm phenotypes compared with the controls except for the 
scleroderma/CREST patient group, where none of the 34 patients were 
positive for the 1,2,3;23;5,10 phenotype (X^=3.12, p(corr) = .08). There 
was a nonsignificant increase in Gm 3;23;5,10 in this disease group
(x2=2.19).
Table 6.2 gives the results for Km(l) typing. The proportion of 
patients in each disease group who are positive for Km(l) is similar to 
that in the control series indicating that Km(l) is not an important 
disease marker in SLE and the connective tissue diseases studied here.
6.3.2 COMPLEMENT COMPONENT C3.
Table 6.3 shows the C3 phenotype and allele frequencies in the SLE 
and CTD patients. In healthy Europeans, the frequency of the C3*S 
allele is about 80% (Welch and Berny 1987). All the disease groups here 
showed similar phenotype distributions with C3S,S the most common 
phenotype followed by C3F,S. The C3F,F phenotype occurred only in a 
small percentage of the patients. Allelic distributions are also 
similar between the disease groups.
6.3.3 LYMPHOCYTOTQXIC ANTIBODIES.
Lymphocytotoxins were present mainly in the lupus patients as shown 
in Table 6.4. LCAs against T-cells were seen in only two of the 68 CTD 
patients (one with CREST and one with MCTD) in contrast to 26% of the 
SLE patients. LCAs with B-cell reactivity were more prevalent and 
generally of a slightly higher titre than those against T-cells and were
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TABLE 6.4 LYMPHOCYTOTOXIC ANTIBODIES IN SLE AND CTD PATIENTS.
SLE PSS/CREST SJOGREN'S PM/DM MCTD/UNCTD
LCA activity N % N % N % N % N %
T-cells
0-2.5 53 73.6 29 96.7 6 100.0 13 100.0 18 94.7
2.6-8.0 19 26.4 1 3.8 0 0 1 5.3
Number
tested
B-cells
72 30 6 13 19
0-2.5 52 72.2 28 93.3 6 100.0 12 92.3 17 89.5
2.6-8.0 20 27.8 2 6.7 0 1 7.7 2 10.5
Number
tested
72 30 6 13 19
TABLE 6.5 RHEUMATOID FACTOR IN SLE AND CTD PATIENTS.
RF Activity
SLE PSS/CREST SJOGREN’S PM/DM MCTD/UNCTD
N % N % N % N % N %
0 48 66.7 22 75.9 0 11 91.7 3 50.0
1 14 19.4 4 13.8 1 16.7 1 8.3 2 12.5
2 5 6.9 2 6.9 1 16.7 0 2 12.5
3 3 4.2 1 3.4 1 16.7 0 1 6.3
4 2 2.8 0 3 50.0 0 3 18.8
Number 72 29 6 12 16
tested.
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seen in five of 68 CTD patients (7.1%) compared with 28% of the SLE 
patients.
6.3.4 RHEUMATOID FACTOR.
Table 6.5 gives the rheumatoid factor results. RF was present in 
ail the disease groups, with about 33% of lupus patients positive for 
RF. All the Sjogren's patients were positive for RF, with three of the 
six patients having the highest possible titre. About 24% of the 
scleroderma/CREST patients and 50% of those with MCTD or UNCTD had RF 
activity. RF was seen in only one of 12 patients with Pm/Dm.
6.3.5 DISCRIMINANT ANALYSIS BETWEEN SLE AND THE CTDs.
Discriminant analysis was initially carried out using the following 
variables: MHC class II RFLPs and DNA-DR types, C4 allotypes, C2 
activity, T-cell receptor RFLPs, Gm haplotypes, C3 phenotypes, 
lymphocytotoxic and rheumatoid factor activity, anti-RNP, anti-SS-A, 
anti-SS-B and sex of the patient. These were used to find variables 
which might discriminate between SLE and the connective tissue diseases 
studied here (all the other CTDs combined). Table 6.6 gives the 
unstandardized canonical discriminant function coefficients of the 
variables which contributed to the discrimination of SLE and the CTDs. 
These were used to classify a patient as having either SLE or a CTD.
With these variables, 54 of 71 SLE patients (76.1%) and 45 of 34 CTD 
patients (53.6%) were classified correctly, with 63.9% correct overall. 
If patients were assigned randomly to the SLE or CTD disease groups, the 
statistical probability of correct assignment would be 50%.
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TABLE 6.6 UNSTANDARDIZED CANONICAL DISCRIMINANT FUNCTION 
COEFFICIENTS WHEN ALL VARIABLES ARE USED TO 
DISCRIMINATE BETWEEN SLE AND THE CTDS.
VARIABLE COEFFICIENT
HLA-DR5 0.829
HLA-DR7 1.492
HLA-DRwlO -2.132
C4A*2 1.058
C4A*6 2.652
C4B*2 -1.142
50% C2 2.071
DRa/Bglll/4.4kb 1.435
DPß/Bglll/19kb -0.756
TCRy/TaqI/3.3kb -1.524
LCAs against T-ceils 0.487
Anti-RNP -1.078
(Constant) -3.485
TABLE 6.7 UNSTANDARDIZED CANONICAL DISCRIMINANT FUNCTION 
COEFFICIENTS OF VARIABLES USED TO DISCRIMINATE 
BETWEEN SLE AND THE CTDS.
VARIABLE COEFFICIENT
HLA-DR3 0.966
C4B*2 -0.857
TCRß/BglII/9.2kb 0.577
LCAs against B cells 0.470
RF -0.492
(Constant) -1.381
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When results for a chosen variable were not available for a 
particular patient, the patient was excluded from the initial analysis 
of the significance of the variables (discriminant step), and the 
computer analysis was carried out on a smaller number of patients than 
those used in the final classification step. This means that ehe number 
of patients can vary slightly depending on the variables used.
Therefore, patients for whom there were no LCA and RF results (27 
patients) were excluded from the next analysis, as were some of the 
variables which were not useful in discriminating between SLE and the 
other CTDs in the initial analysis.
In subsequent analyses, variables which did not contribute to the 
discrimination were removed. When the variables DR3, C4B*2, RF, 
lymphocytotoxins against B-cells, and the TCRß/BglII/9.2kb RFLP were 
used, 45 of 60 or 75% of the SLE patients and 53 of 68 (77.9%) of the 
CTD patients were classified correctly, with 76.6% correct overall. The 
unstandardized canonical discriminant function coefficients are shown in 
Table 6.7. The discriminant analysis could not be improved beyond this 
point when other variables were included.
A correlation matrix of the variables HLA-B8, DR3, C4B*2, LCAs 
against B- and T-cells, RF and the TCRß/BglII/9.2kb RFLP is shown in 
Table 6.8. As expected, HLA-B8 and DR3 showed a high level of 
correlation as do the LCAs against B- and T-cells. However, replacing 
DR3 with the joint occurrence of B8 and DR3 in the discriminant analysis 
did not improve the classification of the patients, with 92 (71.9%) of 
the patients being correctly classified when B8,DR3 was used and 98 
(76.6%) correctly classified when DR3 was used. Similarly, T-cell LCAs 
were not as informative as B-ceil LCAs in the discriminant analysis, 
with 91 (71.1%) of the patients grouped correctly when T-cell LCAs were
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included compared with 98 (76.6%) correctly grouped when B-cell LCAs 
were used.
6.3.6 ANALYSIS OF CLINICAL SUBSETS OF SLE.
The SLE patients were divided into two groups depending on the 
presence or absence of particular ARA classification criteria. The 
number of patients with or without malar rash, discoid rash, oral 
ulcers, arthritis, pericarditis, proteinuria, renal disorders, seizures, 
psychosis, haemolytic anaemia, leukopenia, lymphopenia, 
thrombocytopenia, positive LE cell prep, anti-Sm, false positive test 
for syphilis and antinuclear antibodies was less than ten in the initial 
analysis when all variables were included, so discriminant analysis was 
not performed on these classification criteria.
The classification criteria tested were presence or absence of 
photosensitivity, pleuritis and anti-DNA antibodies. The discriminant 
analysis was initially carried out with all available variables and 
those which were not significant were then removed from the analysis, 
resulting in a smaller number of variables which could be used to define 
these three classification criteria.
6.3.6.1 PHOTOSENSITIVITY.
Presence or absence of photosensitivity was best defined by the 
following variables: HLA-DR4, C4A*2, anti-SS-A, and the DPf3/BglII/19kb 
RFLP. (Unstandardized canonical discriminant function coefficients are 
given in Table 6.9). In this analysis, 34 of 44 (77.3%) of the 
photosensitive patients were grouped correctly and 19 of 28 (67.9%) of
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TABLE 6.9 UNSTANDARDIZED CANONICAL DISCRIMINANT FUNCTION 
COEFFICIENTS OF VARIABLES USED TO DISCRIMINATE 
SLE PATIENTS WITH PHOTOSENSITIVITY.
VARIABLE COEFFICIENT
HLA-DR4 0.809
C4A*2 -1.074
DP0/BglII/19kb -1.501
Anti-SS-A 1.731
(Constant) 0.477
TABLE 6.10 UNSTANDARDIZED CANONICAL DISCRIMINANT FUNCTION 
COEFFICIENTS OF VARIABLES USED TO DISCRIMINATE 
SLE PATIENTS WITH PLEURITIS.
VARIABLE COEFFICIENT
HLA-DR1 -2.290
HLA-DRw8 -2.411
DRct/BglII/3.9kb 1.071
DP£/EcoRV/12kb 1.652
DPß/EcoRV/8kb 2.240
TCRß/BglII/9.2kb -1.880
(Constant) -0.175
TABLE 6.11 UNSTANDARDIZED CANONICAL DISCRIMINANT FUNCTION 
COEFFICIENTS OF VARIABLES USED TO DISCRIMINATE 
SLE PATIENTS WITH ANTI-DNA ANTIBODIES.
VARIABLE COEFFICIENT
HLA-DRw8 2.902
HLA-DRW14 2.528
DRa/BglIl/3.9kb -1.194
TCRa/EcoRV/1.7kb -1.456
LCAs against B-cells 0.486
Anti-SS-B -1.319
Sex 2.050
(Constant) -3.810
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those not photosensitive were correctly classified, with 73.6% correct 
overall. The four discriminating variables were then examined in 
relation to the presence or absence of photosensitivity. Anti-SS-A was 
significantly increased in patients with photosensitvity, (X^=4.0, 
p(corr)=.04), with 11.8% of the photosenstitive negative patients being 
anti-SS-A positive, and 34.1% of the patients who were photosensitive 
being anti-SS-A positive. Of the remaining three variables, DR4 was 
increased and the DP(3/BglII/19kb RFLP was decreased in the 
photosensitive positive patients, but neither was statistically 
significant. The C4A*2 allele may have been included in the 
discriminant function because of the small number of individuals 
carrying this allele (four who were photosensitive, two who were not).
6.3.6.2 PLEURITIS.
The variables HLA-DR1 and -DR8, DPß/EcoRV/12kb and 8kb RFLPs, 
TCRß/BglII/9.2kb and DRa/BglIl/3.9kb RFLPs and were the most useful in 
discriminating patients with pleuritis. With these variables, 20 of 29 
(69.0%) of patients with pleuritis were classified correctly, while 37- 
of 43 (86.0%) of patients without pleuritis were correctly grouped, with 
79.2% correct overall. Table 6.10 gives the unstandardized canonical 
discriminant function coefficients. The discriminating variables in 
this analysis were correlated with the presence or absence of pleuritis, 
and the DPß/EcoRV/12kb RFLP was significantly decreased in patients with 
pleuritis, being present in only 41.9% of pleuritis positive patients 
compared with 73.9% of pleuritis negative patients (X^=6.7, 
p(corr)=.01). The DPß/EcoRV/12kb fragment correlates with the 
DPß/BglII/19kb RFLP, and this fragment was similarly decreased in the
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FIGURE 6.1 a. DPß hybridization of EcoRV digested DNA
b. DP0 hybridization of Bglll digested DNA
a. DP/3/EcoRV
•  •  - 1 2
b. DP/3/BglII
m  -  - 8
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patients with pleuritis, but was not a useful variable in the 
discriminant analysis when the 12kb EcoRV fragment was included (DPß 
RFLPs are shown in Figure 6.1). HLA-DR1, the DRa/BglII/3.9kb and the 
TCRß/BglII/9.2kb RFLPs were all decreased in patients with pleuritis, 
but none was statistically significant. HLA-DRw8 was probably included 
in the discriminant function because of the low frequency of this 
allele, with only one patient HLA-DR8 positive (pleuritis positive).
6.3.6.3 ANTI-DNA ANTIBODIES.
Patients with anti-DNA antibodies were best defined by the 
variables HLA-DRw8, HLA-DRwl4, LCAs against B-cells, DRa/BglII/3.9kb and 
TCRa/EcoRV/1.7kb RFLPs, anti-3S-B, and sex. In this analysis, 49 of 55 
(89.1%) of patients with anti-DNA antibodies and 10 of 17 (58.8%) of 
patients without anti-DNA antibodies were classified correctly, with 
81.9% correct overall. (The unstandardized canonical discriminant 
function coeffiecients are given in Table 6.11). Only 5% of the 
patients without anti-DNA antibodies were males, compared with 18.5% of 
patients with anti-DNA antibodies being male (not statistically 
significant). HLA-DRw8 and DRwl4 were present at a low frequency (one 
DRw8 positive and four DRwl4 positive patients, all with anti-DNA 
antibodies), which probably accounts for their inclusion in the 
discriminant analysis. Alternatively, in combination with the other 
variables in the discriminant function, HLA-DRw8 and DRwl4 may be 
important discriminating variables. The TCRa/EcoRV/1.7kb and 
DRa/BglII/3.9kb RFLPs did not show signifcantly different distributions 
in the anti-DNA positive patients and the anti-SS-B antibodies were 
present in a similar number of patients with and without anti-DNA
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antibodies. It is possible that a combination of these variables may be 
important in patients with anti-DNA antibodies.
6.4 DISCUSSION.
6.4.1 DISCRIMINATION OF SLE FROM CTDs.
Lymphocytotoxic activity against B-cells was one of the most 
important variables in the discriminant analysis between SLE and the 
CTDs. Although only 28% of the SLE patients had LCAs against B-cells, 
very few (7%) of the CTD patients had these antibodies. A much higher 
incidence of LCAs in lupus has been observed in other studies, with up 
to 80% of patients reported to be positive for LCAs (Malave et al. 1976; 
Mittal et al. 1970; Persselin et al. 1977). However, a study of IDDM 
patients (Serjeantson et al. 1981), has shown that the level of LCAs 
decreases dramatically from the time of disease onset. It is not known 
whether a similar phenomenon occurs in SLE, because SLE is not always 
diagnosed at "onset" because of the diversity of clinical features which 
make diagnosis difficult. A patient may have less than the required 
number of ARA criteria for some time before SLE is officially diagnosed, 
and by that time the level of LCAs may have dropped considerably. This 
study included patients who had SLE for some time, which could account 
for the lower level of LCAs observed in this series. Also, 
lymphocytotoxic antibodies have been reported to increase with disease 
activity in lupus (Butler et al. 1972; Winfield et al. 1975b), and the 
patients studied here did not necessarily have active disease at the 
time of blood collection. LCAs may well be an important pathogenic
factor in SLE as indicated by the discriminant analysis here.
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DR3 was also included in the discriminant function, which is 
consistent with the results presented in Chapter 3 where DR3 was 
significantly increased in the SLE patients. Other class II RFLPs do 
not appear to contribute to the discriminant analysis between SLE and 
the CTDs. Surprisingly perhaps, when the joint occurrence of B8 and DR3 
was used in the discriminant analysis instead of DR3 alone, (because B8 
and DR3 are in linkage disequilibrium with the C4A null allele), a 
slight drop was seen in the number of patients correctly classified.
This is because not all C4A null alleles are necessarily on the B8.DR3 
haplotype, (Batchelor et al. 1987), and because patients positive for 
both B8 and DR3 did not necessarily carry these alleles on the same 
chromosome, despite the high level of linkage diseqilibrium between 
them. Complete C4A deficiency was not a significant variable in the 
discriminant analysis, because of the small number (6) of individuals 
with complete C4A deficiency. As described in Chapter 4, DR3 is a 
"marker" for the C4A null allele and its contribution to SLE is 
secondary to partial and complete C4A deficiency. Partial C4A 
deficiency was not included in the discriminant analysis because of the 
difficulty in assigning some null alleles.
Rheumatoid factor and C4B*2 also contributed to the discriminant 
analysis. RF is present in many connective tissue diseases including 
rheumatoid arthritis, Sjogren's syndrome, MCTD and UNCTD. RF selected 
for the CTD patients rather than the SLE patients as shown by the 
negative value in function 1. C4B*2 which correlates negatively with
C4A*Q0, had a higher frequency in the CTDs than in SLE and contributed 
to the discriminant analysis. This enforces once again the importance 
of complete or partial C4A deficiency in SLE. The positive contribution 
of the TCRß/BglII/9.2kb RFLP to the selection of the SLE patients
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reflects the significant decrease of this fragment in the CTD patients 
(Chapter 5).
No Gm phenotypes contributed significantly to the discriminant 
analysis between SLE and the CTDs, nor were Gm phenotype distributions 
different in SLE compared with the controls. This is in contrast to 
other studies where Gm heterozygosity was increased (Whittingham et al. 
1983; Schur et al. 1985) and where interaction between Gm and HLA 
phenotypes was seen (Whittingham et al. 1983; Stenszky et al. 1986). 
Stenszky et al. (1986) have also reported a role for Gm and HLA-B8 in 
patients with renal involvement, but this was not seen in another study 
(Schur et al. 1985). The variables here could not successfully 
discriminate between patients with and without renal involvement, so the 
role of Gm could not be fully investigated.
C3 does not appear to be important in the SLE patients studied 
here, either in the discriminant analysis or the phenotypic 
distributions, which is in agreement with another recent study (Welch 
and Berny 1987). Of the clinical features examined by discriminant 
analysis, (photosensitivity, pleuritis, and anti-DNA antibodies), C3 was 
not a significant variable.
6.4.2 CLINICAL SUBSETS OF SLE.
The three classification criteria analysed by discriminant analysis 
could be partly defined by some of the genetic variables. For example, 
pleuritis patients showed a signiicant decrease in the DPß/EcoRV/12kb 
fragment which correlates with DPwl, w3, w5, and w6 (Hyldig-Nielsen et 
al. 1987). The alternate fragment (8kb) was not increased suggesting 
that there was an increase of DPw2 and DPw4 homozygotes in the pleuritis
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positive patients. This would need to be further examined to see if 
there was a role for DP in pleuritis. Of the clinical variables, 
anti-SS-A antibodies were strongly associated with photosensitivity 
which is in accord with earlier clinical studies associating anti-SS-A 
antibodies with skin lesions (Gilliam and Sonthheimer 1982). Exposure 
to sunlight exacerbates most skin problems in lupus.
The three classification criteria examined did have different 
combinations of variables which were important in the discriminant 
analysis, supporting the hypothesis that different genetic variables are 
responsible for various clinical features. Not all the patients were 
correctly classified with respect to the presence or absence of 
particular classification criteria, but patients are positive for at 
least four of the ARA criteria and therefore could be expected to have 
four different genetic factors involved, which makes it harder to select 
for one primary genetic variable being associated with one clinical 
feature.
6.4.3 GM AND C3 IN THE CTD PATIENTS.
Only the PSS/CREST patients showed a difference in Gm phenotype 
distributions, with none of the patients carrying the 1,2,3;23;5,10 
phenotype. However, none of the Gm specificities were increased or 
decreased, nor was the homozygote to heterozygote ratio different in 
this patient group, so the absence of this phenotype may be a function 
of small sample size. A larger patient group will need to be examined 
to see if this is indeed a significant finding. The other CTDs examined 
have too few patients to make any definite conclusions about the role of 
Gm in these diseases. Complement component C3 did not appear to play an
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important role in the connective tissue diseases studied here, although 
patient numbers in some of the disease groups are low.
6.5 CONCLUSION.
Discriminant analysis between SLE and the CTD patients has shown 
that lymphocytotoxic activity against B cells is an important 
differentiating variable and may play a more important role in the 
pathogenesis of SLE than was previously thought. DR3 was the only MHC 
class II antigen associated with SLE which supports the findings of 
Chapter 3 and refects linkage disequilibrium with the C4A null allele. 
Gm and C3 do not appear to be associated with SLE or clinical subsets 
of SLE. Some genetic heterogeneity in clincal subsets of SLE was 
observed, but no distinguishing genetic factor was found.
CHAPTER SEVEN
GENERAL DISCUSSION: MECHANISMS OF DISEASE IN
SYSTEMIC LUPUS ERYTHEMATOSUS
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Systemic lupus erythematosus is one of many diseases that has shown 
associations with the genes of the major histocompatibility complex. 
Disease associations with MHC genes are rarely absolute, with the 
notable exception of narcolepsy, (Juji et al. 1985; Langdon et al.
1984), and this is often attributed to linkage disequilibrium between 
genes in the MHC, which can make it difficult to distinguish between a 
disease susceptibility gene and a gene merely acting as a "marker1 for 
the actual disease promoting locus. However, there is the possibility 
of more than one gene within the MHC contributing to a disease. In 
addition, an MHC gene and genes outside the MHC (for example the T-cell 
receptor or immunoglobulin genes) may also influence inherited 
disposition to a disease. For example, in IDDM it has been estimated 
that MHC genes contribute, at the most, about 60% of the genetic 
susceptibility (Rotter and Landlaw 1984). It is also likely that 
environmental agents play a role in several MHC associated diseases 
including systemic lupus erythematosus as suggested by a lack of 
concordance in family and twin studies (Arnett et al. 1984).
The mechanisms involved in the MHC class I and II gene disease 
associations are not clear, although several mechanisms have been 
proposed, as recently reviewed by Batchelor and McMichael (1987). The 
MHC class I and II HLA genes encode the proteins which are involved in 
the presentation of antigen on the cell surface, resulting in 
recognition of foreign antigen by the T-cell receptor, and a full immune 
response. There are several ways in which the HLA proteins could be 
involved in susceptibility to a disease, including (1) HLA antigens as 
virus receptors (2) molecular mimicry (3) control of immune 
responsiveness.
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The HLA antigens could act as receptors for viral pathogens, thus 
facilitating viral entry into a cell. Experiments testing this 
hypothesis have given conflicting results. For example, one study 
showed that the HLA-A and -B antigens in man and the equivalent H-2K and 
-2D antigens in mouse were acting as receptors for Semliki Forest virus 
(Helenius et al. 1978). However, it has been reported that Semliki 
Forest virus can infect and replicate in murine cell lines which do not 
express H-2 antigens (Oldstone et al. 1980). In contrast to this, 
another report by Oldstone et al. (1975) indicated that this same virus 
could not replicate in Daudi cells which do not express HLA antigens. A 
recent study has shown that human cytomegalovirus (HCMV), which usually 
affects immunosuppressed patients, has a gene which is very similar to 
the HLA class I genes (Beck and Barrell 1988). HCMV has been shown to 
bind to the ß2-microglobulin protein of the class I antigens (Grundy et 
al. 1987a), raising the possibility that binding to the ß2-microglobulin 
may be an infection mechanism of the. virus (Grundy et al. 1987b). It 
has yet to be shown if the HCMV uses this newly discovered HLA-like 
protein to bind to the HLA antigens. In the case of SLE, there is not a 
100% concordance between the disease and a particular HLA antigen, nor 
are there any HLA antigens seen in SLE which are not seen in a healthy 
population, which argues against an HLA antigen acting as receptor for a 
viral pathogen. However, it should be noted that non-antigenic 
molecular variation occurs in class I (Strominger 1987) and class II 
(Todd et al. 1987) antigens. HLA-DR3 was increased in the Caucasoid 
lupus patients studied here, but is also present at a significant level 
in the general population, suggesting that other factors are more 
important. DNA sequence data have not revealed heterogeneity in the 
DRß 1, DQa or DQß genes in DR3 positive individuals,
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(Boss and Strorainger 1984; Gorski and Mach 1986; Bell et al. 1987; Todd 
et al. 1987), although DR3 is associated with two different DRß3 genes 
(Gorski and Mach 1986; Tiercy et al. 1988). The present study has shown 
an increase in DR3, particularly on the B8.DR3 haplotype which can be 
differentiated from B18.DR3 by RFLP analysis (Chapter 3). However, the 
B8.DR3 haplotype is common in healthy Caucasoid individuals, which does 
not support a particular DR3 variant acting as a viral receptor in SLE.
Another mechanism put forward to explain HLA associations with 
disease is that of molecular mimicry. The HLA proteins could be 
serologically cross reactive with infectious organisms resulting in a 
failure to mount an immune response, or, a reaction against these 
pathogens could result in autoantibodies. Evidence for mimicry comes 
from HLA-B27 and diseases with which it has been associated, for example 
ankylosing spondylitis, (AS), (reviewed by Tiwari and Terasaki 1985). 
Klebsiella pneumoniae has been isolated from patients with AS at a 
higher rate during active disease (Ebringer et al. 1977), and B27 has 
been shown to cross react with antibodies to K.pneumoniae, while 
antibodies to B27 react with K.pneumoniae (Ebringer et al. 1976). 
However, another study did not confirm these results (Archer et al. 
1981). B27 is also increased in frequency in patients with Reiter's
disease and reactive arthropathy, which develop after large bowel or 
urinary tract infections with Shigella, Salmonella, Yersinia or 
Chlamydia or other bacteria. Molecular mimicry may be involved as the 
B27 association is very high, particularly with AS, and no association 
with the class II DR antigens has been seen in these diseases, although 
an immune response should not develop against self-like antigens, and an 
anti-B27 antibody has not yet been found in AS patients. It is possible
that those antigenic sites with self-like epitopes on a pathogenic agent
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could cause an increase in T-supressor cell activity, therefore 
decreasing T-helper cell activity against other more immunogenic sites 
on a pathogenic agent, and letting an infectious agent persist longer 
(Batchelor and McMichael 1987).
A third hypothesis put forward is that the HLA genes are "immune 
response" genes which influence an individuals response to foreign 
antigens. Immune response genes have been mapped in the mouse,
(reviewed by Benacerraf and Germain 1978), and are believed to be 
equivalent to the HLA-D/DR genes in man (Sasazuki et al. 1983). Support 
for this comes from diseases that were initially associated with the 
HLA-B antigens later showing stronger associations with the DR genes. 
Also, HLA-B assocations with a particular disease can differ between 
various ethnic groups which could be explained by different linkage 
disequilibrium relationships with the same immune response gene. One 
study (Melief et al. 1986) has shown that a mouse strain with three 
changes in the H-2K gene does not respond to Sendai virus and dies while 
the normal mouse strain does respond immunologically, suggesting that 
the H-2 antigen determines if there will be a response to a foreign 
antigen. Studies of man have shown that isolated populations which have 
been subjected to a virulent disease, can have different HLA profiles 
compared to the population from which they originated. For example, 
descendants of the Dutch people in Surinan who had zo survive typhoid 
and yellow fever epidemics after emigration from Holland, have different 
HLA antigen frequencies to those who remained in Holland (De Vries et 
al. 1979). The HLA antigens B8 and/or DR3 which are increased in lupus 
studies have been associated with impaired responsiveness in vitro to 
phytohaemagglutinin, concanavalin A and a-helix haemocyanin, (Amer et
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al. 1986; McCombs and Michalski 1982; Kallenberg et al. 1981), which is 
suggestive of immune response involvement by the HLA antigens.
HLA antigens are not necessarily the only MHC genes involved in 
disease susceptibility. Congenital adrenal hyperplasia (CAH) is 
associated with certain HLA haplotypes which is clearly explained by 
linkage disequilibrium with the class III 21-OH genes one of which, (21- 
OHB), is partly deleted in patients with CAH (White et al. 1984). The 
21-OHA gene is not believed to be active in the general population 
(White et al. 1986). Without the 21-hydroxylase enzyme, there is a lack 
of cortisol, a subsequent increase in adrenocorticotrophic hormone, and 
therefore a build-up in the precursors to cortisol. An excess of 
androgens results in CAH, in both the simple virilization and salt 
wasting forms, both of which show different HLA haplotype associations.
The complement genes could also be involved in susceptibility to 
certain diseases, in particular to systemic lupus erythematosus. Early 
studies showed associations with the HLA class I antigens B5 and B8, and 
as serology developed, with the class II antigens DR2 and DR3 (Tiwari 
and Terasaki 1985). However, it is now becoming clear from several 
studies that SLE shows stronger associations with the class III loci 
than with the HLA genes, in particular with deficiencies of complement 
components C2 and C4. Several studies including this one have now 
focussed attention specifically on the deficiency of C4A (Christiansen 
et al. 1983; Howard et al. 1986; Kemp et al. 1987), and this is seen not 
only in Caucasoids, but also several other non-Caucasoid populations 
including American blacks, Japanese and Chinese, where different linkage 
relationships exist. The common locus between different ethnic groups 
is more likely to be the one most important in the disease. SLE is 
characterized by immune complexes which are believed to cause much of
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the tissue damage seen in lupus, so a complement deficiency is very 
likely to be pathogenic as it would allow a build-up of immune 
complexes, facilitating immune complex precipitation. In addition to 
the important role of C4A in binding to amino nucleophiles on immune 
complexes, (discussed in Chapter 4), the classical complement pathway, 
of which C4 is a part, has been shown to be more important than the 
alternative pathway in the prevention of immune precipitation (Webb and 
Whaley 1986; Schifferli et ai. 1986a). This indicates the importance of 
a fully functional classical pathway to stop the initial precipitation 
of immune complexes which would cause tissue damage. However, not all 
the lupus patients studied here have C4A deficiencies, suggesting 
genetic heterogeneity in SLE.
C4B deficiency was not implicated in this study, although other 
researchers have reported an increase of C4B null alleles in lupus 
patients (Fielder et al. 1983; Reveille et al. 1985), particularly in 
DR3 negative patients (Batchelor et al. 1987). It could be that 
deficiency of C4B does play a role in lupus, but that it is not as 
damaging as C4A deficiency (as indicated by the ethnic study and 
logistic analysis results in Chapter 4). In this study, neither 
complete or partial C4B deficiency increased susceptibility to lupus, 
even when HLA-DR3 status was statistically controlled in the logistic 
regression. The differing results may be due to clinical heterogeneity 
between patient study populations. However, the study of the DR3 
negative patients does support the hypothesis that complement deficiency 
is a pathogenic factor in lupus.
It is also possible that different complement deficiencies may be 
present in different clinical subgroups of SLE. For example, it has 
been reported that the clinical presentation in patients with lupus
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associated with C2 deficiency does differ from classical lupus. This 
includes an increase in discoid lesions, a decrease in the incidence of 
renal disease, lower titres or no ANAs and anti-DNA antibodies, and less 
Ig and complement deposits in skin lesions (reviewed by Agnello 1986). 
While there were decreased levels of C2 in many of the lupus patients in 
this series (Chapter 4), this did not appear to be due to inherited C2 
deficiency. Similarly, another study in Australia (Christiansen et al. 
1983) reported no increase of inherited C2 deficiency in their lupus 
patients. However, studies elsewhere have shown C2 deficiency to be 
increased in 3LE (Glass 1976; Rynes 1982). These conflicting results 
could once again be partly explained by clinical heterogeneity in the 
patient series. However, because C4 reacts directly with immune 
complexes, deficiency of C4 may be more critical in SLE than that of C2.
Another indication that the complement system is important in lupus 
comes from studies of the CR1 receptor (reviewed by Atkinson 1986; 
Walport and Lachmann 1983). CR1 binds to either C3b or C4b, which in 
turn are bound to immune complexes, thus facilitating removal of immune 
complexes from the circulation. CR1 is found on B cells, granulocytes, 
macrophages and monocytes, but the majority are found on erythrocytes 
due to the large number of red blood cells in the blood. This means 
that immune complexes can be quickly transported to the liver where they 
are removed. Studies of CR1 have shown a decrease in the number of 
receptors on RBC in SLE patients (Iida et al. 1982; Wilson et al. 1984) 
and also reduced adherence of immune complexes to CR1 (Miyawaka et al. 
1981). At this time it is not clear if these differences are inherited 
(Wilson et al. 1982), or acquired as a result of lupus (Iida et al.
1982; Inada et al. 1982; Kazatchkine et al. 1982; Uko et al. 1985),
although the evidence tends to support an acquired defect. However, it
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is clear that a defect in this receptor, (either by reduced numbers or 
reduced binding capacity), would result in slower clearance of immune 
complexes from the circulation, so there would be more chance of immune 
complex precipitation and deposition and therefore tissue damage. The 
C4, C2, and CR1 studies all point to an important role for the 
complement system in SLE. However, these cannot be the only genes 
involved in lupus as C4 and C2 deficiencies, and lower levels of CR1 are 
also seen in healthy individuals.
Interest is now focussing on the region between the class I and 
class III genes of the MHC, where the tumor necrosis factor genes have 
recently been mapped (Dunham et al. 1987; Carroll et al. 1987). A 
recent report (Jacob and McDevitt 1988) has shown that NZW mice have a 
RFLP in the TNF-a gene which correlates with decreased levels of the 
TNF-a protein. When replacement therapy with a recombinant TNF-a 
protein was performed, there was a delay in the onset of lupus nephritis 
and a longer survival rate in the (NZB x NZW)F1 mice. Untreated FI mice 
had a 95% mortality rate in 12 months compared to 30% in the same time 
in the TNF-a treated mice. Now that the human TNF genes have been 
cloned, studies of this gene should be undertaken in SLE patients to see 
if a similar role for TNF may be found in man also.
There is also the possibility of new genes being found in the area 
of zhe MHC between the class I and III genes, which could play a part in 
diseases. Pulsed field gel electrophoresis has shown that the A1.B8.DR3 
haplotype carries a large deletion of about 40kb between the TNF and 
HLA-B genes (Tokunaga et al. 1988) which is of interest in studies of 
SLE, as many lupus patients have this HLA haplotype. Ethnic studies may
be useful in studying this region as shown for the complement genes in
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this study, to see if there is a common factor in this region which is 
associated with SLE.
Studies of murine lupus models indicate that genes outside the MHC 
are also involved in the pathogenesis of SLE, for example, the lpr gene 
in MRL mice and Y-chromosome linked genes in BXSB mice. Some studies 
have also suggested that the T-cell receptor genes play a role, but 
these have been discrepant (Yanagi et al. 1986; Kotzin et al. 1987). No 
association was seen with the TCR RFLPs in this study (Chapter 5). If 
it was possible to examine a more restricted T cell population, as was 
done by Savill et al. (1987) when looking at synovial fluid from 
patients with rheumatoid arthritis, unusual TCR gene rearrangements may 
be seen. However, because of the systemic, diffuse nature of SLE it 
will be difficult to find a restricted population. A probe specific for 
the variable region of the TCR genes might also be useful to see if 
there is restriction in the V genes that are used by SLE patients.
This study showed no change in Gm phenotypes in SLE patients 
compared with healthy controls, in contrast to several other studies 
(Whittingham et al. 1983; Schur et al. 1985; Stenszky et al. 1986).
This may be explained by clinical or ethnic heterogeneity in the 
different studies. Use of DNA probes for the immunoglobulin genes would 
be interesting and may reveal more heterogeneity than is seen at the 
protein level as has been shown for the HLA genes. For instance, 
heterozygotes and homozygotes for the Gm23 specificity can be 
differentiated by RFLP studies (Jazwinska et al. 1988) which is not 
possible by serology, except in family studies.
It is still not clear what causes the vast array of autoantibodies 
which are seen in lupus patients. A possible mechanism is that 
infection by a virus in susceptible individuals results in death and
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destruction of ceils, releasing DNA, nucleoproteins and other cellular 
contents into the tissues and circulation. Because these are not 
normally seen by the immune system, T-and B-cells may not have been 
selected for nonreactivity with these antigens. Therefore, 
autoantibodies are produced, and individuals with deficiencies in the 
complement system, particularly C4A, would not properly clear the 
resulting immune complexes, which would precipitate, causing tissue 
damage. This in turn would result in more cellular antigens being 
released and another cycle of immune complex damage. However, this is 
only one possible mechanism and does not explain all the features of 
lupus, such as the higher incidence of SLE in women.
This study has shown the value of genetic analyses in understanding 
underlying disease mechanisms in an autoimmune disease for which the 
aetiology is unknown. This should ultimately lead to improved patient 
management and treatment. The earlier reports of HLA-DR associations 
with SLE focussed attention on the immune system and possible 
immunological dysfunction in lupus. However, this study, together with 
other recent publications, suggests a primary role for the complement 
pathway in contributing significantly to the the pathogenesis of 
systemic lupus erythematosus.
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